Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:cholane derivative
go back to main search page
Accession:CHEBI:131657 term browser browse the term
Definition:Any steroid (or derivative) based on a cholane skeleton.
Synonyms:related_synonym: cholane derivatives


show annotations for term's descendants           Sort by:
7-oxolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases reduction
multiple interactions		 ISO HSD11B1 protein results in increased reduction of 7-ketolithocholic acid
[HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Chenodeoxycholic Acid; [HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Ursodeoxycholic Acid		 CTD PMID:21453287 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
chenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions
increases expression
decreases expression		 ISO
EXP		 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA; [pregna-4,17-diene-3,16-dione co-treated with Chenodeoxycholic Acid] results in increased expression of ABCB11 mRNA; Copper Sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; LG 100268 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; Zinc Sulfate inhibits the reaction [Copper Sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]]
Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA; Chenodeoxycholic Acid results in increased expression of ABCB11 protein
Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]
Chenodeoxycholic Acid results in decreased expression of ABCB11 mRNA
Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein]; Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 mRNA]; epiallopregnanolone sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]		 CTD PMID:12519787 PMID:12525500 PMID:14684751 PMID:16423920 PMID:17963371 More... NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA CTD PMID:33819548 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 multiple interactions
increases expression		 ISO
EXP		 [[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which binds to ABCB4 promoter] which results in increased expression of ABCB4 mRNA; [Bezafibrate co-treated with Chenodeoxycholic Acid] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in increased expression of ABCB4 mRNA
Chenodeoxycholic Acid results in increased expression of ABCB4 mRNA		 CTD PMID:14527955 PMID:14623915 PMID:15588777 PMID:25582706 PMID:27174168 More... NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Chenodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 PMID:33819548 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
increases expression
affects expression		 EXP
ISO		 ABCC2 protein affects the reaction [verlukast results in decreased secretion of Chenodeoxycholic Acid]; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]
Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA
Chenodeoxycholic Acid results in increased expression of ABCC2 mRNA
Chenodeoxycholic Acid affects the expression of ABCC2 mRNA		 CTD PMID:20888898 PMID:21262925 PMID:25055961 PMID:25582706 PMID:25747392 More... NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression
multiple interactions		 EXP
ISO		 Chenodeoxycholic Acid results in increased expression of ABCC3 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA		 CTD PMID:20888898 PMID:25055961 PMID:25582706 PMID:27743861 PMID:32152650 More... NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions
decreases expression		 ISO 7-hydroxytheonellasterol inhibits the reaction [[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of ABCC4 mRNA]; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter] CTD PMID:22291955 PMID:32152650 PMID:33819548 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA CTD PMID:33819548 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of ABCG5 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA		 CTD PMID:25055961 PMID:25582706 PMID:27174168 PMID:33819548 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of ABCG8 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA		 CTD PMID:25582706 PMID:27174168 PMID:33819548 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acaca acetyl-CoA carboxylase alpha multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACACA protein] CTD PMID:27773935 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457 		JBrowse link
G Acad11 acyl-CoA dehydrogenase family, member 11 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of ACAD11 mRNA CTD PMID:27174168 NCBI chr 8:104,681,346...104,746,559
Ensembl chr 8:104,681,396...104,746,560 		JBrowse link
G Acads acyl-CoA dehydrogenase short chain multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of ACADS mRNA] CTD PMID:27773935 NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898 		JBrowse link
G Acadsb acyl-CoA dehydrogenase, short/branched chain decreases expression ISO Chenodeoxycholic Acid results in decreased expression of ACADSB mRNA CTD PMID:27174168 NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379 		JBrowse link
G Acat1 acetyl-CoA acetyltransferase 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of ACAT1 mRNA CTD PMID:27174168 NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA CTD PMID:33819548 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA] CTD PMID:27773935 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA CTD PMID:33819548 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA CTD PMID:33819548 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Adh4 alcohol dehydrogenase 4 (class II), pi polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA CTD PMID:33819548 NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591 		JBrowse link
G Adh6 alcohol dehydrogenase 6 (class V) multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA CTD PMID:33819548 NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534 		JBrowse link
G Ahr aryl hydrocarbon receptor decreases expression
increases secretion
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of AHR mRNA
AHR gene mutant form results in increased secretion of Chenodeoxycholic Acid
[AHR gene mutant form affects the susceptibility to Tetrachlorodibenzodioxin] which results in decreased secretion of Chenodeoxycholic Acid		 CTD PMID:27174168 PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of AKR1C1 mRNA CTD PMID:27174168 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 affects binding
decreases activity		 ISO Chenodeoxycholic Acid binds to AKR1C2 protein
Chenodeoxycholic Acid results in decreased activity of AKR1C2 protein		 CTD PMID:8486699 PMID:8573067 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA CTD PMID:33819548 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of AKR7A3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA		 CTD PMID:27174168 PMID:32152650 PMID:33819548 NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394 		JBrowse link
G Alb albumin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA CTD PMID:33819548 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA CTD PMID:33819548 NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA CTD PMID:33819548 NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887 		JBrowse link
G Angptl3 angiopoietin-like 3 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of ANGPTL3 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ANGPTL3 mRNA]		 CTD PMID:27174168 PMID:27773935 NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957 		JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770 		JBrowse link
G Apoa1 apolipoprotein A1 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of APOA1 protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA		 CTD PMID:19445040 PMID:33819548 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Apoa4 apolipoprotein A4 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOA4 mRNA CTD PMID:27174168 NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469 		JBrowse link
G Apoc2 apolipoprotein C2 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of APOC2 mRNA] CTD PMID:27773935 NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476 		JBrowse link
G Apoc3 apolipoprotein C3 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of APOC3 mRNA] CTD PMID:27773935 NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583 		JBrowse link
G Apoc4 apolipoprotein C4 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOC4 mRNA CTD PMID:27174168 NCBI chr 1:79,335,745...79,339,942
Ensembl chr 1:79,335,745...79,339,981 		JBrowse link
G Apoh apolipoprotein H decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOH mRNA CTD PMID:27174168 NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329 		JBrowse link
G Apom apolipoprotein M decreases expression ISO Chenodeoxycholic Acid results in decreased expression of APOM mRNA CTD PMID:27174168 NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA CTD PMID:33819548 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of BAAT mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA		 CTD PMID:27174168 PMID:33819548 NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685 		JBrowse link
G Bach1 BTB domain and CNC homolog 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA CTD PMID:33819548 NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP Chenodeoxycholic Acid results in increased expression of BAX mRNA CTD PMID:17881359 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA
Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of BCL2L1 mRNA]		 CTD PMID:25747392 PMID:33819548 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA CTD PMID:33819548 NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969 		JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions		 ISO Chenodeoxycholic Acid results in increased activity of CASP3 protein
Chenodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein		 CTD PMID:16573382 PMID:19054763 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity		 ISO [Chenodeoxycholic Acid co-treated with ursodoxicoltaurine] results in increased activity of CASP9 protein; Chenodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP9 protein
Chenodeoxycholic Acid results in increased activity of CASP9 protein		 CTD PMID:14976352 PMID:19054763 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression		 ISO Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCL2 mRNA]]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL2 mRNA] CTD PMID:21224055 PMID:27773935 PMID:29883724 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Chenodeoxycholic Acid results in increased expression of CCL20 mRNA CTD PMID:21224055 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression ISO Chenodeoxycholic Acid results in increased expression of CCL3 mRNA CTD PMID:21224055 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions
increases expression		 ISO Bezafibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 mRNA]; Bezafibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 protein]; Fenofibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 mRNA]; Fenofibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 protein]
Chenodeoxycholic Acid results in increased expression of CCL5 mRNA; Chenodeoxycholic Acid results in increased expression of CCL5 protein		 CTD PMID:12126966 PMID:21224055 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Ccl7 C-C motif chemokine ligand 7 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL7 mRNA] CTD PMID:21224055 NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of CCNB1 mRNA] CTD PMID:25747392 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of CCND1 mRNA] CTD PMID:25747392 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100 		JBrowse link
G Cd36 CD36 molecule multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of CD36 mRNA] CTD PMID:35780845 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B affects localization ISO Chenodeoxycholic Acid affects the localization of CDKN1B protein CTD PMID:20818264 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdx2 caudal type homeo box 2 increases expression ISO Chenodeoxycholic Acid results in increased expression of CDX2 mRNA CTD PMID:20818264 NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142 		JBrowse link
G Chi3l1 chitinase 3 like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA CTD PMID:33819548 NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787 		JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions		 EXP
ISO		 Chenodeoxycholic Acid results in decreased expression of COL1A1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA]		 CTD PMID:15980055 PMID:27773935 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A2 mRNA] CTD PMID:27773935 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867 		JBrowse link
G Coro1a coronin 1A multiple interactions
decreases expression		 ISO [Chenodeoxycholic Acid co-treated with Tretinoin] results in decreased expression of CORO1A mRNA
Chenodeoxycholic Acid results in decreased expression of CORO1A mRNA		 CTD PMID:16040207 NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of CPT1A mRNA] CTD PMID:27773935 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199 		JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO Chenodeoxycholic Acid results in increased expression of CSF3 mRNA CTD PMID:21224055 NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603 		JBrowse link
G Cth cystathionine gamma-lyase multiple interactions EXP chenodeoxycholic acid inhibits the reaction [Carbon Tetrachloride decreases expression and activity of cystathionine gamma-lyase in rat liver] RGD PMID:19418582 RGD:15042868 NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA CTD PMID:33819548 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cttn cortactin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA CTD PMID:33819548 NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO Chenodeoxycholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 increases expression ISO Chenodeoxycholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271 		JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 increases expression ISO Chenodeoxycholic Acid results in increased expression of CXCL16 mRNA CTD PMID:21224055 NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA; Chenodeoxycholic Acid results in increased expression of CXCL2 protein
EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 protein]		 CTD PMID:21224055 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases expression ISO Chenodeoxycholic Acid results in increased expression of CXCL1 mRNA CTD PMID:21224055 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA]		 CTD PMID:22961653 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of CYP1A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA		 CTD PMID:27174168 PMID:33819548 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of CYP1A2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA		 CTD PMID:27174168 PMID:33819548 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression
multiple interactions		 EXP
ISO		 Chenodeoxycholic Acid results in decreased expression of CYP27A1 mRNA
Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of CYP27A1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of CYP27A1 protein]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA		 CTD PMID:7832767 PMID:25582706 PMID:33819548 PMID:35780845 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Chenodeoxycholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity
multiple interactions		 EXP
ISO		 Chenodeoxycholic Acid results in decreased activity of CYP2C11 protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA		 CTD PMID:8889968 PMID:33819548 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA CTD PMID:33819548 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of CYP2C8 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA		 CTD PMID:27174168 PMID:33819548
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of CYP2E1 mRNA CTD PMID:27174168 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
increases hydroxylation
decreases expression
decreases activity		 EXP
ISO		 [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Chenodeoxycholic Acid; Chenodeoxycholic Acid inhibits the reaction [Calcitriol results in increased expression of CYP3A2 mRNA]
CYP3A4 protein results in increased hydroxylation of Chenodeoxycholic Acid
Chenodeoxycholic Acid results in decreased expression of CYP3A4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [CYP3A4 protein results in increased hydroxylation of Chenodeoxycholic Acid] which results in increased abundance of muricholic acid; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; Chenodeoxycholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
Chenodeoxycholic Acid results in decreased activity of CYP3A2 protein		 CTD PMID:8889968 PMID:19299527 PMID:20006981 PMID:27174168 PMID:32152650 More... NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions
increases expression		 EXP [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Chenodeoxycholic Acid; Chenodeoxycholic Acid inhibits the reaction [Calcitriol results in increased expression of CYP3A23-3A1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of CYP3A23-3A1 mRNA]
Chenodeoxycholic Acid results in increased expression of CYP3A23-3A1 mRNA		 CTD PMID:20006981 PMID:34461081 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression		 ISO
EXP		 Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of CYP7A1 mRNA]; Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of CYP7A1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of CYP7A1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein		 CTD PMID:17963371 PMID:19072826 PMID:20671298 PMID:20835427 PMID:25055961 More... NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA CTD PMID:33819548 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of CYP8B1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA
Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of CYP8B1 mRNA]; Chenodeoxycholic Acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 mRNA]; Chenodeoxycholic Acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 protein]; Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of CYP8B1 mRNA]		 CTD PMID:25055961 PMID:25582706 PMID:25747392 PMID:32976922 PMID:33819548 More... NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407 		JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063 		JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988 		JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719 		JBrowse link
G Dnajc12 DnaJ heat shock protein family (Hsp40) member C12 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA CTD PMID:33819548 NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521 		JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136 		JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344 		JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:116,923,272...116,945,312
Ensembl chr 2:116,923,272...116,945,264 		JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:59,419,507...59,446,746
Ensembl chr 2:59,419,510...59,446,752 		JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448 		JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118 		JBrowse link
G Edn1 endothelin 1 decreases expression EXP Chenodeoxycholic Acid results in decreased expression of EDN1 mRNA CTD PMID:16357303 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of SERPINE1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein]
Chenodeoxycholic Acid results in increased expression of EGR1 mRNA; Chenodeoxycholic Acid results in increased expression of EGR1 protein		 CTD PMID:19931294 PMID:21224055 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of EIF2AK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA CTD PMID:33819548 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713 		JBrowse link
G Ephx1 epoxide hydrolase 1 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of EPHX1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA		 CTD PMID:27174168 PMID:32152650 NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235 		JBrowse link
G Fabp6 fatty acid binding protein 6 multiple interactions
increases expression		 ISO [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FABP6 mRNA; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased expression of FABP6 mRNA] CTD PMID:15821044 PMID:15935148 PMID:17963371 PMID:25582706 NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282 		JBrowse link
G Fabp7 fatty acid binding protein 7 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of FABP7 mRNA CTD PMID:27174168 NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880 		JBrowse link
G Fasn fatty acid synthase multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FASN protein]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of FASN protein] CTD PMID:27773935 PMID:35780845 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fgf19 fibroblast growth factor 19 increases expression
multiple interactions		 EXP
ISO		 Chenodeoxycholic Acid results in increased expression of FGF15 mRNA; Chenodeoxycholic Acid results in increased expression of FGF19 protein
Chenodeoxycholic Acid results in increased expression of FGF19 mRNA
[[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
[Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein		 CTD PMID:16269825 PMID:17696253 PMID:20835427 PMID:22561792 PMID:25055961 More... NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO Chenodeoxycholic Acid results in increased activity of [JUN protein co-treated with FOS protein] CTD PMID:8631127 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Foxm1 forkhead box M1 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA
Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of FOXM1 mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA]		 CTD PMID:22135065 PMID:25747392 NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684 		JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA CTD PMID:33819548 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Ftl1 ferritin light chain 1 multiple interactions ISO [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA CTD PMID:17724089 NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression		 ISO [Chenodeoxycholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione CTD PMID:17724089 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of GCLM protein
[Chenodeoxycholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA		 CTD PMID:17724089 PMID:33819548 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GGT1 mRNA CTD PMID:33819548 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442 		JBrowse link
G Gjb1 gap junction protein, beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB1 mRNA CTD PMID:33819548 NCBI chr  X:66,501,848...66,509,783
Ensembl chr  X:66,501,820...66,509,925 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA CTD PMID:33819548 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177 		JBrowse link
G Gk glycerol kinase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GK mRNA CTD PMID:33819548 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Got1 glutamic-oxaloacetic transaminase 1 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [Carbon Tetrachloride results in increased secretion of GOT1 protein] CTD PMID:25747392 NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633 		JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression		 ISO [Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein
Chenodeoxycholic Acid results in increased expression of GPBAR1 mRNA		 CTD PMID:17963371 PMID:18180267 PMID:25055961 NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168 		JBrowse link
G Gprc5b G protein-coupled receptor, class C, group 5, member B multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA CTD PMID:33819548 NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP
ISO		 Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in increased activity of GPT protein]
Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]; Chenodeoxycholic Acid inhibits the reaction [Carbon Tetrachloride results in increased secretion of GPT protein]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased activity of GPT protein]		 CTD PMID:25747392 PMID:27743861 PMID:27773935 PMID:32976922 PMID:35780845 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions EXP
ISO		 Chenodeoxycholic Acid binds to and results in decreased activity of GSTA4 protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA		 CTD PMID:3954743 PMID:33819548 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions EXP
ISO		 Chenodeoxycholic Acid binds to and results in decreased activity of GSTM1 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA		 CTD PMID:3954743 PMID:32152650 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions EXP
ISO		 Chenodeoxycholic Acid binds to and results in decreased activity of GSTM2 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA		 CTD PMID:3954743 PMID:32152650 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323 		JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTT1 mRNA CTD PMID:33819548 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585 		JBrowse link
G Hacl1 2-hydroxyacyl-CoA lyase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HGF mRNA; Chenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 PMID:33819548 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hhex hematopoietically expressed homeobox multiple interactions
increases expression		 ISO Chenodeoxycholic Acid promotes the reaction [NR1H4 binds to HHEX intron]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]
NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX protein]
Chenodeoxycholic Acid results in increased expression of HHEX mRNA; Chenodeoxycholic Acid results in increased expression of HHEX protein		 CTD PMID:19072826 NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO HIF1A mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA] CTD PMID:24703425 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase decreases response to substance
multiple interactions
decreases activity		 ISO
EXP		 HMGCR protein results in decreased susceptibility to Chenodeoxycholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HMGCR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HMGCR mRNA
Chenodeoxycholic Acid results in decreased activity of HMGCR protein		 CTD PMID:6832710 PMID:7461467 PMID:33819548 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 affects expression ISO Chenodeoxycholic Acid affects the expression of HMGCS1 mRNA CTD PMID:31437187 NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100 		JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of HMGCS2 mRNA CTD PMID:27174168 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:17724089 PMID:32152650 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hpx hemopexin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HPX mRNA CTD PMID:33819548 NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases activity
increases abundance
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased activity of HSD11B1 protein
HSD11B1 gene mutant form results in increased abundance of Chenodeoxycholic Acid
[HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Chenodeoxycholic Acid		 CTD PMID:10664531 PMID:21453287 PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HSD3B7 mRNA CTD PMID:33819548 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185 		JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA; Chenodeoxycholic Acid results in increased expression of ICAM1 protein
BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]
EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 protein]		 CTD PMID:16582018 PMID:21224055 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IER3 mRNA CTD PMID:33819548 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583 		JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of IFI27 mRNA CTD PMID:33819548 NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294 		JBrowse link
G Ifng interferon gamma multiple interactions EXP Chenodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] CTD PMID:12620498 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of IGFBP1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IGFBP1 mRNA		 CTD PMID:19072826 PMID:33819548 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il10 interleukin 10 decreases abundance ISO IL10 gene mutant form results in decreased abundance of Chenodeoxycholic Acid CTD PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL1B mRNA]] CTD PMID:29883724 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of IL1R1 mRNA CTD PMID:33819548 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IL6 mRNA CTD PMID:33819548 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; Chenodeoxycholic Acid results in increased activity of [JUN protein co-treated with FOS protein] CTD PMID:8631127 PMID:32152650 PMID:33819548 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Kynu kynureninase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of KYNU mRNA CTD PMID:33819548 NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488 		JBrowse link
G Lbp lipopolysaccharide binding protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LBP mRNA CTD PMID:33819548 NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LDLR mRNA CTD PMID:33819548 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LIPC mRNA CTD PMID:33819548 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Lpl lipoprotein lipase multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of LPL mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of LPL mRNA] CTD PMID:27773935 PMID:35780845 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249 		JBrowse link
G Lrp2 LDL receptor related protein 2 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of LRP2 protein
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of LRP2 protein]		 CTD PMID:15375181 NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708 		JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA CTD PMID:33819548 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of MAP1LC3B protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA		 CTD PMID:24189133 PMID:32152650 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP3K5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA CTD PMID:33819548 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions		 ISO Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein
Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of MAPK1 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]		 CTD PMID:19931294 PMID:32976922 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein] CTD PMID:19931294 PMID:32976922 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Chenodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK8 protein] CTD PMID:25496033 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Chenodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein]
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA		 CTD PMID:25496033 PMID:32152650 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA CTD PMID:33819548 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828 		JBrowse link
G Mir15b microRNA 15b increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR15B mRNA CTD PMID:27174168 NCBI chr 2:153,245,200...153,245,297
Ensembl chr 2:153,245,200...153,245,297 		JBrowse link
G Mir190 microRNA 190 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR190A mRNA CTD PMID:27174168 NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071 		JBrowse link
G Mir190b microRNA 190b decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR190B mRNA CTD PMID:27174168 NCBI chr 2:175,514,800...175,514,877
Ensembl chr 2:175,514,800...175,514,877 		JBrowse link
G Mir204 microRNA 204 increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR204 mRNA CTD PMID:27174168 NCBI chr 1:220,316,931...220,317,040
Ensembl chr 1:220,316,931...220,317,040 		JBrowse link
G Mir30a microRNA 30a decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR30A mRNA CTD PMID:27174168 NCBI chr 9:25,737,600...25,737,670
Ensembl chr 9:25,737,600...25,737,670 		JBrowse link
G Mir328 microRNA 328 increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR328 mRNA CTD PMID:27174168 NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849 		JBrowse link
G Mir34a microRNA 34a decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR34A mRNA CTD PMID:27174168 NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103 		JBrowse link
G Mir451a microRNA 451a decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR451A mRNA CTD PMID:27174168 NCBI chr10:62,961,520...62,961,591
Ensembl chr10:62,961,520...62,961,591 		JBrowse link
G Mir486 microRNA 486 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR486-1 mRNA CTD PMID:27174168
G Mir92a2 microRNA 92a-2 increases expression ISO Chenodeoxycholic Acid results in increased expression of MIR92A2 mRNA CTD PMID:27174168 NCBI chr  X:132,421,942...132,422,033
Ensembl chr  X:132,421,942...132,422,033 		JBrowse link
G Mir98 microRNA 98 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of MIR98 mRNA CTD PMID:27174168 NCBI chr  X:20,981,235...20,981,342
Ensembl chr  X:20,981,235...20,981,342 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of MMP2 mRNA] CTD PMID:27773935 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mmut methylmalonyl-CoA mutase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MMUT mRNA CTD PMID:33819548 NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046 		JBrowse link
G Mttp microsomal triglyceride transfer protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MTTP mRNA CTD PMID:33819548 NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239 		JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Chenodeoxycholic Acid analog promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]] CTD PMID:13130122 PMID:14684751 PMID:16819505 NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664 		JBrowse link
G Ncoa2 nuclear receptor coactivator 2 multiple interactions ISO 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; benidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; clevidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Colchicine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; doramectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Felodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Isradipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ivermectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; moxidectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nimodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; pregna-4,17-diene-3,16-dione inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; selamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]] CTD PMID:25257666 PMID:27773686 NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451 		JBrowse link
G Ncor1 nuclear receptor co-repressor 1 multiple interactions ISO 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]]; Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter] CTD PMID:22291955 NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases expression
decreases response to substance		 ISO [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA; Chenodeoxycholic Acid results in increased expression of and results in increased localization of and results in increased activity of NFE2L2 protein
Chenodeoxycholic Acid results in increased expression of NFE2L2 mRNA
NFE2L2 protein results in decreased susceptibility to Chenodeoxycholic Acid		 CTD PMID:17724089 PMID:25582706 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfxl1 nuclear transcription factor, X-box binding-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NFXL1 mRNA CTD PMID:33819548 NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression		 ISO [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA
Chenodeoxycholic Acid results in increased expression of NQO1 mRNA		 CTD PMID:17724089 PMID:25582706 PMID:32152650 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions
increases expression		 ISO
EXP		 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NR0B2 mRNA; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]
Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of NR0B2 protein]; Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of NR0B2 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of NR0B2 mRNA		 CTD PMID:15980055 PMID:16037943 PMID:16269825 PMID:16357303 PMID:16946559 More... NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1d1 nuclear receptor subfamily 1, group D, member 1 affects expression ISO Chenodeoxycholic Acid affects the expression of NR1D1 mRNA CTD PMID:31437187 NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705 		JBrowse link
G Nr1d2 nuclear receptor subfamily 1, group D, member 2 increases expression
affects expression		 ISO Chenodeoxycholic Acid results in increased expression of NR1D2 mRNA
Chenodeoxycholic Acid affects the expression of NR1D2 mRNA		 CTD PMID:19072826 PMID:31437187 NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NR1H2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NR1H2 mRNA CTD PMID:33819548 NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of NR1H3 mRNA CTD PMID:33819548 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
increases expression
increases activity
affects binding
affects activity
increases response to substance		 ISO
EXP		 Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of NR1H4 mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of NR1H4 protein]; epiallopregnanolone sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX protein]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of LRP2 protein]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; Pregnanolone metabolite inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
chenodeoxycholic acid enhances the reaction [glycyrrhetinic acid increases expression of Nr1h4 mRNA in liver]
chenodeoxycholic acid increases expression of Nr1H4 mRNA in rat hepatic stellate cells
chenodeoxycholic acid inhibits the reaction [Carbon Tetrachloride decreases expression of Nr1h4 mRNA in rat liver], increases expression of Nr1H4 mRNA in rat liver
Chenodeoxycholic Acid metabolite results in increased activity of NR1H4 protein; Chenodeoxycholic Acid results in increased activity of NR1H4 protein
Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA; Chenodeoxycholic Acid results in increased expression of NR1H4 protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51A mRNA; [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51B mRNA; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]]
1,4-dihydropyridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 7-hydroxytheonellasterol inhibits the reaction [[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; [[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which binds to ABCB4 promoter] which results in increased expression of ABCB4 mRNA; [[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FABP6 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]] which results in increased expression of UGT1A3 mRNA; [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; abamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; alpha-Linolenic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Am 580 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Aminacrine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Arachidonic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; benazepril inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; benidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid analog promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid inhibits the reaction [Ursodeoxycholic Acid binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 binds to HHEX intron]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; clevidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Colchicine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; cyclopamine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Decitabine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Deoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Docosahexaenoic Acids inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; doramectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; doramectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ethacridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Felodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Felodipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; fluoxastrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; GW 4064 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Isotretinoin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Isradipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ivermectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Lithocholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; manidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Mitomycin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; moxidectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; moxidectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Nimodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nitrendipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; picoxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; pirarubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; pregna-4,17-diene-3,16-dione inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Proflavine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Rotenone inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; selamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; selamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; ST 1481 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; tamibarotene inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Topotecan inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Tretinoin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; trifloxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; UGT1A3 protein affects the reaction [Chenodeoxycholic Acid affects the activity of NR1H4 protein]; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
NR1H4 results in increased susceptibility to Chenodeoxycholic Acid		 CTD
RGD		 PMID:12519787 PMID:12525500 PMID:13130122 PMID:14527955 PMID:14684751 More... RGD:15092071, RGD:1625201, RGD:15042868 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases activity		 ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA; Chenodeoxycholic Acid analog binds to and results in increased activity of NR1I2 protein; Chenodeoxycholic Acid binds to and results in increased activity of NR1I2 protein
Chenodeoxycholic Acid metabolite results in increased activity of NR1I2 protein		 CTD PMID:17963371 PMID:27871908 PMID:32152650 PMID:33819548 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression
multiple interactions
decreases expression		 ISO Chenodeoxycholic Acid results in increased expression of NR1I3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
Chenodeoxycholic Acid results in decreased expression of NR1I3 mRNA		 CTD PMID:16929008 PMID:27174168 PMID:32152650 PMID:33819548 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Pah phenylalanine hydroxylase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PAH mRNA CTD PMID:33819548 NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO [Chenodeoxycholic Acid co-treated with ursodoxicoltaurine] results in increased cleavage of PARP1 protein
Chenodeoxycholic Acid results in increased cleavage of PARP1 protein		 CTD PMID:14976352 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pex3 peroxisomal biogenesis factor 3 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of PEX3 mRNA CTD PMID:27174168 NCBI chr 1:7,912,508...7,954,474
Ensembl chr 1:7,912,506...7,954,518 		JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of PIK3C2A mRNA CTD PMID:33819548 NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472 		JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612 		JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544 		JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PIK3R3 mRNA CTD PMID:33819548 NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583 		JBrowse link
G Plaur plasminogen activator, urokinase receptor increases expression ISO Chenodeoxycholic Acid results in increased expression of PLAUR mRNA CTD PMID:21224055 NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595 		JBrowse link
G Pon1 paraoxonase 1 multiple interactions
decreases expression		 ISO pyrazolanthrone inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16269825 NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360 		JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Chenodeoxycholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression
multiple interactions		 EXP
ISO		 Chenodeoxycholic Acid results in increased expression of PPARA mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPARA mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of PPARA mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of PPARA mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of PPARA protein]		 CTD PMID:15980055 PMID:27773935 PMID:33819548 PMID:35780845 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions		 EXP
ISO		 Chenodeoxycholic Acid results in increased expression of PPARG mRNA
Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of PPARG mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of PPARG protein]		 CTD PMID:15980055 PMID:27174168 PMID:35780845 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA CTD PMID:33819548 NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961 		JBrowse link
G Prkd3 protein kinase D3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PRKD3 mRNA CTD PMID:33819548 NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of PTGS2 mRNA
[SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid] which results in increased expression of PTGS2 mRNA		 CTD PMID:18648741 PMID:21224055 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rab7a RAB7A, member RAS oncogene family decreases expression ISO Chenodeoxycholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889 		JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501 		JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RARA mRNA CTD PMID:33819548 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142 		JBrowse link
G Rasd1 ras related dexamethasone induced 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA CTD PMID:33819548 NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA CTD PMID:33819548 NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124 		JBrowse link
G Reep5 receptor accessory protein 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of REEP5 mRNA CTD PMID:33819548 NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509 		JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824 		JBrowse link
G Rora RAR-related orphan receptor A affects expression ISO Chenodeoxycholic Acid affects the expression of RORA mRNA CTD PMID:31437187 NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931 		JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of SCARB1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA		 CTD PMID:22540009 PMID:32152650 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of SCD1 protein]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCD mRNA		 CTD PMID:27773935 PMID:33819548 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Scp2 sterol carrier protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCP2 mRNA CTD PMID:33819548 NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287 		JBrowse link
G Sdc2 syndecan 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SDC2 mRNA CTD PMID:33819548 NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081 		JBrowse link
G Sele selectin E multiple interactions
increases expression		 ISO BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA] CTD PMID:16582018 NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of SERPINE1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA		 CTD PMID:21224055 PMID:32152650 PMID:33819548 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 decreases expression
multiple interactions		 ISO
EXP		 Chenodeoxycholic Acid results in decreased expression of SLC10A1 mRNA
Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
[Chenodeoxycholic Acid co-treated with Ketoconazole] results in decreased expression of SLC10A1 mRNA; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]]		 CTD PMID:25055961 PMID:27743861 PMID:30985903 PMID:32152650 PMID:32976922 More... NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid] CTD PMID:25466967 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Slc10a7 solute carrier family 10, member 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC10A7 mRNA CTD PMID:33819548 NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464 		JBrowse link
G Slc12a2 solute carrier family 12 member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA CTD PMID:33819548 NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440 		JBrowse link
G Slc17a1 solute carrier family 17 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA CTD PMID:33819548 NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of SLC22A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC22A1 mRNA		 CTD PMID:27174168 PMID:33819548 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc22a7 solute carrier family 22 member 7 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of SLC22A7 mRNA CTD PMID:27174168 NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921 		JBrowse link
G Slc27a5 solute carrier family 27 member 5 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172 		JBrowse link
G Slc35b1 solute carrier family 35, member B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC35B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC35B1 mRNA CTD PMID:33819548 NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274 		JBrowse link
G Slc51a solute carrier family 51 member A multiple interactions
increases expression		 ISO
EXP		 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Calcitriol co-treated with Chenodeoxycholic Acid] results in decreased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]; Chenodeoxycholic Acid promotes the reaction [Oxygen deficiency results in increased expression of SLC51A mRNA]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; HIF1A mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; Oxygen deficiency promotes the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]
Chenodeoxycholic Acid results in increased expression of SLC51A mRNA; Chenodeoxycholic Acid results in increased expression of SLC51A protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51A mRNA		 CTD PMID:16423920 PMID:19562681 PMID:22178739 PMID:22291955 PMID:24703425 More... NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions
increases expression		 ISO
EXP		 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Calcitriol co-treated with Chenodeoxycholic Acid] results in decreased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]
Chenodeoxycholic Acid results in increased expression of SLC51B mRNA; Chenodeoxycholic Acid results in increased expression of SLC51B protein
[Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51B mRNA		 CTD PMID:16423920 PMID:19562681 PMID:22178739 PMID:24703425 PMID:25055961 More... NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 decreases expression
multiple interactions		 EXP Chenodeoxycholic Acid results in decreased expression of SLCO1A2 mRNA
Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLCO1A2 mRNA]		 CTD PMID:27743861 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 increases expression
multiple interactions
increases transport		 ISO Chenodeoxycholic Acid results in increased expression of SLCO1B2 mRNA
Chenodeoxycholic Acid results in increased expression of SLCO1B3 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLCO1B3 mRNA; [SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid] which results in increased expression of PTGS2 mRNA		 CTD PMID:18648741 PMID:25055961 PMID:25582706 PMID:27174168 PMID:33819548 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions ISO Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of SOCS3 mRNA] CTD PMID:25747392 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sorl1 sortilin related receptor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA CTD PMID:33819548 NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513 		JBrowse link
G Sqstm1 sequestosome 1 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of SQSTM1 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA		 CTD PMID:24189133 PMID:32152650 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in decreased expression of SREBF1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of SREBF1 protein]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of SREBF1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of SREBF1 protein]		 CTD PMID:16269825 PMID:27773935 PMID:33819548 PMID:35780845 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Srp72 signal recognition particle 72 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SRP72 mRNA CTD PMID:33819548 NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729 		JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476 		JBrowse link
G Stk11 serine/threonine kinase 11 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of STK11 protein] CTD PMID:32976922 NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315 		JBrowse link
G Sult1b1 sulfotransferase family 1B member 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of SULT1B1 mRNA CTD PMID:27174168 NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483 		JBrowse link
G Sult1c2a sulfotransferase family 1C member 2A increases expression ISO Chenodeoxycholic Acid results in increased expression of SULT1C2 mRNA CTD PMID:27174168 NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734 		JBrowse link
G Sult1e1 sulfotransferase family 1E member 1 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of SULT1E1 mRNA CTD PMID:27174168 NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 increases sulfation
multiple interactions
decreases expression		 ISO SULT2A1 protein results in increased sulfation of Chenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA
NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA]
Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA; Chenodeoxycholic Acid results in decreased expression of SULT2A1 protein		 CTD PMID:16946559 PMID:20102295 PMID:32152650 PMID:33819548 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tef TEF transcription factor, PAR bZIP family member increases expression ISO Chenodeoxycholic Acid results in increased expression of TEF mRNA CTD PMID:19072826 NCBI chr 7:113,317,191...113,341,783
Ensembl chr 7:113,317,283...113,341,783 		JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TFPI mRNA CTD PMID:33819548 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TGFB1 mRNA]] CTD PMID:27773935 PMID:29883724 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TIMP1 mRNA]]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TIMP1 mRNA] CTD PMID:27773935 PMID:29883724 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Tjp2 tight junction protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TJP2 mRNA CTD PMID:33819548 NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295 		JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TLR3 mRNA CTD PMID:33819548 NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA CTD PMID:33819548 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFRSF10A mRNA CTD PMID:33819548 NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TNFRSF9 mRNA CTD PMID:33819548 NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA CTD PMID:33819548 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA CTD PMID:33819548 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions
increases expression		 ISO [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA
Chenodeoxycholic Acid results in increased expression of TXN protein		 CTD PMID:17724089 NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629 		JBrowse link
G Uba5 ubiquitin-like modifier activating enzyme 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBA5 mRNA CTD PMID:33819548 NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894 		JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:42,658,016...42,718,899
Ensembl chr14:42,658,016...42,718,630 		JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of UGP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of UGP2 mRNA CTD PMID:33819548 NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of UGT1A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT1A1 mRNA
Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein]		 CTD PMID:27174168 PMID:32976922 PMID:33819548 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 multiple interactions
increases expression
increases glucuronidation		 ISO [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]] which results in increased expression of UGT1A3 mRNA; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]; shikonin inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Chenodeoxycholic Acid]; UGT1A3 protein affects the reaction [Chenodeoxycholic Acid affects the activity of NR1H4 protein]
Chenodeoxycholic Acid results in increased expression of UGT1A3 mRNA		 CTD PMID:17058234 PMID:20189675 PMID:27174168 PMID:31128210 NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of UGT1A6 mRNA CTD PMID:27174168 NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of UGT1A9 mRNA CTD PMID:27174168 NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt2a3 UDP glucuronosyltransferase family 2 member A3 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of UGT2A3 mRNA CTD PMID:27174168 NCBI chr14:20,572,793...20,590,795
Ensembl chr14:20,572,808...20,590,729 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 decreases expression ISO Chenodeoxycholic Acid results in decreased expression of UGT2B7 mRNA CTD PMID:15821044 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604 		JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression
multiple interactions		 ISO Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of VCAM1 mRNA]
BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]
Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA; Chenodeoxycholic Acid results in increased expression of VCAM1 protein		 CTD PMID:16582018 PMID:21224055 PMID:27773935 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571 		JBrowse link
G Vdr vitamin D receptor multiple interactions
increases expression		 EXP
ISO		 bisindolylmaleimide I inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VDR mRNA]; Chenodeoxycholic Acid promotes the reaction [Calcitriol results in increased expression of VDR mRNA] CTD PMID:20006981 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677 		JBrowse link
G Vipr1 vasoactive intestinal peptide receptor 1 increases expression ISO Chenodeoxycholic Acid results in increased expression of VIPR1 mRNA; Chenodeoxycholic Acid results in increased expression of VIPR1 protein CTD PMID:16037943 NCBI chr 8:121,303,739...121,339,587
Ensembl chr 8:121,310,248...121,339,585 		JBrowse link
cholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 increases expression
multiple interactions		 ISO
EXP		 Cholic Acid results in increased expression of ABCA1 mRNA
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCA1 mRNA		 CTD PMID:14684380 PMID:15694933 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170 		JBrowse link
G Abca8 ATP binding cassette subfamily A member 8 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA CTD PMID:30996006 NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988 		JBrowse link
G Abca9 ATP binding cassette subfamily A member 9 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA CTD PMID:30996006 NCBI chr10:95,077,615...95,137,751
Ensembl chr10:95,079,058...95,139,608 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 increases expression
decreases activity
multiple interactions		 EXP
ISO		 Cholic Acid results in increased expression of ABCB11 mRNA
Cholic Acid results in increased expression of ABCB11 mRNA; Cholic Acid results in increased expression of ABCB11 protein
Cholic Acid results in decreased activity of ABCB11 protein
Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB11 mRNA]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCB11 mRNA		 CTD PMID:11438506 PMID:12971955 PMID:14684380 PMID:15466244 PMID:15694933 More... NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression ISO Cholic Acid results in increased expression of ABCB1A mRNA; Cholic Acid results in increased expression of ABCB1A protein CTD PMID:11438506 PMID:17521389 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb1b ATP-binding cassette, sub-family B member 1B increases expression ISO Cholic Acid results in increased expression of ABCB1B mRNA; Cholic Acid results in increased expression of ABCB1B protein CTD PMID:11438506 NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 affects secretion
increases expression
multiple interactions		 ISO ABCB4 affects the secretion of Cholic Acid
Cholic Acid results in increased expression of ABCB4 mRNA
epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB4 mRNA]		 CTD PMID:12967592 PMID:22961653 PMID:25582706 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Cholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Cholic Acid results in increased expression of ABCC2 mRNA
Cholic Acid results in increased expression of ABCC2 mRNA; Cholic Acid results in increased expression of ABCC2 protein		 CTD PMID:11438506 PMID:12971955 PMID:15694933 PMID:25055961 PMID:25582706 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression ISO Cholic Acid results in increased expression of ABCC3 mRNA CTD PMID:12971955 PMID:25055961 PMID:25582706 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA CTD PMID:30996006 NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of ABCG5 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA		 CTD PMID:25055961 PMID:25582706 PMID:30996006 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of ABCG8 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA		 CTD PMID:25582706 PMID:30996006 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein] CTD PMID:35622622 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion
increases abundance		 ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Cholic Acid]
AHR gene mutant form results in increased secretion of Cholic Acid
AHR gene mutant form results in increased abundance of Cholic Acid		 CTD PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G AKR1C3l1 aldo-keto reductase family 1 member C3-like 1 increases abundance EXP AKR1C4 protein results in increased abundance of Cholic Acid CTD PMID:3468121 NCBI chr17:65,847,580...65,881,488
Ensembl chr17:65,835,634...65,881,488 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein; Diethylnitrosamine inhibits the reaction [Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein] CTD PMID:27151938 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA CTD PMID:30996006 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholic Acid inhibits the reaction [Diethylnitrosamine results in increased cleavage of CASP3 protein] CTD PMID:27151938 PMID:35622622 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cat catalase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein] CTD PMID:16933029 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression		 ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of CCND1 protein
Cholic Acid results in increased expression of CCND1 protein		 CTD PMID:27151938 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cd36 CD36 molecule multiple interactions ISO [bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein] CTD PMID:35622622 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression
multiple interactions		 ISO Cholic Acid results in decreased expression of CDKN1A protein
[Diethylnitrosamine co-treated with Cholic Acid] results in decreased expression of CDKN1A protein		 CTD PMID:27151938 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Chek1 checkpoint kinase 1 increases expression ISO Cholic Acid results in increased expression of CHEK1 protein CTD PMID:20025956 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009 		JBrowse link
G Chrm2 cholinergic receptor, muscarinic 2 increases expression EXP Cholic Acid results in increased expression of CHRM2 mRNA CTD PMID:35584729 NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103 		JBrowse link
G Cldn1 claudin 1 decreases expression EXP Cholic Acid results in decreased expression of CLDN1 mRNA; Cholic Acid results in decreased expression of CLDN1 protein CTD PMID:35584729 NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724 		JBrowse link
G Cldn2 claudin 2 decreases expression EXP Cholic Acid results in decreased expression of CLDN2 mRNA; Cholic Acid results in decreased expression of CLDN2 protein CTD PMID:35584729 NCBI chr  X:103,459,870...103,473,794
Ensembl chr  X:103,459,780...103,474,838 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression EXP
ISO		 Cholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767 PMID:25582706 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Cholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887 		JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 increases expression ISO Cholic Acid results in increased expression of CYP2A4 mRNA CTD PMID:17521389 NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979 		JBrowse link
G Cyp2b2 cytochrome P450, family 2, subfamily b, polypeptide 2 increases expression ISO Cholic Acid results in increased expression of CYP2B13 mRNA CTD PMID:17521389 NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases expression ISO Cholic Acid results in increased expression of CYP2B10 mRNA CTD PMID:17521389 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity EXP Cholic Acid results in decreased activity of CYP2C11 protein CTD PMID:8889968 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity
multiple interactions		 EXP
ISO		 Cholic Acid results in decreased activity of CYP3A2 protein
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid
Cholic Acid metabolite results in decreased activity of CYP3A4 protein
Cholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]		 CTD PMID:8889968 PMID:19299527 PMID:27871908 PMID:34461081 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid CTD PMID:34461081 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression		 EXP
ISO		 [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CYP7A1 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CYP7A1 mRNA
Cholic Acid results in decreased expression of CYP7A1 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA		 CTD PMID:12072388 PMID:14684380 PMID:15694933 PMID:17521389 PMID:20671298 More... NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases expression ISO Cholic Acid results in decreased expression of CYP7B1 mRNA CTD PMID:20671298 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 decreases expression ISO Cholic Acid results in decreased expression of CYP8B1 mRNA CTD PMID:17521389 PMID:25055961 PMID:25582706 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein] CTD PMID:35622622 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Fabp6 fatty acid binding protein 6 increases expression ISO
EXP		 Cholic Acid results in increased expression of FABP6 mRNA CTD PMID:25582706 PMID:35584729 NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282 		JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression		 ISO [[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
Cholic Acid results in increased expression of FGF15 mRNA
Cholic Acid results in increased expression of FGF19 mRNA		 CTD PMID:22561792 PMID:25055961 PMID:25582706 NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Fmo3 flavin containing dimethylaniline monoxygenase 3 increases expression ISO Cholic Acid results in increased expression of FMO3 mRNA CTD PMID:17521389 NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028 		JBrowse link
G Fmo4 flavin containing dimethylaniline monoxygenase 4 increases expression ISO Cholic Acid results in increased expression of FMO4 mRNA CTD PMID:17521389 NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression ISO Cholic Acid results in increased expression of FOSL1 protein CTD PMID:20025956 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression		 ISO Cholic Acid binds to and results in increased activity of GPBAR1 protein
Cholic Acid results in increased expression of GPBAR1 mRNA		 CTD PMID:18180267 PMID:25055961 NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions EXP Cholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]] CTD PMID:3783048 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta3 glutathione S-transferase alpha 3 multiple interactions EXP Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]] CTD PMID:3783048 NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions EXP Cholic Acid binds to and results in decreased activity of GSTA4 protein CTD PMID:3954743 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions EXP Cholic Acid binds to and results in decreased activity of GSTM1 protein CTD PMID:3954743 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions
increases expression		 EXP
ISO		 Cholic Acid binds to and results in decreased activity of GSTM2 protein
Cholic Acid results in increased expression of GSTM2 mRNA		 CTD PMID:3954743 PMID:17521389 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm5 glutathione S-transferase, mu 5 increases expression ISO Cholic Acid results in increased expression of GSTM3 mRNA CTD PMID:17521389 NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553 		JBrowse link
G Hells helicase, lymphoid specific increases expression ISO Cholic Acid results in increased expression of HELLS protein CTD PMID:20025956 NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein] CTD PMID:30273964 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA] CTD PMID:30273964 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of Cholic Acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of IL1B mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA] CTD PMID:12072388 PMID:27151938 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 increases expression ISO Cholic Acid results in increased expression of IL1RL1 protein CTD PMID:20025956 NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256 		JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein] CTD PMID:30273964 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA] CTD PMID:30273964 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of LPL mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein] CTD PMID:14684380 PMID:30273964 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249 		JBrowse link
G Lrp2 LDL receptor related protein 2 increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of LRP2 protein
NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]		 CTD PMID:15375181 NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO Cholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases activity		 ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK1 protein
Cholic Acid results in increased activity of MAPK1 protein		 CTD PMID:27151938 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases activity		 ISO [Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK3 protein
Cholic Acid results in increased activity of MAPK3 protein		 CTD PMID:27151938 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcm3 minichromosome maintenance complex component 3 increases expression ISO Cholic Acid results in increased expression of MCM3 protein CTD PMID:20025956 NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314 		JBrowse link
G Mgst3 microsomal glutathione S-transferase 3 increases expression ISO Cholic Acid results in increased expression of MGST3 mRNA CTD PMID:17521389 NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411 		JBrowse link
G Muc2 mucin 2, oligomeric mucus/gel-forming decreases expression EXP Cholic Acid results in decreased expression of MUC2 mRNA CTD PMID:35584729 NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756 		JBrowse link
G Myl9 myosin light chain 9 increases phosphorylation EXP Cholic Acid results in increased phosphorylation of MYL9 protein CTD PMID:35584729 NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression ISO Cholic Acid results in increased expression of NFE2L2 mRNA CTD PMID:25582706 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkbia NFKB inhibitor alpha increases phosphorylation
multiple interactions		 ISO Cholic Acid results in increased phosphorylation of NFKBIA protein
Cholic Acid promotes the reaction [Diethylnitrosamine results in increased phosphorylation of NFKBIA protein]		 CTD PMID:27151938 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO Cholic Acid results in increased expression of NQO1 mRNA CTD PMID:25582706 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions
increases expression		 EXP
ISO		 [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR0B2 mRNA
Cholic Acid results in increased expression of NR0B2 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA]		 CTD PMID:12072388 PMID:14684380 PMID:15694933 PMID:16002565 PMID:16269825 More... NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions EXP [Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H3 protein CTD PMID:14684380 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 affects binding
decreases expression
increases phosphorylation
increases expression
multiple interactions
increases activity		 ISO
EXP		 Cholic Acid binds to NR1H4 protein
Cholic Acid results in decreased expression of NR1H4 mRNA
Cholic Acid results in increased phosphorylation of NR1H4 protein
Cholic Acid results in increased expression of NR1H4 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA; Cholic Acid binds to and results in increased activity of NR1H4 protein; Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein]; Cholic Acid results in increased phosphorylation of and results in increased activity of NR1H4 protein; NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA]; NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]; NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]
[[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; Cholic Acid analog binds to and results in increased activity of NR1H4 protein; Cholic Acid binds to and results in increased activity of NR1H4 protein
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H4 protein		 CTD PMID:13130122 PMID:14684380 PMID:15375181 PMID:15694933 PMID:19965603 More... NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression
increases activity		 ISO Cholic Acid results in increased expression of NR1I2 mRNA
Cholic Acid metabolite results in increased activity of NR1I2 protein; Cholic Acid results in increased activity of NR1I2 protein		 CTD PMID:25582706 PMID:27871908 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Orm1 orosomucoid 1 increases expression ISO Cholic Acid results in increased expression of ORM1 protein CTD PMID:20025956 NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154 		JBrowse link
G Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 increases expression ISO Cholic Acid results in increased expression of PAPSS2 mRNA CTD PMID:17521389 NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331 		JBrowse link
G Pcna proliferating cell nuclear antigen increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of PCNA protein
[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of PCNA protein		 CTD PMID:27151938 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5 increases expression ISO Cholic Acid results in increased expression of PIK3R5 protein CTD PMID:20025956 NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374 		JBrowse link
G Pon1 paraoxonase 1 decreases expression
multiple interactions		 ISO
EXP		 Cholic Acid results in decreased expression of PON1 mRNA; Cholic Acid results in decreased expression of PON1 protein
[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]		 CTD PMID:16269825 PMID:30273964 NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360 		JBrowse link
G Por cytochrome p450 oxidoreductase increases expression
decreases abundance		 ISO Cholic Acid results in increased expression of POR mRNA
POR gene mutant form results in decreased abundance of Cholic Acid		 CTD PMID:17521389 PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of Cholic Acid CTD PMID:29175453 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Rab7a RAB7A, member RAS oncogene family decreases expression ISO Cholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889 		JBrowse link
G Reg3b regenerating family member 3 beta decreases expression EXP Cholic Acid results in decreased expression of REG3B mRNA CTD PMID:35584729 NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015 		JBrowse link
G Reg3g regenerating family member 3 gamma decreases expression EXP Cholic Acid results in decreased expression of REG3G mRNA CTD PMID:35584729 NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Cholic Acid promotes the reaction [Diethylnitrosamine results in increased expression of RELA protein] CTD PMID:27151938 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rif1 replication timing regulatory factor 1 increases expression ISO Cholic Acid results in increased expression of RIF1 protein CTD PMID:20025956 NCBI chr 3:36,554,689...36,607,961
Ensembl chr 3:36,554,697...36,603,617 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA CTD PMID:22540009 PMID:30996006 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions
decreases expression		 ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA
Cholic Acid results in decreased expression of SLC10A1 mRNA; Cholic Acid results in decreased expression of SLC10A1 protein		 CTD PMID:11438506 PMID:16002565 PMID:17521389 PMID:22540009 PMID:25055961 More... NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 decreases expression
affects expression		 ISO
EXP		 Cholic Acid results in decreased expression of SLC10A2 mRNA
Cholic Acid affects the expression of SLC10A2 mRNA
Cholic Acid results in decreased expression of SLC10A2 protein		 CTD PMID:25582706 PMID:35584729 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Slc22a20 solute carrier family 22 member 20 increases expression ISO Cholic Acid results in increased expression of SLC22A20 mRNA CTD PMID:17521389 NCBI chr 1:203,257,374...203,273,854
Ensembl chr 1:203,257,374...203,273,822 		JBrowse link
G Slc27a5 solute carrier family 27 member 5 multiple interactions ISO Cholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Cholic Acid results in increased expression of SLC2A1 protein CTD PMID:20025956 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416 		JBrowse link
G Slc51a solute carrier family 51 member A increases expression ISO Cholic Acid results in increased expression of SLC51A mRNA CTD PMID:25055961 PMID:25582706 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions
increases expression		 ISO [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA
Cholic Acid results in increased expression of SLC51B mRNA		 CTD PMID:22540009 PMID:22961653 PMID:25055961 PMID:25582706 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression ISO Cholic Acid results in increased expression of SLCO1A4 mRNA CTD PMID:17521389 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 increases uptake
increases expression		 ISO SLCO1B2 protein results in increased uptake of Cholic Acid
Cholic Acid results in increased expression of SLCO1B3 mRNA
SLCO1B3 protein results in increased uptake of Cholic Acid
Cholic Acid results in increased expression of SLCO1B2 mRNA		 CTD PMID:16534140 PMID:20949553 PMID:25055961 PMID:25582706 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 multiple interactions
increases uptake		 ISO Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Cholic Acid] CTD PMID:24285294 NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353 		JBrowse link
G Sod3 superoxide dismutase 3 multiple interactions
increases expression		 ISO NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA] CTD PMID:25496033 NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990 		JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Cholic Acid results in increased expression of SQSTM1 protein CTD PMID:24189133 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein] CTD PMID:29968724 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Stmn1 stathmin 1 increases expression ISO Cholic Acid results in increased expression of STMN1 protein CTD PMID:20025956 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 increases sulfation
increases expression		 ISO SULT2A1 protein results in increased sulfation of Cholic Acid
Cholic Acid results in increased expression of SULT2A1 mRNA		 CTD PMID:17521389 PMID:20102295 PMID:22961653 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tfrc transferrin receptor increases expression ISO Cholic Acid results in increased expression of TFRC protein CTD PMID:20025956 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257 		JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions		 ISO Cholic Acid results in increased expression of TNF mRNA
Diethylnitrosamine promotes the reaction [Cholic Acid results in increased expression of TNF mRNA]		 CTD PMID:27151938 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Vdr vitamin D receptor increases localization ISO Cholic Acid results in increased localization of VDR protein CTD PMID:20371703 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Cholic Acid results in increased expression of VEGFA protein CTD PMID:20025956 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
deoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions
increases expression
decreases expression		 ISO
EXP		 SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of ABCB11 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA
Deoxycholic Acid results in increased expression of ABCB11 mRNA		 CTD PMID:14684751 PMID:21914718 PMID:25055961 PMID:27743861 PMID:32152650 More... NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression
multiple interactions		 ISO Deoxycholic Acid metabolite results in increased expression of ABCB1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA		 CTD PMID:27871908 PMID:33819548 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 affects expression
multiple interactions
increases expression		 ISO Deoxycholic Acid affects the expression of ABCB4 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA
Deoxycholic Acid results in increased expression of ABCB4 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCB4 mRNA]		 CTD PMID:21914718 PMID:25582706 PMID:33819548 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Deoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 PMID:33819548 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
affects expression		 ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC2 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA		 CTD PMID:21914718 PMID:33819548 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases activity
multiple interactions
decreases expression
increases expression
affects expression		 ISO Deoxycholic Acid results in increased activity of ABCC3 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA
Deoxycholic Acid results in decreased expression of ABCC3 mRNA
Deoxycholic Acid results in increased expression of ABCC3 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC3 mRNA]		 CTD PMID:17569508 PMID:21914718 PMID:25055961 PMID:25582706 PMID:32152650 More... NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA CTD PMID:33819548 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 multiple interactions
increases expression		 ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG5 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA		 CTD PMID:21914718 PMID:25055961 PMID:25582706 PMID:33819548 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 multiple interactions
increases expression		 ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG8 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA		 CTD PMID:21914718 PMID:25582706 PMID:33819548 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA CTD PMID:33819548 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA CTD PMID:33819548 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA CTD PMID:33819548 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Adh4 alcohol dehydrogenase 4 (class II), pi polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA CTD PMID:33819548 NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591 		JBrowse link
G Adh6 alcohol dehydrogenase 6 (class V) multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA CTD PMID:33819548 NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534 		JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing decreases expression ISO Deoxycholic Acid results in decreased expression of ADIPOQ mRNA CTD PMID:23911798 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
decreases abundance
increases secretion		 ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Deoxycholic Acid]
AHR gene mutant form results in decreased abundance of Deoxycholic Acid
AHR gene mutant form results in increased secretion of Deoxycholic Acid		 CTD PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA CTD PMID:33819548 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394 		JBrowse link
G Alb albumin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA CTD PMID:33819548 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ALDH1A2 mRNA CTD PMID:16556975 NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107 		JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA CTD PMID:33819548 NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA CTD PMID:33819548 NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887 		JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA CTD PMID:33819548 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Areg amphiregulin increases secretion ISO Deoxycholic Acid results in increased secretion of AREG protein CTD PMID:16213893 NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535 		JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ARNT2 mRNA CTD PMID:16556975 NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153 		JBrowse link
G Atf3 activating transcription factor 3 multiple interactions
increases expression		 ISO MTF1 protein affects the reaction [Deoxycholic Acid results in increased expression of ATF3 mRNA] CTD PMID:32661532 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Atp6v1f ATPase H+ transporting V1 subunit F multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ATP6V1F mRNA CTD PMID:16556975 NCBI chr 4:58,067,666...58,070,628 JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA CTD PMID:33819548 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA CTD PMID:33819548 NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685 		JBrowse link
G Bach1 BTB domain and CNC homolog 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA CTD PMID:33819548 NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 EXP Deoxycholic Acid results in increased expression of BAX mRNA; Deoxycholic Acid results in increased expression of BAX protein
[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein; TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX protein]		 CTD PMID:9562975 PMID:10510466 PMID:17431217 PMID:17881359 PMID:20137712 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases response to substance ISO BCL2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA CTD PMID:33819548 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bnip3 BCL2 interacting protein 3 affects response to substance ISO BNIP3 protein affects the susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA CTD PMID:33819548 NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969 		JBrowse link
G Casp3 caspase 3 affects response to substance
increases cleavage
increases activity
multiple interactions		 ISO
EXP		 CASP3 protein affects the susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased cleavage of CASP3 protein
Deoxycholic Acid results in increased activity of CASP3 protein
Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of CASP3 protein]; Deoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased activity of CASP3 protein]		 CTD PMID:12507930 PMID:16573382 PMID:17644113 PMID:19054763 PMID:20137712 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp6 caspase 6 multiple interactions
increases activity
affects response to substance		 ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP6 protein]
CASP6 protein affects the susceptibility to Deoxycholic Acid		 CTD PMID:12507930 PMID:17644113 NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
increases activity		 ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased activity of CASP9 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of CASP9 protein]; Deoxycholic Acid results in increased cleavage of and results in increased activity of CASP9 protein CTD PMID:17644113 PMID:19054763 PMID:21362092 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases expression ISO Deoxycholic Acid results in increased expression of CCL2 mRNA CTD PMID:21224055 PMID:23911798 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Deoxycholic Acid results in increased expression of CCL20 mRNA CTD PMID:21224055 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 increases expression ISO Deoxycholic Acid results in increased expression of CCL5 mRNA CTD PMID:21224055 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Ccl7 C-C motif chemokine ligand 7 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of CCL7 mRNA
EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CCL7 mRNA]		 CTD PMID:21224055 NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression		 EXP [Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein; TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]; ursodoxicoltaurine inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]
Deoxycholic Acid results in increased expression of CCND1 mRNA; Deoxycholic Acid results in increased expression of CCND1 protein		 CTD PMID:17431217 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100 		JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of and results in decreased localization of CDH1 protein; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein] CTD PMID:22223758 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of CEBPB
NRAS affects the reaction [Deoxycholic Acid results in increased expression of CEBPB]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CEBPB]		 CTD PMID:18444174 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473 		JBrowse link
G Ces1d carboxylesterase 1D decreases expression ISO Deoxycholic Acid results in decreased expression of CES1D mRNA CTD PMID:23911798 NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035 		JBrowse link
G Chi3l1 chitinase 3 like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA CTD PMID:33819548 NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787 		JBrowse link
G Crot carnitine O-octanoyltransferase decreases expression ISO Deoxycholic Acid results in decreased expression of CROT mRNA CTD PMID:27089845 NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109 		JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704 		JBrowse link
G Csf1r colony stimulating factor 1 receptor multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of CSF1R mRNA CTD PMID:16556975 NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199 		JBrowse link
G Csf3 colony stimulating factor 3 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF3 mRNA] CTD PMID:21224055 NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA CTD PMID:33819548 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cttn cortactin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA CTD PMID:33819548 NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO Deoxycholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 increases expression ISO Deoxycholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of CXCL2 mRNA; Deoxycholic Acid results in increased expression of CXCL2 protein
EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 protein]		 CTD PMID:21224055 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of CXCL1 mRNA
EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CXCL1 mRNA]		 CTD PMID:21224055 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA CTD PMID:33819548 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA CTD PMID:33819548 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions
decreases expression		 ISO
EXP		 SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP27A1 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA		 CTD PMID:7832767 PMID:21914718 PMID:25582706 PMID:33819548 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Deoxycholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2B1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2B1 protein] CTD PMID:10453939 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases expression
multiple interactions		 ISO Deoxycholic Acid metabolite results in increased expression of CYP2B6 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA		 CTD PMID:27871908 PMID:32152650 PMID:33819548 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases expression
multiple interactions
decreases activity		 EXP
ISO		 Deoxycholic Acid results in decreased expression of CYP2C11 protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA
Deoxycholic Acid results in decreased activity of CYP2C11 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C11 protein]		 CTD PMID:8889968 PMID:10453939 PMID:33819548 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 decreases expression
multiple interactions		 EXP
ISO		 Deoxycholic Acid results in decreased expression of CYP2C6V1 protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C6V1 protein]		 CTD PMID:10453939 PMID:33819548 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2E1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2E1 protein] CTD PMID:10453939 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
increases hydroxylation
increases expression
affects metabolic processing
decreases activity
decreases expression		 EXP
ISO		 [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Deoxycholic Acid; Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP3A2 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP3A2 protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP3A2 mRNA]
CYP3A4 protein results in increased hydroxylation of Deoxycholic Acid
Deoxycholic Acid metabolite results in increased expression of CYP3A4 mRNA
CYP3A4 protein affects the metabolism of Deoxycholic Acid
Deoxycholic Acid metabolite results in decreased activity of CYP3A4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA
Deoxycholic Acid results in decreased activity of CYP3A2 protein		 CTD PMID:8889968 PMID:10453939 PMID:15708356 PMID:27871908 PMID:32152650 More... NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Deoxycholic Acid CTD PMID:34461081 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cyp4a1 cytochrome P450, family 4, subfamily a, polypeptide 1 decreases expression
multiple interactions		 EXP Deoxycholic Acid results in decreased expression of CYP4A1 protein
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP4A1 protein]		 CTD PMID:10453939 NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464 		JBrowse link
G Cyp4a8 cytochrome P450, family 4, subfamily a, polypeptide 8 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of CYP4A8 mRNA CTD PMID:16556975 NCBI chr 5:128,702,130...128,733,476
Ensembl chr 5:128,702,131...128,733,476 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases activity
multiple interactions
decreases expression		 EXP
ISO		 Deoxycholic Acid results in decreased activity of CYP7A1 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA
Deoxycholic Acid results in decreased expression of CYP7A1 mRNA
[Deoxycholic Acid results in increased activity of NR1H4 protein] which results in increased expression of CYP7A1 mRNA; SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP7A1 mRNA]		 CTD PMID:1175606 PMID:14684751 PMID:20671298 PMID:21914718 PMID:22531947 More... NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions
decreases expression		 ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP7B1 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA		 CTD PMID:21914718 PMID:25582706 PMID:33819548 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 multiple interactions
decreases expression		 ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of CYP8B1 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA		 CTD PMID:21914718 PMID:25055961 PMID:25582706 PMID:33819548 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407 		JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063 		JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988 		JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719 		JBrowse link
G Dnajc12 DnaJ heat shock protein family (Hsp40) member C12 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA CTD PMID:33819548 NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521 		JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136 		JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344 		JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:116,923,272...116,945,312
Ensembl chr 2:116,923,272...116,945,264 		JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:59,419,507...59,446,746
Ensembl chr 2:59,419,510...59,446,752 		JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448 		JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118 		JBrowse link
G Egfr epidermal growth factor receptor increases activity
multiple interactions
decreases response to substance
increases phosphorylation		 ISO
EXP		 Deoxycholic Acid results in increased activity of EGFR protein
Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein]
EGFR protein results in decreased susceptibility to Deoxycholic Acid		 CTD PMID:12507930 PMID:14747693 PMID:16213893 PMID:22223758 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CSF3 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of SERPINE1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 protein]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 mRNA]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased expression of EGR1 protein]
Deoxycholic Acid results in increased expression of EGR1 mRNA; Deoxycholic Acid results in increased expression of EGR1 protein		 CTD PMID:19931294 PMID:21224055 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Ehhadh enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase decreases expression ISO Deoxycholic Acid results in decreased expression of EHHADH mRNA CTD PMID:27089845 NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of EIF2AK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA CTD PMID:33819548 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713 		JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235 		JBrowse link
G Fabp6 fatty acid binding protein 6 increases expression ISO Deoxycholic Acid results in increased expression of FABP6
Deoxycholic Acid results in increased expression of FABP6 mRNA		 CTD PMID:22268002 PMID:25582706 NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282 		JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression		 ISO [[Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
Deoxycholic Acid results in increased expression of FGF15 mRNA
Deoxycholic Acid results in increased expression of FGF19; Deoxycholic Acid results in increased expression of FGF19 mRNA		 CTD PMID:22268002 PMID:22561792 PMID:25055961 PMID:25582706 NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA CTD PMID:33819548 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA CTD PMID:17724089 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA CTD PMID:17724089 PMID:33819548 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GGT1 mRNA CTD PMID:33819548 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442 		JBrowse link
G Gjb1 gap junction protein, beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB1 mRNA CTD PMID:33819548 NCBI chr  X:66,501,848...66,509,783
Ensembl chr  X:66,501,820...66,509,925 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA CTD PMID:33819548 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177 		JBrowse link
G Gk glycerol kinase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GK mRNA CTD PMID:33819548 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 multiple interactions
increases expression
affects binding
increases response to substance		 ISO Deoxycholic Acid binds to and results in increased activity of GPBAR1 protein
Deoxycholic Acid results in increased expression of GPBAR1 mRNA
Deoxycholic Acid binds to GPBAR1 protein
GPBAR1 protein results in increased susceptibility to Deoxycholic Acid		 CTD PMID:23041323 PMID:23566200 PMID:25055961 NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168 		JBrowse link
G Gprc5b G protein-coupled receptor, class C, group 5, member B multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA CTD PMID:33819548 NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932 		JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of GRK2 mRNA CTD PMID:16556975 NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA CTD PMID:33819548 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 affects binding
increases response to substance
multiple interactions		 ISO Deoxycholic Acid binds to GSTP1 protein
GSTP1 protein results in increased susceptibility to Deoxycholic Acid
gamma-Glu-S-BzCys-PhGly diethyl ester inhibits the reaction [GSTP1 protein results in increased susceptibility to Deoxycholic Acid]		 CTD PMID:15300575 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226 		JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTT1 mRNA CTD PMID:33819548 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585 		JBrowse link
G Guca1a guanylate cyclase activator 1A decreases response to substance ISO GUCA1A protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 9:13,588,988...13,598,566
Ensembl chr 9:13,588,525...13,598,565 		JBrowse link
G Hacl1 2-hydroxyacyl-CoA lyase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HGF mRNA; Deoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 PMID:33819548 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HMGCR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HMGCR mRNA CTD PMID:33819548 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmox1 heme oxygenase 1 decreases response to substance
increases expression
multiple interactions		 ISO HMOX1 protein results in decreased susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased expression of HMOX1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA; MTF1 protein affects the reaction [Deoxycholic Acid results in increased expression of HMOX1 mRNA]		 CTD PMID:21362092 PMID:32152650 PMID:32661532 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hoxa1 homeobox A1 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of HOXA1 mRNA CTD PMID:16556975 NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504 		JBrowse link
G Hpx hemopexin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HPX mRNA CTD PMID:33819548 NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328 		JBrowse link
G Hras HRas proto-oncogene, GTPase increases activity ISO Deoxycholic Acid results in increased activity of HRAS protein CTD PMID:18444174 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of Deoxycholic Acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HSD3B7 mRNA CTD PMID:33819548 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 decreases response to substance
multiple interactions		 ISO HSPA5 protein results in decreased susceptibility to Deoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA		 CTD PMID:12507930 PMID:32152650 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185 		JBrowse link
G Htra1 HtrA serine peptidase 1 affects response to substance ISO HTRA1 protein affects the susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379 		JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of ICAM1 mRNA; Deoxycholic Acid results in increased expression of ICAM1 protein
EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Deoxycholic Acid results in increased expression of ICAM1 protein]		 CTD PMID:16582018 PMID:21224055 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IER3 mRNA CTD PMID:33819548 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583 		JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of IFI27 mRNA CTD PMID:33819548 NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294 		JBrowse link
G Ifng interferon gamma multiple interactions EXP Deoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] CTD PMID:12620498 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 decreases expression
multiple interactions		 ISO Deoxycholic Acid results in decreased expression of IGFBP1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IGFBP1 mRNA		 CTD PMID:27089845 PMID:33819548 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il10 interleukin 10 increases expression
decreases abundance
multiple interactions		 ISO Deoxycholic Acid results in increased expression of IL10 mRNA
IL10 gene mutant form results in decreased abundance of Deoxycholic Acid
Deoxycholic Acid promotes the reaction [irinotecan results in decreased secretion of IL10 protein]		 CTD PMID:23911798 PMID:26706406 PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta increases expression ISO Deoxycholic Acid results in increased expression of IL1B mRNA CTD PMID:23911798 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of IL1R1 mRNA CTD PMID:33819548 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of IL6 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IL6 mRNA		 CTD PMID:23911798 PMID:33819548 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Kcnc1 potassium voltage-gated channel subfamily C member 1 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of KCNC1 mRNA CTD PMID:16556975 NCBI chr 1:96,902,953...96,944,744
Ensembl chr 1:96,902,953...96,944,744 		JBrowse link
G Klf4 KLF transcription factor 4 increases expression ISO Deoxycholic Acid results in increased expression of KLF4 mRNA CTD PMID:27151938 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602 		JBrowse link
G Kynu kynureninase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of KYNU mRNA CTD PMID:33819548 NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488 		JBrowse link
G Lbp lipopolysaccharide binding protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LBP mRNA CTD PMID:33819548 NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LDLR mRNA CTD PMID:33819548 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lep leptin decreases expression ISO Deoxycholic Acid results in decreased expression of LEP mRNA CTD PMID:23911798 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262 		JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LIPC mRNA CTD PMID:33819548 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Lipe lipase E, hormone sensitive type decreases expression ISO Deoxycholic Acid results in decreased expression of LIPE mRNA CTD PMID:23911798 NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310 		JBrowse link
G Lmna lamin A/C increases cleavage
multiple interactions		 ISO Deoxycholic Acid results in increased cleavage of LMNA protein
Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of LMNA protein]		 CTD PMID:17644113 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423 		JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of LPL mRNA CTD PMID:16556975 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249 		JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA CTD PMID:33819548 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP3K5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA CTD PMID:33819548 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation		 ISO Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK1 protein]
SL 327 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK1 protein]		 CTD PMID:14747693 PMID:19931294 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK3 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK3 protein]
SL 327 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of MAPK3 protein]		 CTD PMID:14747693 PMID:19931294 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568 		JBrowse link
G Mdh1 malate dehydrogenase 1 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of MDH1 mRNA CTD PMID:16556975 NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925 		JBrowse link
G Mdh2 malate dehydrogenase 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of MDH2 mRNA CTD PMID:16556975 NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA CTD PMID:33819548 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502 		JBrowse link
G Mmut methylmalonyl-CoA mutase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MMUT mRNA CTD PMID:33819548 NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046 		JBrowse link
G Mt2A metallothionein 2A increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of MT2A mRNA
MTF1 protein affects the reaction [Deoxycholic Acid results in increased expression of MT2A mRNA]		 CTD PMID:32661532 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Mtf1 metal-regulatory transcription factor 1 multiple interactions ISO MTF1 protein affects the reaction [Deoxycholic Acid results in increased expression of ATF3 mRNA]; MTF1 protein affects the reaction [Deoxycholic Acid results in increased expression of HMOX1 mRNA]; MTF1 protein affects the reaction [Deoxycholic Acid results in increased expression of MT1M mRNA]; MTF1 protein affects the reaction [Deoxycholic Acid results in increased expression of MT2A mRNA] CTD PMID:32661532 NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136 		JBrowse link
G Mttp microsomal triglyceride transfer protein decreases expression
multiple interactions		 ISO Deoxycholic Acid results in decreased expression of MTTP mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MTTP mRNA		 CTD PMID:27089845 PMID:33819548 NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239 		JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 decreases response to substance ISO NAIP protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542 		JBrowse link
G Nanog Nanog homeobox increases expression ISO Deoxycholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116 		JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Deoxycholic Acid metabolite promotes the reaction [NR1I2 protein binds to NCOA1 protein] CTD PMID:27871908 NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases expression		 ISO [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Deoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA
Deoxycholic Acid results in increased expression of NFE2L2 mRNA		 CTD PMID:17724089 PMID:25582706 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases response to substance ISO NFKB1 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
increases phosphorylation		 ISO benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein]; lactacystin promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein] CTD PMID:17644113 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nfxl1 nuclear transcription factor, X-box binding-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NFXL1 mRNA CTD PMID:33819548 NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of NQO1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA		 CTD PMID:25582706 PMID:32152650 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 increases expression
multiple interactions		 ISO
EXP		 Deoxycholic Acid results in increased expression of NR0B2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NR0B2 mRNA		 CTD PMID:22540009 PMID:25055961 PMID:25582706 PMID:27743861 PMID:33819548 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1d2 nuclear receptor subfamily 1, group D, member 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of NR1D2 mRNA CTD PMID:16556975 NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NR1H2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NR1H2 mRNA CTD PMID:33819548 NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of NR1H3 mRNA CTD PMID:33819548 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions
decreases expression
increases expression		 ISO
EXP		 Deoxycholic Acid results in increased activity of NR1H4 protein
[Cholic Acids co-treated with Deoxycholic Acid] results in decreased expression of NR1H4 mRNA
Deoxycholic Acid results in decreased expression of NR1H4 mRNA
[[Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; Deoxycholic Acid analog binds to and results in increased activity of NR1H4 protein; Deoxycholic Acid binds to and results in increased activity of NR1H4 protein; Deoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]
Deoxycholic Acid results in increased expression of NR1H4 mRNA; Deoxycholic Acid results in increased expression of NR1H4 protein
[Deoxycholic Acid results in increased activity of NR1H4 protein] which results in increased expression of CYP7A1 mRNA		 CTD PMID:13130122 PMID:14684751 PMID:17567710 PMID:22531947 PMID:22561792 More... NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression
increases activity
multiple interactions		 ISO Deoxycholic Acid results in increased expression of NR1I2 mRNA
Deoxycholic Acid results in increased activity of NR1I2 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA; Deoxycholic Acid metabolite binds to and results in increased activity of NR1I2 protein; Deoxycholic Acid metabolite promotes the reaction [NR1I2 protein binds to NCOA1 protein]		 CTD PMID:25582706 PMID:27871908 PMID:32152650 PMID:33819548 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of NR1I3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA		 CTD PMID:16929008 PMID:32152650 PMID:33819548 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Nras NRAS proto-oncogene, GTPase multiple interactions ISO NRAS affects the reaction [Deoxycholic Acid results in increased expression of CEBPB]; NRAS affects the reaction [Deoxycholic Acid results in increased expression of PTGS2] CTD PMID:18444174 NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626 		JBrowse link
G Pah phenylalanine hydroxylase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PAH mRNA CTD PMID:33819548 NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130 		JBrowse link
G Pak1 p21 (RAC1) activated kinase 1 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PAK1 mRNA CTD PMID:16556975 NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PARP1 protein]; cobaltiprotoporphyrin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PARP1 protein] CTD PMID:17644113 PMID:21362092 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pgap2 post-GPI attachment to proteins 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PGAP2 mRNA CTD PMID:16556975 NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114 		JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of PIK3C2A mRNA CTD PMID:33819548 NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472 		JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612 		JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544 		JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PIK3R3 mRNA CTD PMID:33819548 NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583 		JBrowse link
G Pip5k1c phosphatidylinositol-4-phosphate 5-kinase type 1 gamma decreases response to substance ISO PIP5K1C protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 7:8,397,406...8,426,030
Ensembl chr 7:8,397,406...8,425,988 		JBrowse link
G Plaur plasminogen activator, urokinase receptor increases expression ISO Deoxycholic Acid results in increased expression of PLAUR mRNA CTD PMID:21224055 NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595 		JBrowse link
G Plin1 perilipin 1 decreases expression ISO Deoxycholic Acid results in decreased expression of PLIN1 mRNA CTD PMID:23911798 NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828 		JBrowse link
G Pnpla2 patatin-like phospholipase domain containing 2 decreases expression ISO Deoxycholic Acid results in decreased expression of PNPLA2 mRNA CTD PMID:23911798 NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805 		JBrowse link
G Por cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Deoxycholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO Deoxycholic Acid results in increased expression of POU5F1 mRNA CTD PMID:27151938 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance
multiple interactions		 ISO PPARA gene mutant form results in decreased abundance of Deoxycholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPARA mRNA		 CTD PMID:29175453 PMID:33819548 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression ISO Deoxycholic Acid results in decreased expression of PPARG mRNA CTD PMID:23911798 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA CTD PMID:33819548 NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961 		JBrowse link
G Prdx2 peroxiredoxin 2 decreases response to substance ISO PRDX2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194 		JBrowse link
G Prdx4 peroxiredoxin 4 decreases response to substance ISO PRDX4 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr  X:40,026,762...40,044,066
Ensembl chr  X:40,026,651...40,044,066 		JBrowse link
G Prkab1 protein kinase AMP-activated non-catalytic subunit beta 1 decreases response to substance ISO PRKAB1 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661 		JBrowse link
G Prkar1a protein kinase cAMP-dependent type I regulatory subunit alpha multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PRKAR1A mRNA CTD PMID:16556975 NCBI chr10:94,621,042...94,639,534
Ensembl chr10:94,620,039...94,639,041 		JBrowse link
G Prkca protein kinase C, alpha multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PRKCA mRNA CTD PMID:16556975 NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012 		JBrowse link
G Prkcb protein kinase C, beta multiple interactions
increases activity
increases expression		 ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]; lactacystin inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein]
Deoxycholic Acid results in increased activity of PRKCB protein		 CTD PMID:7705931 PMID:17644113 NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536 		JBrowse link
G Prkce protein kinase C, epsilon multiple interactions
increases cleavage		 ISO Aspirin inhibits the reaction [Deoxycholic Acid results in increased cleavage of PRKCE protein] CTD PMID:17644113 NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719 		JBrowse link
G Prkcz protein kinase C, zeta decreases response to substance ISO PRKCZ protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367 		JBrowse link
G Prkd3 protein kinase D3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PRKD3 mRNA CTD PMID:33819548 NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443 		JBrowse link
G Ptges prostaglandin E synthase multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PTGES mRNA CTD PMID:16556975 NCBI chr 3:14,177,892...14,189,236 JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of PTGS2; Deoxycholic Acid results in increased expression of PTGS2 mRNA
[SLCO1B3 protein results in increased transport of Deoxycholic Acid] which results in increased expression of PTGS2 mRNA; NRAS affects the reaction [Deoxycholic Acid results in increased expression of PTGS2]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of PTGS2]		 CTD PMID:18444174 PMID:18648741 PMID:21224055 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Ptpn2 protein tyrosine phosphatase, non-receptor type 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of PTPN2 mRNA CTD PMID:16556975 NCBI chr18:61,229,012...61,294,662
Ensembl chr18:61,229,014...61,294,627 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO Deoxycholic Acid results in increased phosphorylation of and results in increased activity of RAF1 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of RAF1 protein] CTD PMID:14747693 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317 		JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501 		JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions EXP
ISO		 [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of RARA mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RARA mRNA		 CTD PMID:16556975 PMID:33819548 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142 		JBrowse link
G Rasd1 ras related dexamethasone induced 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA CTD PMID:33819548 NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA CTD PMID:33819548 NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124 		JBrowse link
G Reep5 receptor accessory protein 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of REEP5 mRNA CTD PMID:33819548 NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit decreases response to substance
increases localization
increases expression
multiple interactions		 ISO RELA protein results in decreased susceptibility to Deoxycholic Acid
Deoxycholic Acid results in increased localization of RELA protein
Deoxycholic Acid results in increased expression of RELA protein
benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]; lactacystin inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]		 CTD PMID:12507930 PMID:17644113 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Retn resistin decreases expression ISO Deoxycholic Acid results in decreased expression of RETN mRNA CTD PMID:23911798 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620 		JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824 		JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111 		JBrowse link
G Rxrg retinoid X receptor gamma multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of RXRG mRNA CTD PMID:16556975 NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 increases expression
multiple interactions		 ISO Deoxycholic Acid results in increased expression of SCARB1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA		 CTD PMID:22540009 PMID:32152650 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCD mRNA CTD PMID:33819548 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Scp2 sterol carrier protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCP2 mRNA CTD PMID:33819548 NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287 		JBrowse link
G Sdc2 syndecan 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SDC2 mRNA CTD PMID:33819548 NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081 		JBrowse link
G Sele selectin E increases expression ISO Deoxycholic Acid results in increased expression of SELE mRNA CTD PMID:16582018 NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741 		JBrowse link
G Sema6c semaphorin 6C multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SEMA6C mRNA CTD PMID:16556975 NCBI chr 2:182,733,635...182,750,066
Ensembl chr 2:182,737,474...182,746,856 		JBrowse link
G Serpinb5 serpin family B member 5 decreases response to substance ISO SERPINB5 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Deoxycholic Acid results in increased expression of SERPINE1 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA		 CTD PMID:21224055 PMID:32152650 PMID:33819548 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784 		JBrowse link
G Sirpa signal-regulatory protein alpha multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SIRPA mRNA CTD PMID:16556975 NCBI chr 3:116,819,730...116,858,099
Ensembl chr 3:116,819,726...116,858,098 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 increases expression
multiple interactions
decreases expression		 ISO
EXP		 Deoxycholic Acid results in increased expression of SLC10A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
[Cholic Acids co-treated with Deoxycholic Acid] results in decreased expression of SLC10A1 mRNA
Deoxycholic Acid results in decreased expression of SLC10A1 mRNA		 CTD PMID:21914718 PMID:25582706 PMID:28391356 PMID:32152650 PMID:33819548 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a7 solute carrier family 10, member 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC10A7 mRNA CTD PMID:33819548 NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464 		JBrowse link
G Slc12a2 solute carrier family 12 member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA CTD PMID:33819548 NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440 		JBrowse link
G Slc15a2 solute carrier family 15 member 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SLC15A2 mRNA CTD PMID:16556975 NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225 		JBrowse link
G Slc17a1 solute carrier family 17 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA CTD PMID:33819548 NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 decreases expression
multiple interactions		 ISO Deoxycholic Acid results in decreased expression of SLC22A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC22A1 mRNA		 CTD PMID:21914718 PMID:33819548 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc22a7 solute carrier family 22 member 7 affects expression
multiple interactions		 ISO Deoxycholic Acid affects the expression of SLC22A7 mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of SLC22A7 mRNA]		 CTD PMID:21914718 NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921 		JBrowse link
G Slc22a8 solute carrier family 22 member 8 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SLC22A8 mRNA CTD PMID:16556975 NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450 		JBrowse link
G Slc27a2 solute carrier family 27 member 2 multiple interactions ISO Deoxycholic Acid inhibits the reaction [SLC27A2 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208 		JBrowse link
G Slc27a5 solute carrier family 27 member 5 multiple interactions ISO Deoxycholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172 		JBrowse link
G Slc35b1 solute carrier family 35, member B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC35B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC35B1 mRNA CTD PMID:33819548 NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274 		JBrowse link
G Slc51a solute carrier family 51 member A decreases expression
multiple interactions
increases expression		 ISO Deoxycholic Acid results in decreased expression of SLC51A mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA
Deoxycholic Acid results in increased expression of SLC51A mRNA
Deoxycholic Acid results in increased expression of SLC51A; Deoxycholic Acid results in increased expression of SLC51A mRNA
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of SLC51A mRNA]		 CTD PMID:21914718 PMID:22268002 PMID:25055961 PMID:25582706 PMID:32152650 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions
increases expression		 ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of SLC51B mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA
Deoxycholic Acid results in increased expression of SLC51B; Deoxycholic Acid results in increased expression of SLC51B mRNA		 CTD PMID:21914718 PMID:22268002 PMID:25055961 PMID:25582706 PMID:32152650 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 multiple interactions
increases expression		 ISO SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of SLCO1A4 mRNA] CTD PMID:21914718 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 affects expression
increases expression
increases transport
multiple interactions
increases uptake		 ISO Deoxycholic Acid affects the expression of SLCO1B2 mRNA
Deoxycholic Acid results in increased expression of SLCO1B3 mRNA
SLCO1B3 protein results in increased transport of Deoxycholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLCO1B3 mRNA; [SLCO1B3 protein results in increased transport of Deoxycholic Acid] which results in increased expression of PTGS2 mRNA
SLCO1B3 protein results in increased uptake of Deoxycholic Acid		 CTD PMID:16534140 PMID:18648741 PMID:25055961 PMID:25582706 PMID:33819548 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666 PMID:32152650 PMID:33819548 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sorl1 sortilin related receptor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA CTD PMID:33819548 NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513 		JBrowse link
G Sox2 SRY-box transcription factor 2 increases expression ISO Deoxycholic Acid results in increased expression of SOX2 mRNA CTD PMID:27151938 NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA CTD PMID:33819548 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Srp72 signal recognition particle 72 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SRP72 mRNA CTD PMID:33819548 NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729 		JBrowse link
G Sstr3 somatostatin receptor 3 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of SSTR3 mRNA CTD PMID:16556975 NCBI chr 7:110,092,563...110,109,043
Ensembl chr 7:110,092,575...110,099,769 		JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476 		JBrowse link
G Stk11 serine/threonine kinase 11 increases phosphorylation EXP Deoxycholic Acid results in increased phosphorylation of STK11 protein CTD PMID:27743861 NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TFPI mRNA CTD PMID:33819548 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880 		JBrowse link
G Tjp2 tight junction protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TJP2 mRNA CTD PMID:33819548 NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295 		JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TLR3 mRNA CTD PMID:33819548 NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA CTD PMID:33819548 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases secretion
increases expression
decreases expression		 ISO Deoxycholic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Deoxycholic Acid results in increased secretion of TNF protein
Deoxycholic Acid results in increased expression of TNF mRNA
[Deoxycholic Acid results in increased secretion of TNF protein] which results in increased susceptibility to Acetaminophen
Deoxycholic Acid results in decreased expression of TNF mRNA		 CTD PMID:23566200 PMID:23627780 PMID:33662127 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFRSF10A mRNA CTD PMID:33819548 NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TNFRSF9 mRNA CTD PMID:33819548 NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA CTD PMID:33819548 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA CTD PMID:33819548 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Tp53 tumor protein p53 increases expression
multiple interactions		 EXP Deoxycholic Acid results in increased expression of TP53 mRNA
TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of TP53 mRNA]		 CTD PMID:17431217 PMID:20137712 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Traf2 Tnf receptor-associated factor 2 decreases response to substance ISO TRAF2 protein results in decreased susceptibility to Deoxycholic Acid CTD PMID:12507930 NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538 		JBrowse link
G Uba5 ubiquitin-like modifier activating enzyme 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBA5 mRNA CTD PMID:33819548 NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894 		JBrowse link
G Ube2i ubiquitin-conjugating enzyme E2I multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of UBE2I mRNA CTD PMID:16556975 NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443
Ensembl chr10:69,701,618...69,702,443 		JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:42,658,016...42,718,899
Ensembl chr14:42,658,016...42,718,630 		JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of UGP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of UGP2 mRNA CTD PMID:33819548 NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT1A1 mRNA CTD PMID:33819548 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519 		JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of VAMP2 mRNA CTD PMID:16556975 NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809 		JBrowse link
G Vax2 ventral anterior homeobox 2 multiple interactions EXP [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of VAX2 mRNA CTD PMID:16556975 NCBI chr 4:116,195,528...116,219,597
Ensembl chr 4:116,195,528...116,219,594 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression ISO Deoxycholic Acid results in increased expression of VCAM1 mRNA
Deoxycholic Acid results in increased expression of VCAM1 mRNA; Deoxycholic Acid results in increased expression of VCAM1 protein		 CTD PMID:16582018 PMID:21224055 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571 		JBrowse link
glycochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA CTD PMID:33819548 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA CTD PMID:33819548 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA CTD PMID:33819548 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA CTD PMID:33819548 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA CTD PMID:33819548 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA CTD PMID:33819548 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA CTD PMID:33819548 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA CTD PMID:33819548 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA CTD PMID:33819548 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA CTD PMID:33819548 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Adh4 alcohol dehydrogenase 4 (class II), pi polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA CTD PMID:33819548 NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591 		JBrowse link
G Adh6 alcohol dehydrogenase 6 (class V) multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA CTD PMID:33819548 NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534 		JBrowse link
G Agt angiotensinogen multiple interactions
decreases response to substance		 EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]] CTD PMID:23300732 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977 		JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid] CTD PMID:23300732 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA CTD PMID:33819548 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394 		JBrowse link
G Alb albumin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA CTD PMID:33819548 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA CTD PMID:33819548 NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA CTD PMID:33819548 NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887 		JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA CTD PMID:33819548 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Atg5 autophagy related 5 multiple interactions
decreases expression		 ISO TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]
Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA; Glycochenodeoxycholic Acid results in decreased expression of ATG5 protein		 CTD PMID:32439580 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Atp6v0d1 ATPase H+ transporting V0 subunit D1 decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of ATP6V0D1 mRNA CTD PMID:32439580 NCBI chr19:33,403,352...33,447,357
Ensembl chr19:33,403,355...33,447,450 		JBrowse link
G Atp6v1e1 ATPase H+ transporting V1 subunit E1 decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of ATP6V1E1 mRNA CTD PMID:32439580 NCBI chr 4:154,022,358...154,044,486
Ensembl chr 4:154,022,358...154,044,584 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA CTD PMID:33819548 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA CTD PMID:33819548 NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685 		JBrowse link
G Bach1 BTB domain and CNC homolog 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA CTD PMID:33819548 NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447 		JBrowse link
G Bcl2a1 BCL2-related protein A1 increases expression EXP Glycochenodeoxycholic Acid results in increased expression of BCL2A1 mRNA CTD PMID:15767249 NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA CTD PMID:33819548 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bcl2l13 Bcl2-like 13 decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of BCL2L13 protein CTD PMID:32439580 NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985 		JBrowse link
G Becn1 beclin 1 multiple interactions
decreases expression		 ISO TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]
Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA; Glycochenodeoxycholic Acid results in decreased expression of BECN1 protein		 CTD PMID:32439580 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression EXP Glycochenodeoxycholic Acid results in increased expression of BIRC5 mRNA CTD PMID:15767249 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA CTD PMID:33819548 NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
increases activity		 ISO
EXP		 Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Egtazic Acid promotes the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Nitric Oxide inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; 7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]		 CTD PMID:12873810 PMID:15767249 PMID:16322111 PMID:19837105 PMID:20020783 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 increases activity
increases cleavage		 EXP
ISO		 Glycochenodeoxycholic Acid results in increased activity of CASP8 protein
Glycochenodeoxycholic Acid results in increased cleavage of CASP8 protein		 CTD PMID:12873810 PMID:15767249 PMID:25125499 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions		 EXP
ISO		 Glycochenodeoxycholic Acid results in increased activity of CASP9 protein
Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP9 protein]		 CTD PMID:15767249 PMID:16322111 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions
increases expression		 ISO Glycochenodeoxycholic Acid results in decreased expression of and results in increased phosphorylation of CFLAR protein
Glycochenodeoxycholic Acid results in increased expression of CFLAR protein
Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein]		 CTD PMID:25125499 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Chi3l1 chitinase 3 like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA CTD PMID:33819548 NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787 		JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA CTD PMID:33819548 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cttn cortactin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA CTD PMID:33819548 NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164 		JBrowse link
G Cycs cytochrome c, somatic affects localization EXP Glycochenodeoxycholic Acid affects the localization of CYCS protein CTD PMID:15767249 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA CTD PMID:33819548 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA CTD PMID:33819548 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA CTD PMID:33819548 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA CTD PMID:33819548 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA CTD PMID:33819548 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
increases hydroxylation		 ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA
CYP3A4 protein results in increased hydroxylation of Glycochenodeoxycholic Acid		 CTD PMID:32152650 PMID:33819548 PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA CTD PMID:33819548 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA CTD PMID:33819548 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression		 EXP
ISO		 7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA		 CTD PMID:23300732 PMID:32152650 PMID:34979142 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407 		JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063 		JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988 		JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719 		JBrowse link
G Dnajc12 DnaJ heat shock protein family (Hsp40) member C12 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA CTD PMID:33819548 NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521 		JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136 		JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344 		JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:116,923,272...116,945,312
Ensembl chr 2:116,923,272...116,945,264 		JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:59,419,507...59,446,746
Ensembl chr 2:59,419,510...59,446,752 		JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448 		JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of EIF2AK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA CTD PMID:33819548 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713 		JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA CTD PMID:33819548 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA CTD PMID:33819548 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GGT1 mRNA CTD PMID:33819548 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442 		JBrowse link
G Gjb1 gap junction protein, beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB1 mRNA CTD PMID:33819548 NCBI chr  X:66,501,848...66,509,783
Ensembl chr  X:66,501,820...66,509,925 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA CTD PMID:33819548 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177 		JBrowse link
G Gk glycerol kinase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GK mRNA CTD PMID:33819548 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Gprc5b G protein-coupled receptor, class C, group 5, member B multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA CTD PMID:33819548 NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932 		JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions EXP
ISO		 Glycochenodeoxycholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Glycochenodeoxycholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA		 CTD PMID:3783048 PMID:32152650 PMID:33819548 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta3 glutathione S-transferase alpha 3 multiple interactions EXP Glycochenodeoxycholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein] CTD PMID:3783048 NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA CTD PMID:33819548 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323 		JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTT1 mRNA CTD PMID:33819548 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585 		JBrowse link
G Hacl1 2-hydroxyacyl-CoA lyase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HGF mRNA; Glycochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 PMID:33819548 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HMGCR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HMGCR mRNA CTD PMID:33819548 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hpx hemopexin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HPX mRNA CTD PMID:33819548 NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of Glycochenodeoxycholic Acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HSD3B7 mRNA CTD PMID:33819548 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO
EXP		 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA
[Glycochenodeoxycholic Acid co-treated with Scopoletin] results in increased expression of HSPA5 mRNA		 CTD PMID:32152650 PMID:34979142 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185 		JBrowse link
G Huwe1 HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1 multiple interactions ISO Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein] CTD PMID:21507240 NCBI chr  X:20,873,795...21,001,378
Ensembl chr  X:20,873,795...21,001,262 		JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IER3 mRNA CTD PMID:33819548 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583 		JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of IFI27 mRNA CTD PMID:33819548 NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IGFBP1 mRNA CTD PMID:33819548 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of IL1R1 mRNA CTD PMID:33819548 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IL6 mRNA CTD PMID:33819548 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Kynu kynureninase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of KYNU mRNA CTD PMID:33819548 NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488 		JBrowse link
G Lbp lipopolysaccharide binding protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LBP mRNA CTD PMID:33819548 NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LDLR mRNA CTD PMID:33819548 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LIPC mRNA CTD PMID:33819548 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA CTD PMID:33819548 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
decreases expression		 ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32152650 PMID:32439580 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP3K5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA CTD PMID:33819548 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases activity
increases phosphorylation
multiple interactions		 ISO
EXP		 Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein
Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein
7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein]		 CTD PMID:21507240 PMID:23300732 PMID:34979142 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases activity
increases phosphorylation
multiple interactions		 ISO
EXP		 Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein
Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein
7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein]		 CTD PMID:21507240 PMID:23300732 PMID:34979142 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions		 EXP Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK8 protein
7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK8 protein]; Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK8 protein]		 CTD PMID:34979142 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases phosphorylation		 ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein]; [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein] which results in decreased degradation of MCL1 protein; Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein]
Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein; lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein]		 CTD PMID:21507240 PMID:25125499 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA CTD PMID:33819548 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502 		JBrowse link
G Mmut methylmalonyl-CoA mutase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MMUT mRNA CTD PMID:33819548 NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046 		JBrowse link
G Mttp microsomal triglyceride transfer protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MTTP mRNA CTD PMID:33819548 NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239 		JBrowse link
G Nfxl1 nuclear transcription factor, X-box binding-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NFXL1 mRNA CTD PMID:33819548 NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498 		JBrowse link
G Nos2 nitric oxide synthase 2 increases expression EXP Glycochenodeoxycholic Acid results in increased expression of NOS2 mRNA CTD PMID:15767249 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nos3 nitric oxide synthase 3 decreases expression
multiple interactions		 ISO Glycochenodeoxycholic Acid results in decreased expression of NOS3; Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA; Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein
[Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein] which results in decreased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3]		 CTD PMID:19837105 PMID:20020783 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NR0B2 mRNA CTD PMID:33819548 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NR1H2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NR1H2 mRNA CTD PMID:33819548 NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of NR1H3 mRNA CTD PMID:33819548 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Pah phenylalanine hydroxylase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PAH mRNA CTD PMID:33819548 NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage ISO Glycochenodeoxycholic Acid results in increased cleavage of PARP1 protein CTD PMID:25125499 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of PIK3C2A mRNA CTD PMID:33819548 NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472 		JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612 		JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544 		JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PIK3R3 mRNA CTD PMID:33819548 NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPARA mRNA CTD PMID:33819548 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA CTD PMID:33819548 NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961 		JBrowse link
G Prkd3 protein kinase D3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PRKD3 mRNA CTD PMID:33819548 NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443 		JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501 		JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RARA mRNA CTD PMID:33819548 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142 		JBrowse link
G Rasd1 ras related dexamethasone induced 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA CTD PMID:33819548 NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA CTD PMID:33819548 NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124 		JBrowse link
G Reep5 receptor accessory protein 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of REEP5 mRNA CTD PMID:33819548 NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509 		JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824 		JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCD mRNA CTD PMID:33819548 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Scp2 sterol carrier protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCP2 mRNA CTD PMID:33819548 NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287 		JBrowse link
G Sdc2 syndecan 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SDC2 mRNA CTD PMID:33819548 NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 increases uptake
multiple interactions		 ISO SLC10A1 protein results in increased uptake of Glycochenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA		 CTD PMID:29024779 PMID:32152650 PMID:33819548 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a7 solute carrier family 10, member 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC10A7 mRNA CTD PMID:33819548 NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464 		JBrowse link
G Slc12a2 solute carrier family 12 member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA CTD PMID:33819548 NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440 		JBrowse link
G Slc17a1 solute carrier family 17 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA CTD PMID:33819548 NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC22A1 mRNA CTD PMID:33819548 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc35b1 solute carrier family 35, member B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC35B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC35B1 mRNA CTD PMID:33819548 NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274 		JBrowse link
G Slc51a solute carrier family 51 member A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLCO1B3 mRNA CTD PMID:33819548 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sorl1 sortilin related receptor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA CTD PMID:33819548 NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA CTD PMID:33819548 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Srp72 signal recognition particle 72 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SRP72 mRNA CTD PMID:33819548 NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729 		JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tfe3 transcription factor binding to IGHM enhancer 3 multiple interactions
decreases expression		 ISO Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of TFE3 mRNA]; Glycochenodeoxycholic Acid results in decreased expression of and results in decreased activity of TFE3 protein; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32439580 NCBI chr  X:14,729,547...14,742,830
Ensembl chr  X:14,729,550...14,742,571 		JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TFPI mRNA CTD PMID:33819548 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880 		JBrowse link
G Tjp2 tight junction protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TJP2 mRNA CTD PMID:33819548 NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295 		JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TLR3 mRNA CTD PMID:33819548 NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA CTD PMID:33819548 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFRSF10A mRNA CTD PMID:33819548 NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TNFRSF9 mRNA CTD PMID:33819548 NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA CTD PMID:33819548 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA CTD PMID:33819548 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Uba5 ubiquitin-like modifier activating enzyme 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBA5 mRNA CTD PMID:33819548 NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894 		JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:42,658,016...42,718,899
Ensembl chr14:42,658,016...42,718,630 		JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of UGP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of UGP2 mRNA CTD PMID:33819548 NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT1A1 mRNA CTD PMID:33819548 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519 		JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571 		JBrowse link
glycocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport
multiple interactions		 ISO ABCB11 protein affects the transport of Glycocholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA		 CTD PMID:15791618 PMID:32152650 PMID:33819548 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA CTD PMID:33819548 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA CTD PMID:33819548 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Glycocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 PMID:33819548 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA CTD PMID:33819548 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA CTD PMID:33819548 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA CTD PMID:33819548 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA CTD PMID:33819548 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA CTD PMID:33819548 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA CTD PMID:33819548 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA CTD PMID:33819548 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Adh4 alcohol dehydrogenase 4 (class II), pi polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA CTD PMID:33819548 NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591 		JBrowse link
G Adh6 alcohol dehydrogenase 6 (class V) multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA CTD PMID:33819548 NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA CTD PMID:33819548 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394 		JBrowse link
G Alb albumin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA CTD PMID:33819548 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA CTD PMID:33819548 NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA CTD PMID:33819548 NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887 		JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA CTD PMID:33819548 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA CTD PMID:33819548 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA CTD PMID:33819548 NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685 		JBrowse link
G Bach1 BTB domain and CNC homolog 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA CTD PMID:33819548 NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA CTD PMID:33819548 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA CTD PMID:33819548 NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969 		JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100 		JBrowse link
G Chi3l1 chitinase 3 like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA CTD PMID:33819548 NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787 		JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA CTD PMID:33819548 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cttn cortactin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA CTD PMID:33819548 NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164 		JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA CTD PMID:33819548 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA CTD PMID:33819548 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA CTD PMID:33819548 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA CTD PMID:33819548 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA CTD PMID:33819548 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA CTD PMID:33819548 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA CTD PMID:33819548 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407 		JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063 		JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988 		JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719 		JBrowse link
G Dnajc12 DnaJ heat shock protein family (Hsp40) member C12 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA CTD PMID:33819548 NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521 		JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136 		JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344 		JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:116,923,272...116,945,312
Ensembl chr 2:116,923,272...116,945,264 		JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:59,419,507...59,446,746
Ensembl chr 2:59,419,510...59,446,752 		JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448 		JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of EIF2AK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA CTD PMID:33819548 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713 		JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA CTD PMID:33819548 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA CTD PMID:33819548 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GGT1 mRNA CTD PMID:33819548 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442 		JBrowse link
G Gjb1 gap junction protein, beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB1 mRNA CTD PMID:33819548 NCBI chr  X:66,501,848...66,509,783
Ensembl chr  X:66,501,820...66,509,925 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA CTD PMID:33819548 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177 		JBrowse link
G Gk glycerol kinase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GK mRNA CTD PMID:33819548 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Gprc5b G protein-coupled receptor, class C, group 5, member B multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA CTD PMID:33819548 NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932 		JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA CTD PMID:33819548 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323 		JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTT1 mRNA CTD PMID:33819548 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585 		JBrowse link
G Hacl1 2-hydroxyacyl-CoA lyase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HGF mRNA CTD PMID:33819548 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HMGCR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HMGCR mRNA CTD PMID:33819548 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hpx hemopexin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HPX mRNA CTD PMID:33819548 NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HSD3B7 mRNA CTD PMID:33819548 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185 		JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IER3 mRNA CTD PMID:33819548 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583 		JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of IFI27 mRNA CTD PMID:33819548 NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IGFBP1 mRNA CTD PMID:33819548 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il10 interleukin 10 decreases abundance ISO IL10 gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of IL1R1 mRNA CTD PMID:33819548 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IL6 mRNA CTD PMID:33819548 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Kynu kynureninase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of KYNU mRNA CTD PMID:33819548 NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488 		JBrowse link
G Lbp lipopolysaccharide binding protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LBP mRNA CTD PMID:33819548 NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LDLR mRNA CTD PMID:33819548 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LIPC mRNA CTD PMID:33819548 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA CTD PMID:33819548 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP3K5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA CTD PMID:33819548 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA CTD PMID:33819548 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502 		JBrowse link
G Mmut methylmalonyl-CoA mutase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MMUT mRNA CTD PMID:33819548 NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046 		JBrowse link
G Mttp microsomal triglyceride transfer protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MTTP mRNA CTD PMID:33819548 NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239 		JBrowse link
G Nfxl1 nuclear transcription factor, X-box binding-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NFXL1 mRNA CTD PMID:33819548 NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NR0B2 mRNA CTD PMID:33819548 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NR1H2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NR1H2 mRNA CTD PMID:33819548 NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of NR1H3 mRNA CTD PMID:33819548 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions		 ISO Glycocholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA		 CTD PMID:17567710 PMID:32152650 PMID:33819548 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Pah phenylalanine hydroxylase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PAH mRNA CTD PMID:33819548 NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130 		JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of PIK3C2A mRNA CTD PMID:33819548 NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472 		JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612 		JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544 		JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PIK3R3 mRNA CTD PMID:33819548 NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583 		JBrowse link
G Por cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPARA mRNA CTD PMID:33819548 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA CTD PMID:33819548 NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961 		JBrowse link
G Prkd3 protein kinase D3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PRKD3 mRNA CTD PMID:33819548 NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443 		JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501 		JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RARA mRNA CTD PMID:33819548 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142 		JBrowse link
G Rasd1 ras related dexamethasone induced 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA CTD PMID:33819548 NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA CTD PMID:33819548 NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124 		JBrowse link
G Reep5 receptor accessory protein 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of REEP5 mRNA CTD PMID:33819548 NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509 		JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824 		JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCD mRNA CTD PMID:33819548 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Scp2 sterol carrier protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCP2 mRNA CTD PMID:33819548 NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287 		JBrowse link
G Sdc2 syndecan 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SDC2 mRNA CTD PMID:33819548 NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a7 solute carrier family 10, member 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC10A7 mRNA CTD PMID:33819548 NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464 		JBrowse link
G Slc12a2 solute carrier family 12 member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA CTD PMID:33819548 NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440 		JBrowse link
G Slc17a1 solute carrier family 17 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA CTD PMID:33819548 NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC22A1 mRNA CTD PMID:33819548 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc35b1 solute carrier family 35, member B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC35B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC35B1 mRNA CTD PMID:33819548 NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274 		JBrowse link
G Slc51a solute carrier family 51 member A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLCO1B3 mRNA CTD PMID:33819548 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666 PMID:32152650 PMID:33819548 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sorl1 sortilin related receptor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA CTD PMID:33819548 NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA CTD PMID:33819548 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Srp72 signal recognition particle 72 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SRP72 mRNA CTD PMID:33819548 NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729 		JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TFPI mRNA CTD PMID:33819548 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880 		JBrowse link
G Tjp2 tight junction protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TJP2 mRNA CTD PMID:33819548 NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295 		JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TLR3 mRNA CTD PMID:33819548 NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA CTD PMID:33819548 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFRSF10A mRNA CTD PMID:33819548 NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TNFRSF9 mRNA CTD PMID:33819548 NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA CTD PMID:33819548 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA CTD PMID:33819548 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Uba5 ubiquitin-like modifier activating enzyme 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBA5 mRNA CTD PMID:33819548 NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894 		JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:42,658,016...42,718,899
Ensembl chr14:42,658,016...42,718,630 		JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of UGP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of UGP2 mRNA CTD PMID:33819548 NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT1A1 mRNA CTD PMID:33819548 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519 		JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571 		JBrowse link
glycodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA CTD PMID:33819548 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA CTD PMID:33819548 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Glycodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 PMID:33819548 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA CTD PMID:33819548 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA CTD PMID:33819548 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA CTD PMID:33819548 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA CTD PMID:33819548 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA CTD PMID:33819548 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA CTD PMID:33819548 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA CTD PMID:33819548 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Adh4 alcohol dehydrogenase 4 (class II), pi polypeptide multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA CTD PMID:33819548 NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591 		JBrowse link
G Adh6 alcohol dehydrogenase 6 (class V) multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA CTD PMID:33819548 NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534 		JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA CTD PMID:33819548 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394 		JBrowse link
G Alb albumin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA CTD PMID:33819548 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA CTD PMID:33819548 NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA CTD PMID:33819548 NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887 		JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA CTD PMID:33819548 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA CTD PMID:33819548 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA CTD PMID:33819548 NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685 		JBrowse link
G Bach1 BTB domain and CNC homolog 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA CTD PMID:33819548 NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA CTD PMID:33819548 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA CTD PMID:33819548 NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969 		JBrowse link
G Casp3 caspase 3 multiple interactions EXP [Glycodeoxycholic Acid co-treated with Ceruletide] results in decreased activity of CASP3 protein CTD PMID:18832452 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393 		JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100 		JBrowse link
G Chi3l1 chitinase 3 like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA CTD PMID:33819548 NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787 		JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA CTD PMID:33819548 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cttn cortactin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA CTD PMID:33819548 NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164 		JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA CTD PMID:33819548 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA CTD PMID:33819548 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA CTD PMID:33819548 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA CTD PMID:33819548 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA CTD PMID:33819548 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA CTD PMID:33819548
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
increases hydroxylation		 ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA
CYP3A4 protein results in increased hydroxylation of Glycodeoxycholic Acid		 CTD PMID:32152650 PMID:33819548 PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA CTD PMID:33819548 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA CTD PMID:33819548 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407 		JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659 		JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063 		JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988 		JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719 		JBrowse link
G Dnajc12 DnaJ heat shock protein family (Hsp40) member C12 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA CTD PMID:33819548 NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521 		JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136 		JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344 		JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:116,923,272...116,945,312
Ensembl chr 2:116,923,272...116,945,264 		JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:59,419,507...59,446,746
Ensembl chr 2:59,419,510...59,446,752 		JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448 		JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of EIF2AK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA CTD PMID:33819548 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713 		JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA CTD PMID:33819548 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA CTD PMID:33819548 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GGT1 mRNA CTD PMID:33819548 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442 		JBrowse link
G Gjb1 gap junction protein, beta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB1 mRNA CTD PMID:33819548 NCBI chr  X:66,501,848...66,509,783
Ensembl chr  X:66,501,820...66,509,925 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA CTD PMID:33819548 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177 		JBrowse link
G Gk glycerol kinase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GK mRNA CTD PMID:33819548 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Gprc5b G protein-coupled receptor, class C, group 5, member B multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA CTD PMID:33819548 NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932 		JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA CTD PMID:33819548 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323 		JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTT1 mRNA CTD PMID:33819548 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585 		JBrowse link
G Hacl1 2-hydroxyacyl-CoA lyase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HGF mRNA CTD PMID:33819548 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HMGCR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HMGCR mRNA CTD PMID:33819548 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hpx hemopexin multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HPX mRNA CTD PMID:33819548 NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HSD3B7 mRNA CTD PMID:33819548 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185 		JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IER3 mRNA CTD PMID:33819548 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583 		JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of IFI27 mRNA CTD PMID:33819548 NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IGFBP1 mRNA CTD PMID:33819548 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of IL1R1 mRNA CTD PMID:33819548 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IL6 mRNA CTD PMID:33819548 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Kynu kynureninase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of KYNU mRNA CTD PMID:33819548 NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488 		JBrowse link
G Lbp lipopolysaccharide binding protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LBP mRNA CTD PMID:33819548 NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586 		JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LDLR mRNA CTD PMID:33819548 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LIPC mRNA CTD PMID:33819548 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA CTD PMID:33819548 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP3K5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA CTD PMID:33819548 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA CTD PMID:33819548 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892 		JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 PMID:33819548 NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502 		JBrowse link
G Mmut methylmalonyl-CoA mutase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MMUT mRNA CTD PMID:33819548 NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046 		JBrowse link
G Mttp microsomal triglyceride transfer protein multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MTTP mRNA CTD PMID:33819548 NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239 		JBrowse link
G Myl9 myosin light chain 9 multiple interactions EXP Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein] CTD PMID:29660437 NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333 		JBrowse link
G Nfxl1 nuclear transcription factor, X-box binding-like 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NFXL1 mRNA CTD PMID:33819548 NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NR0B2 mRNA CTD PMID:33819548 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NR1H2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NR1H2 mRNA CTD PMID:33819548 NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of NR1H3 mRNA CTD PMID:33819548 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions		 ISO Glycodeoxycholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA		 CTD PMID:17567710 PMID:32152650 PMID:33819548 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Pah phenylalanine hydroxylase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PAH mRNA CTD PMID:33819548 NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130 		JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of PIK3C2A mRNA CTD PMID:33819548 NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472 		JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612 		JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544 		JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pik3r3 phosphoinositide-3-kinase regulatory subunit 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PIK3R3 mRNA CTD PMID:33819548 NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583 		JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Glycodeoxycholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPARA mRNA CTD PMID:33819548 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Ppp1r12a protein phosphatase 1, regulatory subunit 12A multiple interactions EXP Glycodeoxycholic Acid inhibits the reaction [15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid results in increased phosphorylation of PPP1R12A protein] CTD PMID:29660437 NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425 		JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA CTD PMID:33819548 NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961 		JBrowse link
G Prkd3 protein kinase D3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PRKD3 mRNA CTD PMID:33819548 NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443 		JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501 		JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RARA mRNA CTD PMID:33819548 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142 		JBrowse link
G Rasd1 ras related dexamethasone induced 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA CTD PMID:33819548 NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186 		JBrowse link
G Rdh16 retinol dehydrogenase 16 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA CTD PMID:33819548 NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124 		JBrowse link
G Reep5 receptor accessory protein 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of REEP5 mRNA CTD PMID:33819548 NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509 		JBrowse link
G Rhoa ras homolog family member A multiple interactions EXP Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein] CTD PMID:29660437 NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746 		JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824 		JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCD mRNA CTD PMID:33819548 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Scp2 sterol carrier protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCP2 mRNA CTD PMID:33819548 NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287 		JBrowse link
G Sdc2 syndecan 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SDC2 mRNA CTD PMID:33819548 NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a7 solute carrier family 10, member 7 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC10A7 mRNA CTD PMID:33819548 NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464 		JBrowse link
G Slc12a2 solute carrier family 12 member 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA CTD PMID:33819548 NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440 		JBrowse link
G Slc17a1 solute carrier family 17 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA CTD PMID:33819548 NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC22A1 mRNA CTD PMID:33819548 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc35b1 solute carrier family 35, member B1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC35B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC35B1 mRNA CTD PMID:33819548 NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274 		JBrowse link
G Slc51a solute carrier family 51 member A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA CTD PMID:32152650 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA CTD PMID:32152650 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLCO1B3 mRNA CTD PMID:33819548 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sorl1 sortilin related receptor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA CTD PMID:33819548 NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA CTD PMID:33819548 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Srp72 signal recognition particle 72 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SRP72 mRNA CTD PMID:33819548 NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729 		JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 PMID:33819548 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tfpi tissue factor pathway inhibitor multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TFPI mRNA CTD PMID:33819548 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880 		JBrowse link
G Tjp2 tight junction protein 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TJP2 mRNA CTD PMID:33819548 NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295 		JBrowse link
G Tlr3 toll-like receptor 3 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TLR3 mRNA CTD PMID:33819548 NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA CTD PMID:33819548 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFRSF10A mRNA CTD PMID:33819548 NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TNFRSF9 mRNA CTD PMID:33819548 NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA CTD PMID:33819548 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA CTD PMID:33819548 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Uba5 ubiquitin-like modifier activating enzyme 5 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBA5 mRNA CTD PMID:33819548 NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894 		JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:42,658,016...42,718,899
Ensembl chr14:42,658,016...42,718,630 		JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of UGP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of UGP2 mRNA CTD PMID:33819548 NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT1A1 mRNA CTD PMID:33819548 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519 		JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571 		JBrowse link
glycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
increases hydroxylation		 ISO [CYP3A4 protein results in increased hydroxylation of glycolithocholic acid] which results in increased abundance of glycohyodeoxycholic acid CTD PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of glycolithocholic acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of glycolithocholic acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 increases sulfation ISO SULT2A1 protein results in increased sulfation of glycolithocholic acid CTD PMID:36473578 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
glycoursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases hydroxylation ISO CYP3A4 protein results in increased hydroxylation of glycoursodeoxycholic acid CTD PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Edn1 endothelin 1 decreases expression ISO glycoursodeoxycholic acid results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Slc4a2 solute carrier family 4 member 2 multiple interactions ISO [glycoursodeoxycholic acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form CTD PMID:18188457 NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965 		JBrowse link
G Tp53 tumor protein p53 multiple interactions EXP glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
hyodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor increases secretion ISO AHR gene mutant form results in increased secretion of hyodeoxycholic acid CTD PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions EXP [CYP2D6 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of hyodeoxycholic acid CTD PMID:18039809 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO [CYP3A4 protein results in increased hydroxylation of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid; [CYP3A4 protein results in increased metabolism of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid CTD PMID:19487251 PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of hyodeoxycholic acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases glucuronidation
multiple interactions
increases glycosylation
affects metabolic processing		 ISO UGT2B7 protein alternative form results in increased glucuronidation of hyodeoxycholic acid; UGT2B7 protein results in increased glucuronidation of hyodeoxycholic acid
[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased metabolism of hyodeoxycholic acid
UGT2B7 protein results in increased glycosylation of hyodeoxycholic acid
UGT2B7 protein affects the metabolism of hyodeoxycholic acid		 CTD PMID:8423545 PMID:8517101 PMID:12527334 PMID:21415305 PMID:36473578 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604 		JBrowse link
lithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 decreases expression
increases expression
multiple interactions		 ISO Lithocholic Acid results in decreased expression of ABCA1 mRNA; Lithocholic Acid results in decreased expression of ABCA1 protein
Lithocholic Acid results in increased expression of ABCA1 mRNA
NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCA1 mRNA]		 CTD PMID:15883047 PMID:20977460 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 increases expression
decreases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of ABCB11 mRNA
Lithocholic Acid results in decreased expression of ABCB11 mRNA
Lithocholic Acid promotes the reaction [NR1H3 protein results in increased expression of ABCB11 mRNA]
[Lithocholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA		 CTD PMID:17256725 PMID:17963371 PMID:20359477 PMID:20977460 PMID:23034213 More... NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of ABCB1 mRNA
VDR protein promotes the reaction [Lithocholic Acid results in increased expression of ABCB1 mRNA]		 CTD PMID:19460946 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb1b ATP-binding cassette, sub-family B member 1B increases expression ISO Lithocholic Acid results in increased expression of ABCB1B mRNA CTD PMID:20977460 NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 increases expression ISO Lithocholic Acid results in increased expression of ABCB4 mRNA CTD PMID:20359477 PMID:25582706 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of ABCC1 mRNA; Lithocholic Acid results in increased expression of ABCC1 protein
Lithocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC1 protein; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC1 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC1 mRNA]		 CTD PMID:16101123 PMID:18032408 PMID:20977460 PMID:23034213 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression
affects localization
multiple interactions		 ISO
EXP		 Lithocholic Acid results in increased expression of ABCC2 mRNA
Lithocholic Acid results in increased expression of ABCC2 mRNA; Lithocholic Acid results in increased expression of ABCC2 protein
Lithocholic Acid affects the localization of ABCC2 protein
[Cyclosporine results in decreased activity of ABCC2 protein] which results in increased abundance of Lithocholic Acid; [Lithocholic Acid results in increased activity of NR1I2 protein] which results in increased expression of ABCC2 mRNA
[Lithocholic Acid binds to and results in increased activity of NR1I2 protein] which results in increased expression of ABCC2 mRNA
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC2 protein; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC2 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC2 protein]		 CTD PMID:14570758 PMID:16436656 PMID:18032408 PMID:20888898 PMID:20977460 More... NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions
decreases expression
increases expression
increases activity		 ISO [Lithocholic Acid co-treated with 1,4-bis(2-(3,5-dichloropyridyloxy))benzene] results in increased expression of ABCC3 mRNA; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC3 mRNA]; NR1I3 protein affects the reaction [Lithocholic Acid results in increased expression of ABCC3 mRNA]
Lithocholic Acid results in decreased expression of ABCC3 mRNA
Lithocholic Acid results in increased activity of ABCC3 protein
[Lithocholic Acid results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA
Lithocholic Acid results in increased expression of ABCC3 mRNA; Lithocholic Acid results in increased expression of ABCC3 protein		 CTD PMID:14570758 PMID:15358766 PMID:15824121 PMID:16436656 PMID:18032408 More... NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 increases expression
decreases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of ABCC4 mRNA
Lithocholic Acid results in decreased expression of ABCC4 mRNA
1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [Lithocholic Acid results in increased expression of ABCC4 mRNA]; [Lithocholic Acid co-treated with 1,4-bis(2-(3,5-dichloropyridyloxy))benzene] results in increased expression of ABCC4 protein; [Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC4 protein; Lithocholic Acid promotes the reaction [NR1H3 protein results in increased expression of ABCC4 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC4 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC4 mRNA]		 CTD PMID:17256725 PMID:18032408 PMID:20977460 PMID:23034213 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcc5 ATP binding cassette subfamily C member 5 multiple interactions
increases expression		 ISO [Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC5 protein; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC5 mRNA]
Lithocholic Acid results in increased expression of ABCC5 mRNA; Lithocholic Acid results in increased expression of ABCC5 protein		 CTD PMID:18032408 PMID:20977460 PMID:23034213 NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253 		JBrowse link
G Abcc6 ATP binding cassette subfamily C member 6 decreases expression ISO Lithocholic Acid results in decreased expression of ABCC6 protein CTD PMID:18032408 NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions
increases expression		 ISO NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCG2 mRNA] CTD PMID:20977460 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 multiple interactions
increases expression		 ISO [Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in increased expression of ABCG5 mRNA
Lithocholic Acid results in increased expression of ABCG5 mRNA		 CTD PMID:20359477 PMID:25055961 PMID:25582706 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 decreases expression
increases expression		 ISO Lithocholic Acid results in decreased expression of ABCG8 mRNA
Lithocholic Acid results in increased expression of ABCG8 mRNA		 CTD PMID:20359477 PMID:25582706 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Acaca acetyl-CoA carboxylase alpha multiple interactions
decreases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of ACACA mRNA] CTD PMID:20359477 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457 		JBrowse link
G Acadvl acyl-CoA dehydrogenase, very long chain decreases expression ISO Lithocholic Acid results in decreased expression of ACADVL mRNA CTD PMID:20359477 NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 decreases expression
multiple interactions		 ISO Lithocholic Acid results in decreased expression of ACSL1 mRNA
Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of ACSL1 mRNA]		 CTD PMID:20359477 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
decreases abundance
increases secretion		 ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Lithocholic Acid]
AHR gene mutant form results in decreased abundance of Lithocholic Acid
AHR gene mutant form results in increased secretion of Lithocholic Acid		 CTD PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 affects binding
decreases activity		 ISO AKR1C1 protein binds to Lithocholic Acid
Lithocholic Acid results in decreased activity of AKR1C1 protein		 CTD PMID:8573067 PMID:12604236 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 affects binding
decreases activity		 ISO AKR1C2 protein binds to Lithocholic Acid; Lithocholic Acid binds to AKR1C2 protein
Lithocholic Acid results in decreased activity of AKR1C2 protein		 CTD PMID:8486699 PMID:8573067 PMID:12604236 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 decreases activity ISO Lithocholic Acid results in decreased activity of AKR1C3 protein CTD PMID:12604236 PMID:21851338 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Alb albumin affects binding ISO Lithocholic Acid analog binds to ALB protein CTD PMID:19900495 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated multiple interactions ISO [Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein; EGF protein promotes the reaction [Lithocholic Acid results in increased activity of ALPL protein] CTD PMID:19646460 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446 		JBrowse link
G Anxa1 annexin A1 increases expression ISO Lithocholic Acid results in increased expression of ANXA1 mRNA CTD PMID:20359477 NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343 		JBrowse link
G Anxa2 annexin A2 multiple interactions
increases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of ANXA2 mRNA] CTD PMID:20359477 NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658 		JBrowse link
G Anxa3 annexin A3 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of ANXA3 mRNA
Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of ANXA3 mRNA]		 CTD PMID:20359477 NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617 		JBrowse link
G Anxa4 annexin A4 multiple interactions
increases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of ANXA4 mRNA] CTD PMID:20359477 NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161 		JBrowse link
G Anxa5 annexin A5 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of ANXA5 mRNA
Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of ANXA5 mRNA]		 CTD PMID:20359477 NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369 		JBrowse link
G Apoa4 apolipoprotein A4 increases expression ISO Lithocholic Acid results in increased expression of APOA4 mRNA CTD PMID:20359477 NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469 		JBrowse link
G Apoc1 apolipoprotein C1 decreases expression ISO Lithocholic Acid results in decreased expression of APOC1 mRNA CTD PMID:20359477 NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375 		JBrowse link
G Apoc2 apolipoprotein C2 increases expression ISO Lithocholic Acid results in increased expression of APOC2 mRNA CTD PMID:20359477 NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476 		JBrowse link
G Apoc4 apolipoprotein C4 decreases expression ISO Lithocholic Acid results in decreased expression of APOC4 mRNA CTD PMID:20359477 NCBI chr 1:79,335,745...79,339,942
Ensembl chr 1:79,335,745...79,339,981 		JBrowse link
G Ar androgen receptor multiple interactions
affects binding		 ISO Lithocholic Acid inhibits the reaction [Dihydrotestosterone binds to AR protein]
Lithocholic Acid binds to AR protein		 CTD PMID:15206167 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase decreases expression
multiple interactions		 ISO Lithocholic Acid results in decreased expression of BAAT mRNA
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of BAAT mRNA]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of BAAT mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of BAAT mRNA]]; Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of BAAT mRNA]		 CTD PMID:19196849 NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO [Lithocholic Acid co-treated with 1,4-bis(2-(3,5-dichloropyridyloxy))benzene] results in decreased expression of BAK1 protein; [Lithocholic Acid co-treated with Phenobarbital] results in decreased expression of BAK1 protein; [Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in decreased expression of BAK1 protein CTD PMID:19433268 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 EXP
ISO		 Lithocholic Acid results in increased expression of BAX mRNA
[Lithocholic Acid co-treated with 1,4-bis(2-(3,5-dichloropyridyloxy))benzene] results in decreased expression of BAX protein; [Lithocholic Acid co-treated with 1,4-bis(2-(3,5-dichloropyridyloxy))benzene] results in increased expression of BAX mRNA; [Lithocholic Acid co-treated with oltipraz] results in increased expression of BAX mRNA; [Lithocholic Acid co-treated with Phenobarbital] results in decreased expression of BAX protein; [Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in decreased expression of BAX protein; Phenobarbital inhibits the reaction [Lithocholic Acid results in increased expression of BAX mRNA]		 CTD PMID:17881359 PMID:19433268 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
increases expression		 ISO 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in increased expression of BCL2L1 mRNA]; [Lithocholic Acid co-treated with oltipraz] results in increased expression of BCL2L1 mRNA; Phenobarbital inhibits the reaction [Lithocholic Acid results in increased expression of BCL2L1 mRNA]; Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of BCL2L1 mRNA] CTD PMID:19433268 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions
increases expression		 ISO Lithocholic Acid inhibits the reaction [Vitamin D results in increased expression of BGLAP mRNA]
Lithocholic Acid results in increased expression of BGLAP mRNA		 CTD PMID:20055894 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases cleavage		 ISO [[[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein; [[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein; [[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Lithocholic Acid results in increased cleavage of and results in increased activity of BID protein]
Lithocholic Acid results in increased cleavage of BID protein		 CTD PMID:19054763 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Brca2 BRCA2, DNA repair associated decreases response to substance ISO BRCA2 protein results in decreased susceptibility to Lithocholic Acid CTD PMID:20028873 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567 		JBrowse link
G Calr calreticulin affects expression EXP Lithocholic Acid affects the expression of CALR mRNA CTD PMID:18246545 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414 		JBrowse link
G Camp cathelicidin antimicrobial peptide multiple interactions
increases expression		 ISO [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CAMP mRNA; HR protein promotes the reaction [Lithocholic Acid results in increased expression of CAMP mRNA]
Lithocholic Acid analog results in increased expression of CAMP mRNA; Lithocholic Acid results in increased expression of CAMP mRNA; Lithocholic Acid results in increased expression of CAMP protein		 CTD PMID:18180267 PMID:19733911 PMID:22466564 NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543 		JBrowse link
G Casp1 caspase 1 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of CASP1 mRNA; Lithocholic Acid results in increased expression of CASP1 protein
Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of CASP1 mRNA]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of CASP1 protein]		 CTD PMID:29794447 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp2 caspase 2 multiple interactions ISO benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Lithocholic Acid results in increased cleavage of and results in increased activity of CASP2 protein]; Lithocholic Acid results in increased cleavage of and results in increased activity of CASP2 protein CTD PMID:19054763 NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379 		JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases expression		 ISO Lithocholic Acid results in increased cleavage of CASP3 protein
[[[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Lithocholic Acid results in increased cleavage of and results in increased activity of CASP3 protein]; Lithocholic Acid results in increased cleavage of and results in increased activity of CASP3 protein; TNF protein promotes the reaction [Lithocholic Acid results in increased expression of CASP3 protein]
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in increased cleavage of CASP3 protein]; Phenobarbital inhibits the reaction [Lithocholic Acid results in increased cleavage of CASP3 protein]; Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased cleavage of CASP3 protein]		 CTD PMID:19054763 PMID:19433268 PMID:23627780 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO [[[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein; [[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein; [[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein; [[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Lithocholic Acid results in increased cleavage of and results in increased activity of CASP8 protein]; Lithocholic Acid results in increased cleavage of and results in increased activity of CASP8 protein CTD PMID:19054763 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO [[[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein; [[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Lithocholic Acid results in increased cleavage of and results in increased activity of CASP9 protein]; Lithocholic Acid results in increased cleavage of and results in increased activity of CASP9 protein CTD PMID:19054763 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cav1 caveolin 1 multiple interactions ISO Lithocholic Acid results in increased localization of [VDR protein co-treated with CAV1 protein] CTD PMID:20371703 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705 		JBrowse link
G Ccnb1 cyclin B1 increases expression ISO Lithocholic Acid results in increased expression of CCNB1 mRNA CTD PMID:19000923 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Cct6a chaperonin containing TCP1 subunit 6A decreases expression ISO Lithocholic Acid results in decreased expression of CCT6A protein CTD PMID:21224350 NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337 		JBrowse link
G Cd14 CD14 molecule increases expression
multiple interactions		 ISO Lithocholic Acid analog results in increased expression of CD14 mRNA; Lithocholic Acid results in increased expression of CD14 mRNA
Benzo(a)pyrene promotes the reaction [Lithocholic Acid results in increased expression of CD14 mRNA]		 CTD PMID:18180267 PMID:19244278 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261 		JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CDH1 mRNA; Lithocholic Acid inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [TNF protein results in decreased expression of and affects the localization of CDH1 protein]]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of CDH1 protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of CDH1 protein]] CTD PMID:15489543 PMID:31472180 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cers1 ceramide synthase 1 increases expression ISO Lithocholic Acid results in increased expression of CERS1 mRNA CTD PMID:21480330 NCBI chr16:19,097,309...19,112,519
Ensembl chr16:19,104,466...19,112,519 		JBrowse link
G Cers2 ceramide synthase 2 increases expression ISO Lithocholic Acid results in increased expression of CERS2 mRNA CTD PMID:21480330 NCBI chr 2:182,890,527...182,898,805
Ensembl chr 2:182,890,493...182,933,314 		JBrowse link
G Ces1d carboxylesterase 1D decreases expression
multiple interactions		 ISO Lithocholic Acid results in decreased expression of CES1D mRNA
Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of CES1D mRNA]		 CTD PMID:20359477 NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035 		JBrowse link
G Cfl1 cofilin 1 increases expression ISO Lithocholic Acid results in increased expression of CFL1 protein CTD PMID:21224350 NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587 		JBrowse link
G Chka choline kinase alpha increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of CHKA mRNA
SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of CHKA mRNA]		 CTD PMID:21480330 PMID:23034213 NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516 		JBrowse link
G Chpt1 choline phosphotransferase 1 multiple interactions
decreases expression		 ISO [Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in decreased expression of CHPT1 mRNA
Lithocholic Acid results in decreased expression of CHPT1 mRNA		 CTD PMID:20359477 PMID:21480330 NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103 		JBrowse link
G Cldn1 claudin 1 multiple interactions ISO Lithocholic Acid inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [TNF protein results in decreased expression of and affects the localization of CLDN1 protein]]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of CLDN1 protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of CLDN1 protein]] CTD PMID:31472180 NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724 		JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression ISO Lithocholic Acid results in increased expression of COL1A1 mRNA CTD PMID:16436656 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 decreases expression ISO Lithocholic Acid results in decreased expression of CPT2 mRNA CTD PMID:20359477 NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO [PPARA protein co-treated with CREB1 protein] promotes the reaction [Lithocholic Acid results in increased expression of PTGS2 mRNA] CTD PMID:18648741 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816 		JBrowse link
G Crot carnitine O-octanoyltransferase multiple interactions
decreases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of CROT mRNA] CTD PMID:20359477 NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [Lithocholic Acid binds to VDR protein] which results in decreased activity of CTNNB1 mRNA CTD PMID:20043299 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression ISO Lithocholic Acid results in increased expression of CXCL2 mRNA CTD PMID:24742700 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity ISO Lithocholic Acid results in decreased activity of CYP1A1 protein CTD PMID:18420780 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity
increases metabolic processing
multiple interactions		 ISO
EXP		 Lithocholic Acid results in decreased activity of CYP1A2 protein
CYP1A2 protein results in increased metabolism of Lithocholic Acid
[CYP1A2 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of Lithocholic Acid analog		 CTD PMID:18039809 PMID:18420780 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Lithocholic Acid results in decreased activity of CYP1B1 protein CTD PMID:18420780 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1 multiple interactions
increases expression		 ISO
EXP		 [Lithocholic Acid analog binds to and results in increased activity of VDR protein] which results in increased expression of CYP24A1 mRNA; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CYP24A1 mRNA; Benzo(a)pyrene promotes the reaction [Lithocholic Acid results in increased expression of CYP24A1 mRNA]; HR protein inhibits the reaction [Lithocholic Acid results in increased expression of CYP24A1 mRNA]; Lithocholic Acid inhibits the reaction [NCOR2 protein binds to CYP24A1 promoter]; Lithocholic Acid inhibits the reaction [Vitamin D results in increased expression of CYP24A1 mRNA]; Lithocholic Acid promotes the reaction [VDR protein binds to CYP24A1 promoter]
Lithocholic Acid analog results in increased expression of CYP24A1 mRNA; Lithocholic Acid results in increased expression of CYP24A1 mRNA
[Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CYP24A1 mRNA; Vitamin D inhibits the reaction [Lithocholic Acid results in increased expression of CYP24A1 mRNA]		 CTD PMID:15489543 PMID:17535892 PMID:18180267 PMID:19244278 PMID:20055894 More... NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383 		JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of CYP26A1 mRNA
Lithocholic Acid promotes the reaction [Tretinoin results in increased expression of CYP26A1 mRNA]		 CTD PMID:18059332 NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions
decreases expression		 ISO 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP27A1 mRNA]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP27A1 mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP27A1 mRNA]]; Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP27A1 mRNA] CTD PMID:19196849 PMID:20359477 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Lithocholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887 		JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 decreases activity ISO Lithocholic Acid results in decreased activity of CYP2A4 protein CTD PMID:18420780 NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 decreases activity
increases expression
multiple interactions		 ISO Lithocholic Acid results in decreased activity of CYP2B10 protein
Lithocholic Acid results in increased expression of CYP2B10 mRNA
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Lithocholic Acid] results in increased expression of CYP2B10 mRNA; [Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in increased expression of CYP2B10 mRNA; [Pregnenolone Carbonitrile co-treated with Lithocholic Acid] results in increased expression of CYP2B10 mRNA; NR1I3 protein affects the reaction [Lithocholic Acid results in increased expression of CYP2B10 mRNA]; NR1I3 protein promotes the reaction [[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Lithocholic Acid] results in increased expression of CYP2B10 mRNA]; NR1I3 protein promotes the reaction [[Pregnenolone Carbonitrile co-treated with Lithocholic Acid] results in increased expression of CYP2B10 mRNA]		 CTD PMID:15358766 PMID:18420780 PMID:19433268 PMID:20359477 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 increases metabolic processing
decreases activity
multiple interactions		 EXP CYP2C11 protein results in increased metabolism of Lithocholic Acid
Lithocholic Acid results in decreased activity of CYP2C11 protein
[CYP2C11 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of 3-oxocholan-24-oic acid		 CTD PMID:8889968 PMID:18039809 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp2c22 cytochrome P450, family 2, subfamily c, polypeptide 22 increases expression EXP Lithocholic Acid results in increased expression of CYP2C22 mRNA CTD PMID:21311750 NCBI chr 1:238,991,698...239,031,323
Ensembl chr 1:238,991,610...239,021,738 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 increases metabolic processing
decreases activity
multiple interactions		 EXP
ISO		 CYP2C6V1 protein results in increased metabolism of Lithocholic Acid
Lithocholic Acid results in decreased activity of CYP2C29 protein
[CYP2C6V1 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of Lithocholic Acid analog		 CTD PMID:18039809 PMID:18420780 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2d1 cytochrome P450, family 2, subfamily d, polypeptide 1 multiple interactions
increases metabolic processing		 EXP [CYP2D1 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of Lithocholic Acid analog CTD PMID:18039809 NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases metabolic processing
decreases activity
multiple interactions		 EXP
ISO		 CYP2D6 protein results in increased metabolism of Lithocholic Acid
Lithocholic Acid results in decreased activity of CYP2D22 protein
[CYP2D6 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of hyodeoxycholic acid		 CTD PMID:18039809 PMID:18420780 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases activity ISO Lithocholic Acid results in decreased activity of CYP2E1 protein CTD PMID:18420780 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 multiple interactions ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Lithocholic Acid] results in increased expression of CYP39A1 mRNA; [Phenobarbital co-treated with Lithocholic Acid] results in increased expression of CYP39A1 mRNA; NR1I3 protein promotes the reaction [[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Lithocholic Acid] results in increased expression of CYP39A1 mRNA]; NR1I3 protein promotes the reaction [[Phenobarbital co-treated with Lithocholic Acid] results in increased expression of CYP39A1 mRNA] CTD PMID:19196849 NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases expression
increases hydroxylation
increases activity
increases oxidation
multiple interactions
increases metabolic processing
affects metabolic processing
decreases activity		 EXP
ISO		 Lithocholic Acid results in increased expression of CYP3A2 mRNA
CYP3A4 protein results in increased hydroxylation of Lithocholic Acid
Lithocholic Acid results in increased activity of CYP3A4 protein mutant form
CYP3A4 protein results in increased oxidation of Lithocholic Acid
[CYP3A4 protein results in increased hydroxylation of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid; [CYP3A4 protein results in increased metabolism of Lithocholic Acid] which results in increased abundance of 3-ketocholanoic acid; [CYP3A4 protein results in increased metabolism of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid; [CYP3A4 protein results in increased metabolism of Lithocholic Acid] which results in increased abundance of Ursodeoxycholic Acid; [CYP3A4 protein results in increased oxidation of Lithocholic Acid] which results in increased chemical synthesis of 3-ketocholanoic acid; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CYP3A4 mRNA; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of Lithocholic Acid]; Lithocholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; tocotrienol, alpha inhibits the reaction [CYP3A4 protein results in increased oxidation of Lithocholic Acid]; tocotrienol, delta inhibits the reaction [CYP3A4 protein results in increased oxidation of Lithocholic Acid]; Tocotrienols inhibits the reaction [CYP3A4 protein results in increased oxidation of Lithocholic Acid]; VDR protein promotes the reaction [Lithocholic Acid results in increased expression of CYP3A4 mRNA]
CYP3A4 protein affects the metabolism of Lithocholic Acid
Lithocholic Acid results in decreased activity of CYP3A2 protein
CYP3A2 protein results in increased metabolism of Lithocholic Acid
[CYP3A2 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of 3-oxocholan-24-oic acid; [CYP3A2 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of Lithocholic Acid analog; [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] affects the abundance of Lithocholic Acid		 CTD PMID:8889968 PMID:15489543 PMID:15578590 PMID:15708356 PMID:17965521 More... NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions
increases expression
increases metabolic processing		 EXP [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] affects the abundance of Lithocholic Acid; [CYP3A23-3A1 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of 3-oxocholan-24-oic acid; [CYP3A23-3A1 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of Lithocholic Acid analog; [Lithocholic Acid binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A23-3A1 mRNA; Chenodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of CYP3A23-3A1 mRNA] CTD PMID:18039809 PMID:20006981 PMID:20888898 PMID:21311750 PMID:34461081 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases expression
increases oxidation
multiple interactions		 EXP
ISO		 Lithocholic Acid results in increased expression of CYP3A9 mRNA
CYP3A5 protein results in increased oxidation of Lithocholic Acid
[CYP3A5 protein results in increased oxidation of Lithocholic Acid] which results in increased chemical synthesis of 3-ketocholanoic acid; CYP3A5 gene polymorphism affects the reaction [CYP3A5 gene results in increased oxidation of Lithocholic Acid]; Ketoconazole inhibits the reaction [CYP3A5 protein results in increased oxidation of Lithocholic Acid]; plastochromanol 8 inhibits the reaction [CYP3A5 protein results in increased oxidation of Lithocholic Acid]; tocotrienol, alpha inhibits the reaction [CYP3A5 protein results in increased oxidation of Lithocholic Acid]; tocotrienol, delta inhibits the reaction [CYP3A5 protein results in increased oxidation of Lithocholic Acid]; Tocotrienols inhibits the reaction [CYP3A5 protein results in increased oxidation of Lithocholic Acid]		 CTD PMID:20888898 PMID:31102695 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cyp4f1 cytochrome P450, family 4, subfamily f, polypeptide 1 decreases expression
multiple interactions		 ISO Lithocholic Acid results in decreased expression of CYP4F14 mRNA
Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of CYP4F14 mRNA]		 CTD PMID:20359477 NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046 		JBrowse link
G Cyp51 cytochrome P450, family 51 decreases expression ISO Lithocholic Acid results in decreased expression of CYP51 mRNA CTD PMID:20359477 NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases expression
multiple interactions
decreases activity		 EXP
ISO		 Lithocholic Acid results in decreased expression of CYP7A1 mRNA
[Lithocholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7A1 mRNA]; [Lithocholic Acid results in increased activity of NR1H4 protein] which results in increased expression of CYP7A1 mRNA; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7A1 mRNA]]; Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7A1 mRNA]
Lithocholic Acid results in decreased activity of CYP7A1 protein		 CTD PMID:1175606 PMID:16436656 PMID:17963371 PMID:19196849 PMID:20359477 More... NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases expression
multiple interactions		 ISO Lithocholic Acid results in decreased expression of CYP7B1 mRNA
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7B1 mRNA]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7B1 mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7B1 mRNA]]; Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7B1 mRNA]		 CTD PMID:19196849 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 multiple interactions
decreases expression		 ISO 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP8B1 mRNA]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP8B1 mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP8B1 mRNA]]; Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP8B1 mRNA]; Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of CYP8B1 mRNA] CTD PMID:16436656 PMID:19196849 PMID:20359477 PMID:25582706 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Degs1 delta(4)-desaturase, sphingolipid 1 increases expression ISO Lithocholic Acid results in increased expression of DEGS1 mRNA CTD PMID:21480330 NCBI chr13:93,946,154...93,953,677
Ensembl chr13:93,946,157...93,953,664 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 increases oxidation ISO DHRS11 protein results in increased oxidation of Lithocholic Acid CTD PMID:30926317 NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295 		JBrowse link
G Dio2 iodothyronine deiodinase 2 increases expression
multiple interactions
increases activity		 ISO Lithocholic Acid results in increased expression of DIO2 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithocholic Acid results in increased activity of DIO2 protein]		 CTD PMID:19036883 NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809 		JBrowse link
G Dio3 iodothyronine deiodinase 3 increases activity ISO Lithocholic Acid results in increased activity of DIO3 protein CTD PMID:19036883 NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660 		JBrowse link
G Dmp1 dentin matrix acidic phosphoprotein 1 increases expression ISO Lithocholic Acid results in increased expression of DMP1 mRNA CTD PMID:19000923 NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323 		JBrowse link
G Efna1 ephrin A1 multiple interactions ISO Lithocholic Acid analog inhibits the reaction [EPHA2 protein binds to EFNA1 protein]; Lithocholic Acid inhibits the reaction [[EPHA2 protein binds to EFNA1 protein] which results in increased phosphorylation of EPHA2 protein]; Lithocholic Acid inhibits the reaction [EFNA1 protein binds to EPHA2 protein]; Lithocholic Acid inhibits the reaction [EPHA2 protein binds to EFNA1 protein] CTD PMID:21479221 PMID:22529030 PMID:23489211 NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866 		JBrowse link
G Efnb2 ephrin B2 multiple interactions ISO Lithocholic Acid inhibits the reaction [[EPHB4 protein binds to EFNB2 protein] which results in increased phosphorylation of EPHB4 protein] CTD PMID:21479221 NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO EGF protein promotes the reaction [Lithocholic Acid results in increased activity of ALPL protein]; EGF protein promotes the reaction [Lithocholic Acid results in increased activity of TGFB1 protein] CTD PMID:19646460 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Epha2 Eph receptor A2 multiple interactions
increases expression		 ISO Lithocholic Acid analog binds to and results in decreased phosphorylation of and results in decreased activity of EPHA2 protein; Lithocholic Acid analog inhibits the reaction [EPHA2 protein binds to EFNA1 protein]; Lithocholic Acid binds to and results in decreased activity of EPHA2 protein; Lithocholic Acid inhibits the reaction [[EPHA2 protein binds to EFNA1 protein] which results in increased phosphorylation of EPHA2 protein]; Lithocholic Acid inhibits the reaction [EFNA1 protein binds to EPHA2 protein]; Lithocholic Acid inhibits the reaction [EPHA2 protein binds to EFNA1 protein]
Lithocholic Acid results in increased expression of EPHA2 protein
Lithocholic Acid inhibits the reaction [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein]		 CTD PMID:21479221 PMID:22529030 PMID:22845314 PMID:23489211 NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117 		JBrowse link
G Ephb4 EPH receptor B4 multiple interactions ISO Lithocholic Acid inhibits the reaction [[EPHB4 protein binds to EFNB2 protein] which results in increased phosphorylation of EPHB4 protein] CTD PMID:21479221 NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314 		JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in increased expression of EPHX1 mRNA CTD PMID:20359477 NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235 		JBrowse link
G Fabp6 fatty acid binding protein 6 increases expression ISO Lithocholic Acid results in increased expression of FABP6 mRNA CTD PMID:15821044 PMID:25582706 NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282 		JBrowse link
G Fads1 fatty acid desaturase 1 decreases expression ISO Lithocholic Acid results in decreased expression of FADS1 mRNA CTD PMID:20359477 NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734 		JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO Lithocholic Acid results in decreased expression of FADS2 mRNA CTD PMID:20359477 NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789 		JBrowse link
G Fads6 fatty acid desaturase 6 decreases expression ISO Lithocholic Acid results in decreased expression of FADS6 mRNA CTD PMID:20359477 NCBI chr10:100,522,981...100,538,181
Ensembl chr10:100,522,981...100,538,181 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO [[[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein; [[[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein] which results in increased activity of CASP9 protein; [[[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein] which results in increased cleavage of BID protein; [[Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein] which results in increased activity of CASP8 protein; [Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased activity of FAS protein; [Lithocholic Acid results in increased abundance of Reactive Oxygen Species] which results in increased localization of and results in increased activity of FAS protein; Lithocholic Acid results in increased localization of and results in increased activity of FAS protein CTD PMID:19054763 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Fasn fatty acid synthase multiple interactions
decreases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of FASN mRNA] CTD PMID:20359477 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fgb fibrinogen beta chain multiple interactions EXP [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGB mRNA CTD PMID:21311750 NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979 		JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression		 ISO [Lithocholic Acid results in increased activity of NR1H4 protein] which results in increased expression of FGF19 mRNA; [Lithocholic Acid results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; NR1I2 protein promotes the reaction [Lithocholic Acid results in increased expression of FGF19 mRNA]
Lithocholic Acid results in increased expression of FGF15 mRNA		 CTD PMID:17696253 PMID:22561792 PMID:25055961 PMID:25582706 NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Ftl1 ferritin light chain 1 multiple interactions ISO [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA CTD PMID:17724089 NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725 		JBrowse link
G Gcg glucagon multiple interactions
increases secretion		 ISO GNAT3 protein promotes the reaction [Lithocholic Acid results in increased secretion of GCG protein] CTD PMID:23341498 NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
decreases expression
multiple interactions
affects expression		 ISO Lithocholic Acid results in increased expression of GCLC mRNA; Lithocholic Acid results in increased expression of GCLC protein
Lithocholic Acid results in decreased expression of GCLC mRNA
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Lithocholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione; Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione]; S-Adenosylmethionine inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]
Lithocholic Acid affects the expression of GCLC mRNA; Lithocholic Acid affects the expression of GCLC protein
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of GCLC mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of GCLC protein]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in decreased expression of GCLC mRNA]		 CTD PMID:17724089 PMID:20146260 PMID:20977460 PMID:29794447 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit affects expression
decreases expression
multiple interactions
increases expression		 ISO Lithocholic Acid affects the expression of GCLM mRNA; Lithocholic Acid affects the expression of GCLM protein
Lithocholic Acid results in decreased expression of GCLM mRNA
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in decreased expression of GCLM mRNA]
Lithocholic Acid results in increased expression of GCLM protein
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA; [Lithocholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione; Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione]		 CTD PMID:17724089 PMID:20146260 PMID:29794447 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gnat3 G protein subunit alpha transducin 3 multiple interactions ISO GNAT3 protein promotes the reaction [Lithocholic Acid results in increased secretion of GCG protein] CTD PMID:23341498 NCBI chr 4:17,162,500...17,212,283
Ensembl chr 4:17,162,490...17,212,283 		JBrowse link
G Got1 glutamic-oxaloacetic transaminase 1 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of GOT1 protein
cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of GOT1 protein]		 CTD PMID:38104874 NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633 		JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 affects binding
increases expression
multiple interactions
increases response to substance		 ISO Lithocholic Acid binds to GPBAR1 protein
Lithocholic Acid results in increased expression of GPBAR1 mRNA
[Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Lithocholic Acid analog binds to and results in increased activity of GPBAR1 protein; Lithocholic Acid binds to and results in increased activity of GPBAR1 protein
GPBAR1 protein results in increased susceptibility to Lithocholic Acid		 CTD PMID:17963371 PMID:18180267 PMID:20023205 PMID:21454404 PMID:23041323 More... NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of GPT protein
cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of GPT protein]
cryptotanshinone inhibits the reaction [Lithocholic Acid results in increased expression of GPT protein]; dihydrotanshinone I inhibits the reaction [Lithocholic Acid results in increased expression of GPT protein]; Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of GPT protein]; tanshinone inhibits the reaction [Lithocholic Acid results in increased expression of GPT protein]		 CTD PMID:24742700 PMID:36804361 PMID:38104874 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO Lithocholic Acid results in increased phosphorylation of and results in decreased activity of GSK3B protein CTD PMID:20512997 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gss glutathione synthetase affects expression
multiple interactions		 ISO Lithocholic Acid affects the expression of GSS mRNA; Lithocholic Acid affects the expression of GSS protein
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]		 CTD PMID:20146260 NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO
EXP		 Lithocholic Acid binds to and results in decreased activity of GSTA1 protein
Lithocholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Lithocholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]		 CTD PMID:3783048 PMID:12206662 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression EXP Lithocholic Acid results in increased expression of GSTA2 mRNA CTD PMID:21311750 NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798 		JBrowse link
G Gsta3 glutathione S-transferase alpha 3 multiple interactions EXP Lithocholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein] CTD PMID:3783048 NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions
increases expression		 EXP Lithocholic Acid binds to and results in decreased activity of GSTA4 protein
Lithocholic Acid results in increased expression of GSTA4 mRNA		 CTD PMID:3954743 PMID:21311750 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 increases expression
multiple interactions		 ISO
EXP		 Lithocholic Acid results in increased expression of GSTM1 mRNA
NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of GSTM1 mRNA]
Lithocholic Acid binds to and results in decreased activity of GSTM1 protein		 CTD PMID:3954743 PMID:20977460 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions
increases expression		 EXP Lithocholic Acid binds to and results in decreased activity of GSTM2 protein
Lithocholic Acid results in increased expression of GSTM2 mRNA		 CTD PMID:3954743 PMID:21311750 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of HIF1A mRNA; Lithocholic Acid results in increased expression of HIF1A protein
cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of HIF1A mRNA]; cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of HIF1A protein]		 CTD PMID:38104874 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO [Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in increased expression of HMGCR mRNA CTD PMID:20359477 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 multiple interactions
decreases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of HMGCS2 mRNA] CTD PMID:20359477 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression
increases expression		 ISO NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of HMOX1 protein]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in decreased expression of HMOX1 mRNA]
Lithocholic Acid results in increased expression of HMOX1 mRNA; Lithocholic Acid results in increased expression of HMOX1 protein
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of HMOX1 protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of HMOX1 protein]]		 CTD PMID:17724089 PMID:20977460 PMID:24742700 PMID:29794447 PMID:31472180 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hnf1a HNF1 homeobox A decreases expression EXP Lithocholic Acid results in decreased expression of HNF1A mRNA CTD PMID:20888898 NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha decreases expression
multiple interactions		 EXP
ISO		 Lithocholic Acid results in decreased expression of HNF4A mRNA
[Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in decreased expression of HNF4A mRNA		 CTD PMID:20359477 PMID:20888898 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320 		JBrowse link
G Hr HR, lysine demethylase and nuclear receptor corepressor multiple interactions ISO HR protein inhibits the reaction [Lithocholic Acid results in increased activity of VDR protein]; HR protein inhibits the reaction [Lithocholic Acid results in increased expression of CYP24A1 mRNA]; HR protein promotes the reaction [Lithocholic Acid results in increased expression of CAMP mRNA]; Lithocholic Acid promotes the reaction [VDR protein binds to HR protein]; trichostatin A inhibits the reaction [HR protein inhibits the reaction [Lithocholic Acid results in increased activity of VDR protein]] CTD PMID:22466564 NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases phosphorylation ISO Lithocholic Acid results in increased phosphorylation of HSPB1 protein CTD PMID:21224350 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743 		JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression ISO Lithocholic Acid results in increased expression of ICAM1 mRNA; Lithocholic Acid results in increased expression of ICAM1 protein CTD PMID:16582018 PMID:24742700 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Idh1 isocitrate dehydrogenase (NADP(+)) 1 decreases expression ISO Lithocholic Acid results in decreased expression of IDH1 mRNA CTD PMID:20359477 NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708 		JBrowse link
G Il10 interleukin 10 increases expression
decreases abundance		 ISO Lithocholic Acid results in increased expression of IL10 mRNA
IL10 gene mutant form results in decreased abundance of Lithocholic Acid		 CTD PMID:24742700 PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression		 ISO cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of IL1B mRNA]; Lithocholic Acid inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Lithocholic Acid inhibits the reaction [IL1B protein results in increased expression of CXCL8 protein]; Lithocholic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]
Lithocholic Acid results in increased expression of and results in increased secretion of IL1B protein; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of and results in increased secretion of IL1B protein]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of IL1B mRNA]		 CTD PMID:18515093 PMID:24742700 PMID:29794447 PMID:38104874 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of IL6 mRNA; Lithocholic Acid results in increased expression of IL6 protein
cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of IL6 mRNA]; cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of IL6 protein]
Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of IL6 protein]		 CTD PMID:24742700 PMID:29794447 PMID:38104874 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO [Lithocholic Acid co-treated with Glucose] results in increased secretion of INS protein CTD PMID:23022524 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G Itgam integrin subunit alpha M increases expression ISO Lithocholic Acid analog results in increased expression of ITGAM mRNA CTD PMID:18180267 NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503 		JBrowse link
G Itgb1 integrin subunit beta 1 decreases metabolic processing ISO Lithocholic Acid results in decreased metabolism of ITGB1 protein CTD PMID:21224350 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO Lithocholic Acid results in increased expression of JUN mRNA CTD PMID:19000923 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit increases expression ISO Lithocholic Acid results in increased expression of JUNB mRNA CTD PMID:19000923 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035 		JBrowse link
G Kcnma1 potassium calcium-activated channel subfamily M alpha 1 multiple interactions
increases response to substance		 ISO
EXP		 [KCNMB1 protein co-treated with KCNMA1 protein] results in increased susceptibility to Lithocholic Acid; Lithocholic Acid promotes the reaction [[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium]; Lithocholic Acid results in increased activity of [KCNMB1 protein co-treated with KCNMA1 protein]
KCNMA1 mRNA alternative form results in increased susceptibility to Lithocholic Acid
KCNMA1 mRNA alternative form results in increased susceptibility to Lithocholic Acid; KCNMA1 protein results in increased susceptibility to Lithocholic Acid
Lithocholic Acid analog results in increased activity of [KCNMB1 protein co-treated with KCNMA1 protein]; Lithocholic Acid results in increased activity of [KCNMB1 protein co-treated with KCNMA1 protein]		 CTD PMID:18242174 PMID:18650555 PMID:22123969 PMID:28090300 NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198 		JBrowse link
G Kcnmb1 potassium calcium-activated channel subfamily M regulatory beta subunit 1 multiple interactions
increases response to substance
affects binding
increases activity		 ISO
EXP		 [KCNMB1 protein co-treated with KCNMA1 protein] results in increased susceptibility to Lithocholic Acid; Lithocholic Acid promotes the reaction [[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium]; Lithocholic Acid results in increased activity of [KCNMB1 protein co-treated with KCNMA1 protein]
KCNMB1 protein results in increased susceptibility to Lithocholic Acid
Lithocholic Acid analog results in increased activity of [KCNMB1 protein co-treated with KCNMA1 protein]; Lithocholic Acid results in increased activity of [KCNMB1 protein co-treated with KCNMA1 protein]
Lithocholic Acid binds to KCNMB1 protein
Lithocholic Acid analog results in increased activity of KCNMB1 protein; Lithocholic Acid results in increased activity of KCNMB1 protein		 CTD PMID:17468198 PMID:18650555 PMID:19852931 PMID:22123969 PMID:22945504 NCBI chr10:18,557,510...18,614,824
Ensembl chr10:18,557,904...18,565,798 		JBrowse link
G Klk6 kallikrein related-peptidase 6 multiple interactions EXP [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of KLK6 mRNA CTD PMID:21311750 NCBI chr 1:94,278,863...94,286,136
Ensembl chr 1:94,280,340...94,286,121 		JBrowse link
G Lcat lecithin cholesterol acyltransferase decreases expression
multiple interactions		 ISO Lithocholic Acid results in decreased expression of LCAT mRNA
[Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in decreased expression of LCAT mRNA		 CTD PMID:20359477 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231 		JBrowse link
G Ldlr low density lipoprotein receptor decreases expression ISO Lithocholic Acid results in decreased expression of LDLR mRNA CTD PMID:20359477 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lpcat1 lysophosphatidylcholine acyltransferase 1 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of LPCAT1 mRNA
NR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT1 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT1 mRNA]		 CTD PMID:21480330 PMID:23034213 NCBI chr 1:29,766,070...29,816,401
Ensembl chr 1:29,766,071...29,816,401 		JBrowse link
G Lpcat2 lysophosphatidylcholine acyltransferase 2 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of LPCAT2 mRNA
NR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT2 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT2 mRNA]		 CTD PMID:21480330 PMID:23034213 NCBI chr19:14,088,389...14,152,742
Ensembl chr19:14,089,686...14,152,829 		JBrowse link
G Lpcat3 lysophosphatidylcholine acyltransferase 3 decreases expression ISO Lithocholic Acid results in decreased expression of LPCAT3 mRNA CTD PMID:21480330 NCBI chr 4:157,468,397...157,509,889
Ensembl chr 4:157,468,290...157,509,880 		JBrowse link
G Lpcat4 lysophosphatidylcholine acyltransferase 4 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of LPCAT4 mRNA
NR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT4 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT4 mRNA]		 CTD PMID:21480330 PMID:23034213 NCBI chr 3:99,044,729...99,052,963
Ensembl chr 3:99,044,729...99,052,875 		JBrowse link
G Lpl lipoprotein lipase increases expression ISO Lithocholic Acid results in increased expression of LPL mRNA CTD PMID:20359477 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249 		JBrowse link
G Lrp2 LDL receptor related protein 2 decreases expression ISO Lithocholic Acid results in decreased expression of LRP2 protein CTD PMID:15375181 NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708 		JBrowse link
G Lypla1 lysophospholipase 1 multiple interactions
decreases expression		 ISO [Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in decreased expression of LYPLA1 mRNA
Lithocholic Acid results in decreased expression of LYPLA1 mRNA		 CTD PMID:20359477 PMID:21480330 NCBI chr 5:14,679,605...14,708,774
Ensembl chr 5:14,679,606...14,708,746 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO Lithocholic Acid results in increased expression of and results in increased activity of MAF protein; S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein] CTD PMID:20146260 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO Lithocholic Acid results in increased expression of and results in increased activity of MAFG protein; S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein] CTD PMID:20146260 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO MAP2K1 protein promotes the reaction [Lithocholic Acid results in increased expression of PLAUR mRNA] CTD PMID:19782465 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases activity		 ISO [Lithocholic Acid results in increased activity of MAPK1 protein] which results in increased expression of PLAUR mRNA; MAPK1 protein promotes the reaction [Lithocholic Acid results in increased expression of PLAUR mRNA] CTD PMID:19782465 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases activity		 ISO [Lithocholic Acid results in increased activity of MAPK3 protein] which results in increased expression of PLAUR mRNA CTD PMID:19782465 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member affects localization
multiple interactions
increases expression		 ISO Lithocholic Acid affects the localization of MCL1 protein
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid affects the localization of MCL1 protein]; [Lithocholic Acid co-treated with oltipraz] results in increased expression of MCL1 mRNA; Phenobarbital inhibits the reaction [Lithocholic Acid affects the localization of MCL1 protein]; Phenobarbital inhibits the reaction [Lithocholic Acid results in increased expression of MCL1 mRNA]; Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid affects the localization of MCL1 protein]		 CTD PMID:19433268 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression
increases expression		 ISO Lithocholic Acid results in decreased expression of MMP2 protein
Lithocholic Acid results in increased expression of MMP2 mRNA		 CTD PMID:16436656 PMID:21224350 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases expression ISO Lithocholic Acid results in decreased expression of MMP9 protein CTD PMID:21224350 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mras muscle RAS oncogene homolog affects binding EXP Lithocholic Acid binds to MRAS protein CTD PMID:18641422 NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408 		JBrowse link
G Mt1 metallothionein 1 increases expression EXP Lithocholic Acid results in increased expression of MT1A mRNA CTD PMID:21311750 NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049 		JBrowse link
G Mt2A metallothionein 2A increases expression EXP Lithocholic Acid results in increased expression of MT2A mRNA CTD PMID:21311750 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Lithocholic Acid inhibits the reaction [NR1I3 protein binds to NCOA1 protein]
Lithocholic Acid promotes the reaction [VDR protein binds to NCOA1 protein]		 CTD PMID:15489543 PMID:21917910 PMID:22466564 PMID:23015691 NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664 		JBrowse link
G Ncor1 nuclear receptor co-repressor 1 multiple interactions ISO Lithocholic Acid inhibits the reaction [VDR protein binds to NCOR1 protein] CTD PMID:22466564 NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032 		JBrowse link
G Ncor2 nuclear receptor co-repressor 2 multiple interactions ISO Lithocholic Acid inhibits the reaction [NCOR2 protein binds to CYP24A1 promoter]; Lithocholic Acid inhibits the reaction [VDR protein binds to NCOR2 protein]; Lithocholic Acid promotes the reaction [VDR protein binds to NCOR2 protein] CTD PMID:21917910 PMID:22466564 NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
decreases expression
decreases response to substance		 ISO [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN1 mRNA; Lithocholic Acid results in increased localization of and results in increased activity of NFE2L2 protein; NFE2L2 protein inhibits the reaction [Lithocholic Acid results in increased expression of GSTA4 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCA1 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC1 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC2 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC2 protein]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC4 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC5 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCG2 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of GCLC mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of GSTM1 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of NQO1 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of TXNRD1 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of TXNRD1 protein]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 mRNA]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 protein]
Lithocholic Acid results in decreased expression of NFE2L2 mRNA; Lithocholic Acid results in decreased expression of NFE2L2 protein
NFE2L2 protein results in decreased susceptibility to Lithocholic Acid
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of GCLM mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA; [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of NFE2L2 protein]; Lithocholic Acid results in decreased expression of and results in decreased activity of NFE2L2 protein; Lithocholic Acid results in increased expression of and results in increased localization of and results in increased activity of NFE2L2 protein; S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 protein]]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of NFE2L2 protein]]		 CTD PMID:17724089 PMID:20146260 PMID:20977460 PMID:29794447 PMID:31472180 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO Lithocholic Acid inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Lithocholic Acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]]; VDR protein promotes the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]] CTD PMID:18515093 PMID:31472180 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions
increases expression		 ISO Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of NLRP3 mRNA]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of NLRP3 protein]
Lithocholic Acid results in increased expression of NLRP3 mRNA; Lithocholic Acid results in increased expression of NLRP3 protein		 CTD PMID:29794447 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
decreases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of NQO1 mRNA
Lithocholic Acid results in decreased expression of NQO1 mRNA
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of NQO1 mRNA]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in decreased expression of NQO1 mRNA]		 CTD PMID:17724089 PMID:20977460 PMID:29794447 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 increases expression
multiple interactions
decreases expression		 EXP
ISO		 Lithocholic Acid results in increased expression of NR0B2 mRNA
Lithocholic Acid results in increased expression of NR0B2 mRNA; Lithocholic Acid results in increased expression of NR0B2 protein
[Lithocholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA
[Lithocholic Acid binds to VDR protein] which results in increased expression of NR0B2 mRNA
Lithocholic Acid results in decreased expression of NR0B2 mRNA
[Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in decreased expression of NR0B2 mRNA		 CTD PMID:17963371 PMID:19562681 PMID:20359477 PMID:20888898 PMID:22540009 More... NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 decreases expression
decreases response to substance
multiple interactions		 EXP
ISO		 Lithocholic Acid results in decreased expression of NR1H3 mRNA
NR1H3 protein results in decreased susceptibility to Lithocholic Acid
Lithocholic Acid inhibits the reaction [NR1H3 protein results in increased expression of SLC51A mRNA]; Lithocholic Acid inhibits the reaction [NR1H3 protein results in increased expression of SLCO1B2 mRNA]; Lithocholic Acid promotes the reaction [NR1H3 protein results in increased expression of ABCB11 mRNA]; Lithocholic Acid promotes the reaction [NR1H3 protein results in increased expression of ABCC4 mRNA]; NR1H3 protein inhibits the reaction [Lithocholic Acid results in decreased expression of SLC10A1 mRNA]; NR1H3 protein inhibits the reaction [Lithocholic Acid results in increased expression of SLC10A2 mRNA]; NR1H3 protein inhibits the reaction [Lithocholic Acid results in increased expression of SLC51B mRNA]		 CTD PMID:17256725 PMID:20359477 PMID:20888898 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
increases expression
increases activity
increases response to substance
decreases expression		 EXP
ISO		 [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGB mRNA; [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of UGT2B15 mRNA; Lithocholic Acid binds to and results in increased activity of NR1H4 protein; NR1H4 protein inhibits the reaction [Lithocholic Acid results in increased expression of CYP3A11 mRNA]
[Lithocholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Lithocholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Lithocholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Lithocholic Acid promotes the reaction [NR1H4 protein binds to UGT2B7 promoter]] which results in decreased expression of UGT2B7 mRNA; [Lithocholic Acid results in increased activity of NR1H4 protein] which results in increased expression of FGF19 mRNA; Lithocholic Acid analog binds to and results in increased activity of NR1H4 protein; Lithocholic Acid binds to and results in decreased activity of NR1H4 protein; Lithocholic Acid binds to and results in increased activity of NR1H4 protein; Lithocholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Lithocholic Acid inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]; Lithocholic Acid promotes the reaction [NR1H4 protein binds to UGT2B7 promoter]
Lithocholic Acid results in increased expression of NR1H4 mRNA
NR1H4 protein results in increased susceptibility to Lithocholic Acid; NR1H4 results in increased susceptibility to Lithocholic Acid
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid inhibits the reaction [NR1I3 protein results in increased expression of NR1H4 mRNA]]; [Lithocholic Acid results in increased activity of NR1H4 protein] which results in increased expression of CYP7A1 mRNA; Lithocholic Acid inhibits the reaction [NR1I3 protein results in increased expression of NR1H4 mRNA]; NR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT1 mRNA]; NR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT2 mRNA]; NR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT4 mRNA]; NR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of TGFB1 mRNA]; Phenobarbital inhibits the reaction [Lithocholic Acid inhibits the reaction [NR1I3 protein results in increased expression of NR1H4 mRNA]]
Lithocholic Acid results in decreased expression of NR1H4 mRNA		 CTD PMID:12875239 PMID:14684751 PMID:15489543 PMID:15821044 PMID:17963371 More... NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 decreases response to substance
increases response to substance
decreases expression
multiple interactions
increases localization
increases activity		 ISO
EXP		 NR1I2 protein results in decreased susceptibility to Lithocholic Acid
NR1I2 results in increased susceptibility to Lithocholic Acid
Lithocholic Acid results in decreased expression of NR1I2 mRNA; Lithocholic Acid results in decreased expression of NR1I2 protein
[Lithocholic Acid binds to and results in increased activity of NR1I2 protein] which results in increased expression of ABCC2 mRNA; [Lithocholic Acid binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A23-3A1 mRNA; [NR1I2 protein co-treated with RXRA protein] promotes the reaction [Lithocholic Acid results in increased expression of SULT2A1 mRNA]; Lithocholic Acid binds to and results in increased activity of NR1I2 protein
Lithocholic Acid results in increased localization of NR1I2 protein
[Lithocholic Acid results in increased activity of NR1I2 protein] which results in increased expression of ABCC2 mRNA; [Lithocholic Acid results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Lithocholic Acid results in increased activity of NR1I2 protein] which results in increased expression of CYP3A11 mRNA; [Lithocholic Acid results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; Lithocholic Acid analog binds to and results in increased activity of NR1I2 protein; Lithocholic Acid binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [Lithocholic Acid results in increased expression of FGF19 mRNA]		 CTD PMID:12370413 PMID:14570758 PMID:15358766 PMID:15883047 PMID:16054614 More... NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases expression
decreases response to substance
decreases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of NR1I3 mRNA
NR1I3 protein results in decreased susceptibility to Lithocholic Acid
Lithocholic Acid results in decreased expression of NR1I3 mRNA
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid inhibits the reaction [NR1I3 protein results in increased expression of NR1H4 mRNA]]; 1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein]; [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased activity of NR1I3 protein] which results in decreased susceptibility to Lithocholic Acid; [Phenobarbital results in increased activity of NR1I3 protein] which results in decreased susceptibility to Lithocholic Acid; Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein; Lithocholic Acid inhibits the reaction [NR1I3 protein binds to NCOA1 protein]; Lithocholic Acid inhibits the reaction [NR1I3 protein results in increased expression of NR1H4 mRNA]; NR1I3 protein affects the reaction [Lithocholic Acid results in increased expression of ABCC3 mRNA]; NR1I3 protein affects the reaction [Lithocholic Acid results in increased expression of CYP2B10 mRNA]; NR1I3 protein affects the reaction [Lithocholic Acid results in increased expression of CYP3A11 mRNA]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of BAAT mRNA]]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP27A1 mRNA]]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7A1 mRNA]]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7B1 mRNA]]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of CYP8B1 mRNA]]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of UGT1A1 mRNA]]; NR1I3 protein promotes the reaction [[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Lithocholic Acid] results in increased expression of CYP2B10 mRNA]; NR1I3 protein promotes the reaction [[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Lithocholic Acid] results in increased expression of CYP39A1 mRNA]; NR1I3 protein promotes the reaction [[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Lithocholic Acid] results in increased expression of CYP3A11 mRNA]; NR1I3 protein promotes the reaction [[Phenobarbital co-treated with Lithocholic Acid] results in increased expression of CYP39A1 mRNA]; NR1I3 protein promotes the reaction [[Phenobarbital co-treated with Lithocholic Acid] results in increased expression of CYP3A11 mRNA]; NR1I3 protein promotes the reaction [[Pregnenolone Carbonitrile co-treated with Lithocholic Acid] results in increased expression of CYP2B10 mRNA]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of BAAT mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP27A1 mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP7B1 mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of CYP8B1 mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of UGT1A1 mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in increased abundance of Bile Acids and Salts]]; oltipraz inhibits the reaction [Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein]; Phenobarbital inhibits the reaction [Lithocholic Acid inhibits the reaction [NR1I3 protein results in increased expression of NR1H4 mRNA]]; Phenobarbital promotes the reaction [Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein]; Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein]		 CTD PMID:14742670 PMID:15358766 PMID:16929008 PMID:19196849 PMID:19433268 More... NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Nr5a2 nuclear receptor subfamily 5, group A, member 2 decreases expression EXP Lithocholic Acid results in decreased expression of NR5A2 mRNA CTD PMID:20888898 NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326 		JBrowse link
G Ocln occludin multiple interactions ISO Lithocholic Acid inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [TNF protein results in decreased expression of and affects the localization of OCLN protein]]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of OCLN protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of OCLN protein]] CTD PMID:31472180 NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150 		JBrowse link
G Orm1 orosomucoid 1 increases expression ISO Lithocholic Acid results in increased expression of ORM1 mRNA CTD PMID:19000923 NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases activity		 ISO 3-aminobenzamide inhibits the reaction [Lithocholic Acid analog results in increased activity of PARP1 protein] CTD PMID:2120135 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pctp phosphatidylcholine transfer protein decreases expression ISO Lithocholic Acid results in decreased expression of PCTP mRNA CTD PMID:20359477 NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867 		JBrowse link
G Pcyt1b phosphate cytidylyltransferase 1B, choline increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of PCYT1B mRNA
SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of PCYT1B mRNA]		 CTD PMID:21480330 PMID:23034213 NCBI chr  X:58,378,090...58,471,623
Ensembl chr  X:58,378,116...58,468,935 		JBrowse link
G Pgk1 phosphoglycerate kinase 1 increases expression ISO Lithocholic Acid results in increased expression of PGK1 protein CTD PMID:21224350 NCBI chr  X:71,271,454...71,287,429
Ensembl chr  X:71,271,440...71,287,418 		JBrowse link
G Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5 increases expression ISO Lithocholic Acid results in increased expression of PIK3R5 mRNA CTD PMID:19000923 NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374 		JBrowse link
G Plaur plasminogen activator, urokinase receptor multiple interactions
increases expression		 ISO [Lithocholic Acid results in increased activity of MAPK1 protein] which results in increased expression of PLAUR mRNA; [Lithocholic Acid results in increased activity of MAPK3 protein] which results in increased expression of PLAUR mRNA; MAP2K1 protein promotes the reaction [Lithocholic Acid results in increased expression of PLAUR mRNA]; MAPK1 protein promotes the reaction [Lithocholic Acid results in increased expression of PLAUR mRNA] CTD PMID:19782465 NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595 		JBrowse link
G Pld1 phospholipase D1 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of PLD1 mRNA
SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of PLD1 mRNA]		 CTD PMID:21480330 PMID:23034213 NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692 		JBrowse link
G Pld2 phospholipase D2 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of PLD2 mRNA
SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of PLD2 mRNA]		 CTD PMID:21480330 PMID:23034213 NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808 		JBrowse link
G Plpp1 phospholipid phosphatase 1 increases expression ISO Lithocholic Acid results in increased expression of PLPP1 mRNA CTD PMID:20359477 NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268 		JBrowse link
G Plpp2 phospholipid phosphatase 2 increases expression ISO Lithocholic Acid results in increased expression of PLPP2 mRNA CTD PMID:20359477 NCBI chr 7:10,175,918...10,184,032
Ensembl chr 7:10,175,948...10,184,071 		JBrowse link
G Plscr1 phospholipid scramblase 1 multiple interactions
increases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of PLSCR1 mRNA] CTD PMID:20359477 NCBI chr 8:92,784,279...92,804,698
Ensembl chr 8:92,784,356...92,804,692 		JBrowse link
G Polb DNA polymerase beta multiple interactions EXP Lithocholic Acid analog binds to and results in decreased activity of POLB protein; Lithocholic Acid binds to and results in decreased activity of POLB protein; Lithocholic Acid binds to and results in decreased activity of POLB protein mutant form CTD PMID:15311928 PMID:15656580 PMID:16996474 NCBI chr16:69,379,438...69,402,710
Ensembl chr16:69,379,400...69,404,812 		JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Lithocholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases expression
multiple interactions		 ISO Lithocholic Acid results in decreased expression of PPARA mRNA
[PPARA protein co-treated with CREB1 protein] promotes the reaction [Lithocholic Acid results in increased expression of PTGS2 mRNA]
[Lithocholic Acid co-treated with Pregnenolone Carbonitrile] results in decreased expression of PPARA mRNA		 CTD PMID:18648741 PMID:20359477 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Prkcb protein kinase C, beta increases activity ISO Lithocholic Acid results in increased activity of PRKCB protein CTD PMID:7705931 NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536 		JBrowse link
G Psmb4 proteasome 20S subunit beta 4 decreases expression
affects expression		 EXP Lithocholic Acid results in decreased expression of PSMB4 mRNA
Lithocholic Acid affects the expression of PSMB4 mRNA		 CTD PMID:18246545 NCBI chr 2:182,442,757...182,445,532
Ensembl chr 2:182,442,756...182,445,746 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression		 ISO [PPARA protein co-treated with CREB1 protein] promotes the reaction [Lithocholic Acid results in increased expression of PTGS2 mRNA]; [SLCO1B3 protein results in increased transport of Lithocholic Acid] which results in increased expression of PTGS2 mRNA CTD PMID:18648741 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Ptk2 protein tyrosine kinase 2 multiple interactions ISO Lithocholic Acid results in decreased phosphorylation of and results in decreased activity of PTK2 protein CTD PMID:21224350 NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783 		JBrowse link
G Pxn paxillin multiple interactions ISO Lithocholic Acid results in decreased phosphorylation of and results in decreased activity of PXN protein CTD PMID:21224350 NCBI chr12:41,060,791...41,107,952
Ensembl chr12:41,060,791...41,107,931 		JBrowse link
G Pycard PYD and CARD domain containing multiple interactions
increases expression		 ISO Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of PYCARD mRNA]; Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of PYCARD protein]
Lithocholic Acid results in increased expression of PYCARD mRNA; Lithocholic Acid results in increased expression of PYCARD protein		 CTD PMID:29794447 NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955 		JBrowse link
G Rab12 RAB12, member RAS oncogene family affects binding EXP Lithocholic Acid binds to RAB12 protein CTD PMID:18641422 NCBI chr 9:106,480,301...106,506,895
Ensembl chr 9:106,480,301...106,506,910 		JBrowse link
G Rab3a RAB3A, member RAS oncogene family affects binding EXP Lithocholic Acid binds to RAB3A protein CTD PMID:18641422 NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336 		JBrowse link
G Rab3d RAB3D, member RAS oncogene family affects binding EXP Lithocholic Acid binds to RAB3D protein CTD PMID:18641422 NCBI chr 8:20,438,622...20,449,269
Ensembl chr 8:20,439,294...20,449,185 		JBrowse link
G Rangap1 RAN GTPase activating protein 1 increases phosphorylation ISO Lithocholic Acid results in increased phosphorylation of RANGAP1 protein CTD PMID:21224350 NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Lithocholic Acid inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein]] CTD PMID:18515093 PMID:31472180 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rnh1 ribonuclease/angiogenin inhibitor 1 increases expression ISO Lithocholic Acid results in increased expression of RNH1 protein CTD PMID:21224350 NCBI chr 1:196,269,293...196,281,763
Ensembl chr 1:196,269,293...196,281,910 		JBrowse link
G Rxra retinoid X receptor alpha multiple interactions ISO
EXP		 Lithocholic Acid promotes the reaction [VDR protein binds to RXRA protein]
[NR1I2 protein co-treated with RXRA protein] promotes the reaction [Lithocholic Acid results in increased expression of SULT2A1 mRNA]		 CTD PMID:12370413 PMID:15578590 PMID:15824121 PMID:20153625 PMID:21917910 NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712 		JBrowse link
G Rxrb retinoid X receptor beta affects binding ISO Lithocholic Acid binds to RXRB protein CTD PMID:11939783 NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773 		JBrowse link
G S100g S100 calcium binding protein G increases expression ISO
EXP		 Lithocholic Acid results in increased expression of S100G mRNA CTD PMID:15824121 PMID:17535892 NCBI chr  X:31,705,853...31,708,422
Ensembl chr  X:31,705,866...31,708,433 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 decreases expression
increases expression		 ISO Lithocholic Acid results in decreased expression of SCARB1 mRNA; Lithocholic Acid results in decreased expression of SCARB1 protein
Lithocholic Acid results in increased expression of SCARB1 mRNA		 CTD PMID:15883047 PMID:19000923 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions
decreases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of SCD1 mRNA] CTD PMID:20359477 PMID:21480330 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Sgms1 sphingomyelin synthase 1 increases expression ISO Lithocholic Acid results in increased expression of SGMS1 mRNA CTD PMID:21480330 NCBI chr 1:229,996,673...230,259,591
Ensembl chr 1:229,998,119...230,259,603 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of SIRT1 protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of SIRT1 protein]] CTD PMID:31472180 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions
decreases expression		 ISO [Lithocholic Acid co-treated with 1,4-bis(2-(3,5-dichloropyridyloxy))benzene] results in increased expression of SLC10A1 mRNA; NR1H3 protein inhibits the reaction [Lithocholic Acid results in decreased expression of SLC10A1 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in decreased expression of SLC10A1 mRNA]
Lithocholic Acid results in decreased expression of SLC10A1 mRNA; Lithocholic Acid results in decreased expression of SLC10A1 protein		 CTD PMID:12637555 PMID:16436656 PMID:17256725 PMID:18032408 PMID:20977460 More... NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 multiple interactions
increases expression		 ISO NR1H3 protein inhibits the reaction [Lithocholic Acid results in increased expression of SLC10A2 mRNA] CTD PMID:17256725 PMID:25582706 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Lithocholic Acid results in increased expression of SLC2A1 mRNA CTD PMID:19000923 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416 		JBrowse link
G Slc51a solute carrier family 51 member A multiple interactions
increases expression		 EXP
ISO		 [Lithocholic Acid binds to VDR protein] which affects the expression of SLC51A mRNA
Lithocholic Acid results in increased expression of SLC51A mRNA
Lithocholic Acid inhibits the reaction [NR1H3 protein results in increased expression of SLC51A mRNA]		 CTD PMID:17256725 PMID:19562681 PMID:25055961 PMID:25582706 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions
increases expression		 ISO
EXP		 NR1H3 protein inhibits the reaction [Lithocholic Acid results in increased expression of SLC51B mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of SLC51B mRNA]
[Lithocholic Acid binds to VDR protein] which affects the expression of SLC51B mRNA		 CTD PMID:17256725 PMID:19562681 PMID:23034213 PMID:25055961 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression ISO Lithocholic Acid results in increased expression of SLCO1A4 mRNA CTD PMID:23034213 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 decreases expression
increases transport
increases expression
increases uptake
multiple interactions		 ISO Lithocholic Acid results in decreased expression of SLCO1B2 mRNA
SLCO1B3 protein results in increased transport of Lithocholic Acid
Lithocholic Acid results in increased expression of SLCO1B3 mRNA
SLCO1B3 protein results in increased uptake of Lithocholic Acid
[SLCO1B3 protein results in increased transport of Lithocholic Acid] which results in increased expression of PTGS2 mRNA
Lithocholic Acid results in increased expression of SLCO1B2 mRNA
Lithocholic Acid inhibits the reaction [NR1H3 protein results in increased expression of SLCO1B2 mRNA]		 CTD PMID:12637555 PMID:16534140 PMID:17256725 PMID:18648741 PMID:25055961 More... NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Smad3 SMAD family member 3 multiple interactions
increases response to substance		 ISO SMAD3 protein promotes the reaction [Lithocholic Acid results in decreased expression of SLC10A1 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC1 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of ABCC4 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of CHKA mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT1 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT2 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT4 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of PCYT1B mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of PLD1 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of PLD2 mRNA]; SMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of SLC51B mRNA]
SMAD3 protein results in increased susceptibility to Lithocholic Acid		 CTD PMID:23034213 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960 		JBrowse link
G Smpd3 sphingomyelin phosphodiesterase 3 increases expression ISO Lithocholic Acid results in increased expression of SMPD3 mRNA CTD PMID:21480330 NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749 		JBrowse link
G Sod1 superoxide dismutase 1 increases expression EXP Lithocholic Acid results in increased expression of SOD1 mRNA CTD PMID:21311750 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sptlc1 serine palmitoyltransferase, long chain base subunit 1 increases expression ISO Lithocholic Acid results in increased expression of SPTLC1 mRNA CTD PMID:21480330 NCBI chr17:11,877,249...11,916,295
Ensembl chr17:11,877,249...11,916,295 		JBrowse link
G Sptlc2 serine palmitoyltransferase, long chain base subunit 2 increases expression ISO Lithocholic Acid results in increased expression of SPTLC2 mRNA CTD PMID:21480330 NCBI chr 6:106,948,682...107,031,532
Ensembl chr 6:106,950,949...107,031,542 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions
decreases expression		 ISO Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in decreased expression of SREBF1 mRNA] CTD PMID:20359477 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G St3gal1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 multiple interactions ISO Lithocholic Acid analog results in decreased expression of and results in decreased activity of ST3GAL1 protein CTD PMID:21224350 NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236 		JBrowse link
G St3gal3 ST3 beta-galactoside alpha-2,3-sialyltransferase 3 decreases activity ISO Lithocholic Acid analog results in decreased activity of ST3GAL3 protein CTD PMID:21224350 NCBI chr 5:131,470,348...131,670,794
Ensembl chr 5:131,470,348...131,670,810 		JBrowse link
G St3gal4 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 increases phosphorylation ISO Lithocholic Acid results in increased phosphorylation of ST3GAL4 protein CTD PMID:21224350 NCBI chr 8:33,415,666...33,465,319
Ensembl chr 8:33,415,671...33,524,389 		JBrowse link
G St6gal1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 decreases activity ISO Lithocholic Acid analog results in decreased activity of ST6GAL1 protein CTD PMID:21224350 NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of and results in increased phosphorylation of STAT3 mRNA]; Lithocholic Acid results in increased expression of and results in increased phosphorylation of STAT3 mRNA CTD PMID:38104874 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Stim1 stromal interaction molecule 1 affects localization EXP Lithocholic Acid affects the localization of STIM1 protein CTD PMID:18342630 NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363 		JBrowse link
G Stmn1 stathmin 1 increases expression ISO Lithocholic Acid results in increased expression of STMN1 mRNA CTD PMID:19000923 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 increases sulfation
multiple interactions
increases expression		 ISO
EXP		 SULT2A1 protein results in increased sulfation of Lithocholic Acid
[Cyclosporine results in decreased activity of SULT2A1 protein] which results in increased abundance of Lithocholic Acid
[NR1I2 protein co-treated with RXRA protein] promotes the reaction [Lithocholic Acid results in increased expression of SULT2A1 mRNA]		 CTD PMID:12370413 PMID:20102295 PMID:21839837 PMID:26198044 PMID:36473578 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tfrc transferrin receptor increases expression ISO Lithocholic Acid results in increased expression of TFRC mRNA CTD PMID:19000923 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of TGFB1 mRNA
EGF protein promotes the reaction [Lithocholic Acid results in increased activity of TGFB1 protein]
NR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of TGFB1 mRNA]		 CTD PMID:19646460 PMID:21480330 PMID:23034213 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tgfbr1 transforming growth factor, beta receptor 1 increases expression ISO Lithocholic Acid results in increased expression of TGFBR1 mRNA CTD PMID:23034213 NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777 		JBrowse link
G Tgfbr2 transforming growth factor, beta receptor 2 increases expression ISO Lithocholic Acid results in increased expression of TGFBR2 mRNA CTD PMID:23034213 NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 increases expression ISO Lithocholic Acid results in increased expression of TIMP1 mRNA CTD PMID:16436656 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO Lithocholic Acid inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [TNF protein results in decreased expression of and affects the localization of TJP1 protein]]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of TJP1 protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of TJP1 protein]] CTD PMID:31472180 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression		 ISO cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of TNF mRNA]; cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of TNF protein]; Lithocholic Acid inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [TNF protein results in decreased expression of and affects the localization of CDH1 protein]]; Lithocholic Acid inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [TNF protein results in decreased expression of and affects the localization of CLDN1 protein]]; Lithocholic Acid inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [TNF protein results in decreased expression of and affects the localization of OCLN protein]]; Lithocholic Acid inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [TNF protein results in decreased expression of and affects the localization of TJP1 protein]]; Lithocholic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of CDH1 protein]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of CLDN1 protein]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of NFE2L2 protein]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of OCLN protein]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of and affects the localization of TJP1 protein]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of HMOX1 protein]; Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of SIRT1 protein]; Lithocholic Acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; TNF protein promotes the reaction [Lithocholic Acid results in increased expression of CASP3 protein]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of CDH1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of CLDN1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of HMOX1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of NFE2L2 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of OCLN protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of SIRT1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of TJP1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein]]; VDR protein promotes the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]
Vardenafil Dihydrochloride inhibits the reaction [Lithocholic Acid results in increased expression of TNF protein]
Lithocholic Acid results in increased expression of TNF mRNA; Lithocholic Acid results in increased expression of TNF protein		 CTD PMID:18515093 PMID:21480330 PMID:23566200 PMID:23627780 PMID:29794447 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO Lithocholic Acid inhibits the reaction [Vitamin D results in increased expression of TNFSF11 mRNA] CTD PMID:20055894 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Trap1 TNF receptor-associated protein 1 decreases expression ISO Lithocholic Acid results in decreased expression of TRAP1 protein CTD PMID:21224350 NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981 		JBrowse link
G Trpv6 transient receptor potential cation channel, subfamily V, member 6 multiple interactions
increases expression		 ISO
EXP		 [Lithocholic Acid analog binds to and results in increased activity of VDR protein] which results in increased expression of TRPV6 mRNA; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of TRPV6 mRNA
Lithocholic Acid results in increased expression of TRPV6 mRNA		 CTD PMID:15489543 PMID:17535892 PMID:18180267 NCBI chr 4:70,507,347...70,523,013
Ensembl chr 4:70,507,348...70,523,017 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions
increases expression		 ISO [Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN1 mRNA
Lithocholic Acid results in increased expression of TXN protein		 CTD PMID:17724089 NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629 		JBrowse link
G Txnrd1 thioredoxin reductase 1 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of TXNRD1 mRNA; Lithocholic Acid results in increased expression of TXNRD1 protein
[Lithocholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA
NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of TXNRD1 mRNA]; NFE2L2 protein promotes the reaction [Lithocholic Acid results in increased expression of TXNRD1 protein]		 CTD PMID:17724089 PMID:20977460 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions
decreases expression		 ISO 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of UGT1A1 mRNA]; NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [Lithocholic Acid results in decreased expression of UGT1A1 mRNA]]; NR1I3 protein promotes the reaction [Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of UGT1A1 mRNA]]; Phenobarbital inhibits the reaction [Lithocholic Acid results in decreased expression of UGT1A1 mRNA] CTD PMID:19196849 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 increases expression
multiple interactions		 ISO Lithocholic Acid results in increased expression of UGT1A3 mRNA
[Uridine Diphosphate Glucuronic Acid co-treated with UGT1A3 protein] results in increased metabolism of Lithocholic Acid		 CTD PMID:20189675 PMID:36473578 NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt2b UDP glycosyltransferase 2 family, polypeptide B increases glucuronidation EXP UGT2B protein results in increased glucuronidation of Lithocholic Acid CTD PMID:2429951 NCBI chr14:20,630,572...20,665,062
Ensembl chr14:20,630,250...20,651,776 		JBrowse link
G Ugt2b1 UDP glucuronosyltransferase 2 family, polypeptide B1 increases expression EXP Lithocholic Acid results in increased expression of UGT2B17 mRNA CTD PMID:21311750 NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986 		JBrowse link
G Ugt2b15 UDP glucuronosyltransferase family 2 member B15 multiple interactions EXP [Lithocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of UGT2B15 mRNA CTD PMID:21311750 NCBI chr14:20,768,015...20,783,599
Ensembl chr14:20,768,015...20,783,589 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 multiple interactions ISO [Lithocholic Acid promotes the reaction [NR1H4 protein binds to UGT2B7 promoter]] which results in decreased expression of UGT2B7 mRNA; Lithocholic Acid promotes the reaction [NR1H4 protein binds to UGT2B7 promoter] CTD PMID:15821044 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression ISO Lithocholic Acid results in increased expression of VCAM1 mRNA; Lithocholic Acid results in increased expression of VCAM1 protein CTD PMID:16582018 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
G Vdr vitamin D receptor multiple interactions
affects binding
increases phosphorylation
increases activity
increases expression
decreases expression		 ISO
EXP		 Lithocholic Acid binds to and results in increased activity of VDR protein; Lithocholic Acid binds to and results in increased activity of VDR protein mutant form; Lithocholic Acid promotes the reaction [VDR protein binds to RXRA protein]; VDR protein promotes the reaction [Lithocholic Acid results in increased expression of CYP3A4 mRNA]; VDR protein promotes the reaction [Lithocholic Acid results in increased expression of CYP3A4 protein]
Lithocholic Acid analog binds to VDR protein; Lithocholic Acid binds to VDR protein; Lithocholic Acid binds to VDR protein mutant form
Lithocholic Acid results in increased phosphorylation of VDR protein
[Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CYP24A1 mRNA; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of KLK6 mRNA; [Lithocholic Acid binds to VDR protein] which affects the expression of SLC51A mRNA; [Lithocholic Acid binds to VDR protein] which affects the expression of SLC51B mRNA; [Lithocholic Acid binds to VDR protein] which results in increased expression of NR0B2 mRNA; Lithocholic Acid binds to and results in increased activity of VDR protein
Lithocholic Acid metabolite results in increased activity of VDR protein; Lithocholic Acid results in increased activity of VDR protein
[Lithocholic Acid analog binds to and results in increased activity of VDR protein] which results in increased expression of CYP24A1 mRNA; [Lithocholic Acid analog binds to and results in increased activity of VDR protein] which results in increased expression of TRPV6 mRNA; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CAMP mRNA; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CDH1 mRNA; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CYP24A1 mRNA; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of CYP3A4 mRNA; [Lithocholic Acid binds to and results in increased activity of VDR protein] which results in increased expression of TRPV6 mRNA; [Lithocholic Acid binds to VDR protein] which results in decreased activity of CTNNB1 mRNA; HR protein inhibits the reaction [Lithocholic Acid results in increased activity of VDR protein]; Lithocholic Acid analog binds to and results in increased activity of VDR protein; Lithocholic Acid binds to and results in increased activity of and results in increased localization of VDR protein; Lithocholic Acid binds to and results in increased activity of VDR protein; Lithocholic Acid binds to and results in increased activity of VDR protein mutant form; Lithocholic Acid inhibits the reaction [1,25-dihydroxy-26,27-dimethylcholecalciferol binds to VDR protein]; Lithocholic Acid inhibits the reaction [VDR protein binds to NCOR1 protein]; Lithocholic Acid inhibits the reaction [VDR protein binds to NCOR2 protein]; Lithocholic Acid promotes the reaction [VDR protein binds to CYP24A1 promoter]; Lithocholic Acid promotes the reaction [VDR protein binds to HR protein]; Lithocholic Acid promotes the reaction [VDR protein binds to NCOA1 protein]; Lithocholic Acid promotes the reaction [VDR protein binds to NCOR2 protein]; Lithocholic Acid promotes the reaction [VDR protein binds to RXRA protein]; Lithocholic Acid results in increased expression of and results in increased activity of VDR protein; Lithocholic Acid results in increased localization of [VDR protein co-treated with CAV1 protein]; trichostatin A inhibits the reaction [HR protein inhibits the reaction [Lithocholic Acid results in increased activity of VDR protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of CDH1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of CLDN1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of HMOX1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of NFE2L2 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of OCLN protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of SIRT1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in decreased expression of TJP1 protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]]; VDR protein affects the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein]]; VDR protein promotes the reaction [Lithocholic Acid inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]]; VDR protein promotes the reaction [Lithocholic Acid results in increased expression of ABCB1 mRNA]; VDR protein promotes the reaction [Lithocholic Acid results in increased expression of CYP3A4 mRNA]
Lithocholic Acid results in increased expression of VDR mRNA; Lithocholic Acid results in increased expression of VDR protein
Lithocholic Acid results in decreased expression of VDR mRNA		 CTD PMID:14525957 PMID:15489543 PMID:15578590 PMID:15824121 PMID:17963371 More... NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Lithocholic Acid results in increased expression of VEGFA mRNA CTD PMID:19000923 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Wdr1 WD repeat domain 1 decreases expression ISO Lithocholic Acid results in decreased expression of WDR1 protein CTD PMID:21224350 NCBI chr14:72,258,032...72,291,768
Ensembl chr14:72,257,956...72,291,766 		JBrowse link
G Zeb2 zinc finger E-box binding homeobox 2 increases expression ISO Lithocholic Acid results in increased expression of ZEB2 mRNA CTD PMID:19000923 NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157 		JBrowse link
lithocholic acid sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO sulfolithocholic acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Gsta4 glutathione S-transferase alpha 4 multiple interactions EXP sulfolithocholic acid binds to and results in decreased activity of GSTA4 protein CTD PMID:3954743 NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions EXP sulfolithocholic acid binds to and results in decreased activity of GSTM1 protein CTD PMID:3954743 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions EXP sulfolithocholic acid binds to and results in decreased activity of GSTM2 protein CTD PMID:3954743 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
obeticholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin decreases expression ISO obeticholic acid results in decreased expression of A2M mRNA CTD PMID:27939613 NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786 		JBrowse link
G Abca1 ATP binding cassette subfamily A member 1 decreases expression ISO obeticholic acid results in decreased expression of ABCA1 mRNA CTD PMID:27939613 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions
increases expression		 ISO
EXP		 obeticholic acid promotes the reaction [PRMT1 protein binds to ABCB11 promoter]
Obeticholic acid inhibits the reaction [ethanol decreases expression of Abcb11 protein in liver]
[obeticholic acid co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCB11 protein; obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in decreased expression of ABCB11 protein]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein]
obeticholic acid results in increased expression of ABCB11 mRNA
obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCB11 mRNA]; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB11 mRNA]		 CTD
RGD		 PMID:15644430 PMID:15911693 PMID:27255380 PMID:27939613 PMID:29660435 More... RGD:15036816 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 multiple interactions
increases expression		 EXP
ISO		 obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB4 mRNA]
obeticholic acid results in increased expression of ABCB4 mRNA		 CTD PMID:15644430 PMID:27255380 PMID:27939613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
increases expression		 EXP
ISO		 obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCC2 mRNA]
[obeticholic acid co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC2 protein; [triptolide co-treated with Lipopolysaccharides co-treated with obeticholic acid] results in increased expression of ABCC2 mRNA; NR1H4 promotes the reaction [obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 protein]
obeticholic acid results in increased expression of ABCC2 mRNA		 CTD PMID:15644430 PMID:27255380 PMID:29660435 PMID:36328986 PMID:36787806 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions EXP
ISO		 obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCC3 mRNA]
[obeticholic acid co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC3 protein		 CTD PMID:32673658 PMID:36787806 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [obeticholic acid co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC4 protein CTD PMID:36787806 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 decreases expression ISO obeticholic acid results in decreased expression of ABCG1 mRNA CTD PMID:27939613 NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948 		JBrowse link
G Acaa1a acetyl-CoA acyltransferase 1A increases expression ISO obeticholic acid results in increased expression of ACAA1 mRNA CTD PMID:27939613 NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624 		JBrowse link
G Acaa2 acetyl-CoA acyltransferase 2 increases expression ISO obeticholic acid results in increased expression of ACAA2 mRNA CTD PMID:27939613 NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249 		JBrowse link
G Acaca acetyl-CoA carboxylase alpha decreases expression ISO obeticholic acid results in decreased expression of ACACA mRNA CTD PMID:27939613 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457 		JBrowse link
G Acot9 acyl-CoA thioesterase 9 increases expression ISO obeticholic acid results in increased expression of ACOT9 mRNA CTD PMID:27939613 NCBI chr  X:40,073,197...40,123,573
Ensembl chr  X:40,064,810...40,123,559 		JBrowse link
G Acox1 acyl-CoA oxidase 1 increases expression ISO obeticholic acid results in increased expression of ACOX1 mRNA CTD PMID:26655953 PMID:27939613 NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232 		JBrowse link
G Acox2 acyl-CoA oxidase 2 increases expression ISO obeticholic acid results in increased expression of ACOX2 mRNA CTD PMID:27939613 NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160 		JBrowse link
G Acox3 acyl-CoA oxidase 3, pristanoyl increases expression ISO obeticholic acid results in increased expression of ACOX3 mRNA CTD PMID:27939613 NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 decreases expression ISO obeticholic acid results in decreased expression of ACSL1 mRNA CTD PMID:27939613 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Acsl4 acyl-CoA synthetase long-chain family member 4 increases expression ISO obeticholic acid results in increased expression of ACSL4 mRNA CTD PMID:27939613 NCBI chr  X:105,942,794...106,006,573
Ensembl chr  X:105,942,799...106,006,427 		JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 increases expression ISO obeticholic acid results in increased expression of ACSL5 mRNA CTD PMID:27939613 NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607 		JBrowse link
G Acsl6 acyl-CoA synthetase long-chain family member 6 increases expression ISO obeticholic acid results in increased expression of ACSL6 mRNA CTD PMID:27939613 NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757 		JBrowse link
G Adamtsl2 ADAMTS-like 2 decreases expression ISO obeticholic acid results in decreased expression of ADAMTSL2 mRNA CTD PMID:27939613 NCBI chr 3:10,397,774...10,434,557
Ensembl chr 3:10,404,626...10,434,554 		JBrowse link
G Adcy1 adenylate cyclase 1 increases expression ISO obeticholic acid results in increased expression of ADCY1 mRNA CTD PMID:27939613 NCBI chr14:81,911,240...82,020,594
Ensembl chr14:81,911,099...82,028,969 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide decreases expression ISO obeticholic acid results in decreased expression of ADH1C mRNA CTD PMID:27939613 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 decreases expression ISO obeticholic acid results in decreased expression of AGPAT2 mRNA CTD PMID:27939613 NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371 		JBrowse link
G Agpat5 1-acylglycerol-3-phosphate O-acyltransferase 5 decreases expression ISO obeticholic acid results in decreased expression of AGPAT5 mRNA CTD PMID:27939613 NCBI chr16:70,939,480...70,985,745
Ensembl chr16:70,943,135...70,985,560 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 decreases expression ISO obeticholic acid results in decreased expression of AKR1D1 mRNA CTD PMID:27939613 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
decreases expression		 ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of AKT1 protein]; obeticholic acid promotes the reaction [Dietary Fats results in decreased phosphorylation of AKT1 protein]
obeticholic acid results in decreased phosphorylation of AKT1 protein
obeticholic acid results in decreased expression of AKT1 mRNA		 CTD PMID:27865854 PMID:27939613 PMID:35267068 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Akt2 AKT serine/threonine kinase 2 decreases expression ISO obeticholic acid results in decreased expression of AKT2 mRNA CTD PMID:27939613 NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817 		JBrowse link
G Alb albumin decreases expression
multiple interactions		 ISO
EXP		 obeticholic acid results in decreased expression of ALB mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of ALB mRNA; [Dietary Fats co-treated with obeticholic acid] results in decreased expression of ALB protein		 CTD PMID:27939613 PMID:35267068 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Aldoa aldolase, fructose-bisphosphate A decreases expression ISO obeticholic acid results in decreased expression of ALDOA mRNA CTD PMID:27939613 NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182 		JBrowse link
G Aldob aldolase, fructose-bisphosphate B decreases expression ISO obeticholic acid results in decreased expression of ALDOB mRNA CTD PMID:27939613 NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116 		JBrowse link
G Aldoc aldolase, fructose-bisphosphate C increases expression ISO obeticholic acid results in increased expression of ALDOC mRNA CTD PMID:27939613 NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066 		JBrowse link
G Amn amnion associated transmembrane protein decreases expression ISO obeticholic acid results in decreased expression of AMN mRNA CTD PMID:27939613 NCBI chr 6:130,311,372...130,318,815
Ensembl chr 6:130,311,372...130,318,815 		JBrowse link
G Apoa1 apolipoprotein A1 decreases expression ISO obeticholic acid results in decreased expression of APOA1 mRNA CTD PMID:27939613 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Apoa2 apolipoprotein A2 increases expression ISO obeticholic acid results in increased expression of APOA2 mRNA CTD PMID:27939613 NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355 		JBrowse link
G Apob apolipoprotein B increases expression ISO obeticholic acid results in increased expression of APOB mRNA CTD PMID:27939613 NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497 		JBrowse link
G Apoc2 apolipoprotein C2 increases expression ISO obeticholic acid results in increased expression of APOC2 mRNA CTD PMID:27939613 NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476 		JBrowse link
G Apoc3 apolipoprotein C3 decreases expression ISO obeticholic acid results in decreased expression of APOC3 mRNA CTD PMID:27939613 NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583 		JBrowse link
G Apoe apolipoprotein E decreases expression ISO obeticholic acid results in decreased expression of APOE mRNA CTD PMID:27939613 NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932 		JBrowse link
G Aspg asparaginase decreases expression ISO obeticholic acid results in decreased expression of ASPG mRNA CTD PMID:27939613 NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268 		JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA] CTD PMID:35439472 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Bad BCL2-associated agonist of cell death decreases expression ISO obeticholic acid results in decreased expression of BAD mRNA CTD PMID:27939613 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions		 ISO obeticholic acid results in increased expression of BCL2 mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of BCL2 protein		 CTD PMID:27939613 PMID:35267068 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bid BH3 interacting domain death agonist decreases expression ISO obeticholic acid results in decreased expression of BID mRNA CTD PMID:27939613 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO obeticholic acid results in decreased expression of BIRC3 mRNA CTD PMID:27939613 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802 		JBrowse link
G C5ar2 complement C5a receptor 2 decreases expression ISO obeticholic acid results in decreased expression of C5AR2 mRNA CTD PMID:27939613 NCBI chr 1:76,930,381...76,945,432
Ensembl chr 1:76,930,383...76,959,517 		JBrowse link
G Car14 carbonic anhydrase 14 increases expression ISO obeticholic acid results in increased expression of CA14 mRNA CTD PMID:27939613 NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693 		JBrowse link
G Casp3 caspase 3 multiple interactions EXP
ISO		 obeticholic acid promotes the reaction [Cycloheximide results in increased activity of CASP3 protein]
obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of CASP3 protein]		 CTD PMID:15860571 PMID:26655953 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp4 caspase 4 multiple interactions ISO obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in increased cleavage of CASP4 protein] CTD PMID:36328986 NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092 		JBrowse link
G Casp8 caspase 8 increases expression ISO obeticholic acid results in increased expression of CASP8 mRNA CTD PMID:27939613 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CCL2 mRNA] CTD PMID:27865854 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCNB1 protein] CTD PMID:29660435 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCND1 protein] CTD PMID:29660435 PMID:35439472 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccs copper chaperone for superoxide dismutase decreases expression ISO obeticholic acid results in decreased expression of CCS mRNA CTD PMID:27939613 NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915 		JBrowse link
G Cd14 CD14 molecule decreases expression ISO obeticholic acid results in decreased expression of CD14 mRNA CTD PMID:27939613 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261 		JBrowse link
G Cldn5 claudin 5 multiple interactions ISO obeticholic acid inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 protein] CTD PMID:36720452 NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992 		JBrowse link
G Clic4 chloride intracellular channel 4 increases expression ISO obeticholic acid results in increased expression of CLIC4 mRNA CTD PMID:27939613 NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452 		JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions		 EXP
ISO		 obeticholic acid results in decreased expression of COL1A1 mRNA; obeticholic acid results in decreased expression of COL1A1 protein
obeticholic acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA]
obeticholic acid inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]		 CTD PMID:15860571 PMID:15980055 PMID:27939613 PMID:30745416 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions
increases expression		 ISO
EXP		 obeticholic acid promotes the reaction [Palmitic Acid results in increased expression of CPT1A mRNA]
obeticholic acid results in increased expression of CPT1A protein
Obeticholic acid inhibits the reaction [ethanol decreases expression of CPT1a mRNA and protein in liver]
obeticholic acid inhibits the reaction [Ethanol results in decreased expression of CPT1A protein]
obeticholic acid results in increased expression of CPT1A mRNA		 CTD
RGD		 PMID:26655953 PMID:27939613 PMID:27939985 PMID:32738331 PMID:27939985 RGD:15036816 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 increases expression ISO obeticholic acid results in increased expression of CPT2 mRNA CTD PMID:27939613 NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095 		JBrowse link
G Crct1 cysteine-rich C-terminal 1 decreases expression ISO obeticholic acid results in decreased expression of CRCT1 mRNA CTD PMID:27939613 NCBI chr 2:178,633,789...178,635,274
Ensembl chr 2:178,634,092...178,634,394 		JBrowse link
G Creb3l1 cAMP responsive element binding protein 3-like 1 decreases expression ISO obeticholic acid results in decreased expression of CREB3L1 mRNA CTD PMID:27939613 NCBI chr 3:77,952,589...77,993,513
Ensembl chr 3:77,952,540...77,993,456 		JBrowse link
G Creb3l3 cAMP responsive element binding protein 3-like 3 increases expression ISO obeticholic acid results in increased expression of CREB3L3 mRNA CTD PMID:27939613 NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048 		JBrowse link
G Crp C-reactive protein decreases expression ISO obeticholic acid results in decreased expression of CRP mRNA CTD PMID:27939613 NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CXCL2 mRNA] CTD PMID:27865854 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of CXCL1 mRNA] CTD PMID:27865854 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP19A1 mRNA CTD PMID:27939613 NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP1A1 mRNA CTD PMID:27939613 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions
decreases expression
decreases activity		 ISO
EXP		 obeticholic acid inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of Acetaminophen]; obeticholic acid inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin]
obeticholic acid results in decreased expression of CYP1A2 mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of CYP1A2 mRNA; [Dietary Fats co-treated with obeticholic acid] results in decreased expression of CYP1A2 protein
obeticholic acid results in decreased activity of CYP1A2 protein		 CTD PMID:27939613 PMID:35267068 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP27A1 mRNA CTD PMID:27939613 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases expression ISO obeticholic acid results in decreased expression of CYP2C8 mRNA CTD PMID:27939613
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases expression ISO obeticholic acid results in increased expression of CYP2D6 mRNA CTD PMID:27939613 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP2E1 mRNA CTD PMID:27939613 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp2r1 cytochrome P450, family 2, subfamily r, polypeptide 1 increases expression ISO obeticholic acid results in increased expression of CYP2R1 mRNA CTD PMID:27939613 NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759 		JBrowse link
G Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP2S1 mRNA CTD PMID:27939613 NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303 		JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO obeticholic acid results in increased expression of CYP2U1 mRNA CTD PMID:27939613 NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882 		JBrowse link
G Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP39A1 mRNA CTD PMID:27939613 NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775 		JBrowse link
G Cyp3a18 cytochrome P450, family 3, subfamily a, polypeptide 18 decreases expression ISO obeticholic acid results in decreased expression of CYP3A43 mRNA CTD PMID:27939613 NCBI chr12:8,880,509...8,930,382
Ensembl chr12:8,880,528...8,930,381 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
decreases expression
decreases activity		 ISO
EXP		 obeticholic acid inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; obeticholic acid inhibits the reaction [CYP3A4 protein results in increased metabolism of Testosterone]
obeticholic acid results in decreased expression of CYP3A2 mRNA
obeticholic acid results in decreased expression of CYP3A4 mRNA
obeticholic acid results in decreased activity of CYP3A4 protein		 CTD PMID:27939613 PMID:35267068 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 decreases expression EXP obeticholic acid results in decreased expression of CYP3A23-3A1 mRNA CTD PMID:35267068 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 decreases expression ISO obeticholic acid results in decreased expression of CYP3A5 mRNA CTD PMID:27939613 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cyp4f1 cytochrome P450, family 4, subfamily f, polypeptide 1 decreases expression ISO obeticholic acid results in decreased expression of CYP4F12 mRNA CTD PMID:27939613 NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046 		JBrowse link
G Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 decreases expression ISO obeticholic acid results in decreased expression of CYP4F3 mRNA CTD PMID:27939613 NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940 		JBrowse link
G Cyp4f39 cytochrome P450, family 4, subfamily f, polypeptide 39 decreases expression ISO obeticholic acid results in decreased expression of CYP4F22 mRNA CTD PMID:27939613 NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:11,433,371...11,536,181 		JBrowse link
G Cyp51 cytochrome P450, family 51 decreases expression ISO obeticholic acid results in decreased expression of CYP51A1 mRNA CTD PMID:27939613 NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases expression
multiple interactions		 ISO
EXP		 obeticholic acid results in decreased expression of CYP7A1 mRNA
obeticholic acid inhibits the reaction [Isoniazid results in increased expression of CYP7A1 mRNA]
Obeticholic acid inhibits the reaction [ethanol increases expression of Cyp7a1 protein in liver]
obeticholic acid decreases expression of CYP7a1 mRNA in liver in porcine serum induced model of cirrhosis in rat
obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP7A1 protein]; obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in decreased expression of CYP7A1 protein]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]		 CTD
RGD		 PMID:15644430 PMID:15911693 PMID:27939613 PMID:29660435 PMID:32673658 More... RGD:15036816, RGD:15045602 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 decreases expression
multiple interactions
increases expression		 EXP
ISO		 obeticholic acid results in decreased expression of CYP8B1 mRNA
obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 mRNA]
obeticholic acid results in increased expression of CYP8B1 mRNA		 CTD PMID:15644430 PMID:27939613 PMID:29660435 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of DDIT3 protein] CTD PMID:26655953 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 decreases expression ISO obeticholic acid results in decreased expression of DGAT2 mRNA CTD PMID:27939613 NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428 		JBrowse link
G Dhcr7 7-dehydrocholesterol reductase increases expression ISO obeticholic acid results in increased expression of DHCR7 mRNA CTD PMID:27939613 NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055 		JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 increases expression ISO obeticholic acid results in increased expression of DNAJB11 mRNA CTD PMID:27939613 NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407 		JBrowse link
G Dpyd dihydropyrimidine dehydrogenase decreases expression ISO obeticholic acid results in decreased expression of DPYD mRNA CTD PMID:27939613 NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982 		JBrowse link
G Dusp6 dual specificity phosphatase 6 increases expression ISO obeticholic acid results in increased expression of DUSP6 mRNA CTD PMID:27939613 NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185 		JBrowse link
G Ecsit ECSIT signaling integrator decreases expression ISO obeticholic acid results in decreased expression of ECSIT mRNA CTD PMID:27939613 NCBI chr 8:20,605,583...20,618,453
Ensembl chr 8:20,605,583...20,618,390 		JBrowse link
G Elovl1 ELOVL fatty acid elongase 1 increases expression ISO obeticholic acid results in increased expression of ELOVL1 mRNA CTD PMID:27939613 NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958 		JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 increases expression ISO obeticholic acid results in increased expression of ELOVL2 mRNA CTD PMID:27939613 NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848 		JBrowse link
G Elovl6 ELOVL fatty acid elongase 6 decreases expression ISO obeticholic acid results in decreased expression of ELOVL6 mRNA CTD PMID:27939613 NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186 		JBrowse link
G Elovl7 ELOVL fatty acid elongase 7 increases expression ISO obeticholic acid results in increased expression of ELOVL7 mRNA CTD PMID:27939613 NCBI chr 2:39,789,229...39,858,579
Ensembl chr 2:39,789,250...39,856,845 		JBrowse link
G Enc1 ectodermal-neural cortex 1 increases expression ISO obeticholic acid results in increased expression of ENC1 mRNA CTD PMID:27939613 NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713 		JBrowse link
G Eno1 enolase 1 decreases expression ISO obeticholic acid results in decreased expression of ENO1 mRNA CTD PMID:27939613 NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336 		JBrowse link
G Eno3 enolase 3 increases expression ISO obeticholic acid results in increased expression of ENO3 mRNA CTD PMID:27939613 NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921 		JBrowse link
G Fabp6 fatty acid binding protein 6 multiple interactions
increases expression		 ISO NR1H4 gene mutant form inhibits the reaction [obeticholic acid results in increased expression of FABP6 mRNA] CTD PMID:22918042 NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282 		JBrowse link
G Fadd Fas associated via death domain increases expression ISO obeticholic acid results in increased expression of FADD mRNA CTD PMID:27939613 NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions EXP Obeticholic acid inhibits the reaction [ethanol increases expression of Fas mRNA and protein in liver] RGD PMID:27939985 RGD:15036816 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Fasn fatty acid synthase multiple interactions
decreases expression		 ISO obeticholic acid inhibits the reaction [Palmitic Acid results in increased expression of FASN mRNA]
obeticholic acid inhibits the reaction [Ethanol results in increased expression of FASN protein]
obeticholic acid results in decreased expression of FASN mRNA		 CTD PMID:26655953 PMID:27939613 PMID:27939985 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fbp1 fructose-bisphosphatase 1 decreases expression ISO obeticholic acid results in decreased expression of FBP1 mRNA CTD PMID:27939613 NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071 		JBrowse link
G Fdps farnesyl diphosphate synthase decreases expression ISO obeticholic acid results in decreased expression of FDPS mRNA CTD PMID:27939613 NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776 		JBrowse link
G Fetub fetuin B increases expression ISO obeticholic acid results in increased expression of FETUB mRNA CTD PMID:27939613 NCBI chr11:78,082,158...78,093,022
Ensembl chr11:78,082,156...78,095,135 		JBrowse link
G Fgf19 fibroblast growth factor 19 increases expression
multiple interactions
increases secretion		 ISO
EXP		 obeticholic acid results in increased expression of FGF15 mRNA
Obeticholic acid inhibits the reaction [ethanol decreases expression of FGF19 protein in liver and intestine]
obeticholic acid results in increased secretion of FGF19 protein
obeticholic acid results in increased expression of FGF19 mRNA
NR1H4 gene mutant form inhibits the reaction [obeticholic acid results in increased expression of FGF15 mRNA]		 CTD
RGD		 PMID:22918042 PMID:27939613 PMID:27939985 RGD:15036816 NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 decreases expression ISO obeticholic acid results in decreased expression of FGFR4 mRNA CTD PMID:27939613 NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242 		JBrowse link
G Fn1 fibronectin 1 decreases expression EXP obeticholic acid decreases expression of fibronectin mRNA in liver in porcine serum induced model of cirrhosis in rat RGD PMID:15980055 RGD:1625201 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases expression ISO obeticholic acid results in decreased expression of FOS mRNA CTD PMID:27939613 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Foxm1 forkhead box M1 multiple interactions
increases expression		 ISO NR1H4 affects the reaction [obeticholic acid results in increased expression of FOXM1 mRNA]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of FOXM1 protein] CTD PMID:22135065 PMID:29660435 NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684 		JBrowse link
G Foxp3 forkhead box P3 increases expression ISO obeticholic acid results in increased expression of FOXP3 mRNA CTD PMID:27939613 NCBI chr  X:14,908,494...14,924,994
Ensembl chr  X:14,908,494...14,923,838 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression ISO obeticholic acid results in decreased expression of GAPDH mRNA CTD PMID:27939613 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression ISO obeticholic acid results in increased expression of GCLM mRNA CTD PMID:26655953 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gfer growth factor, augmenter of liver regeneration multiple interactions ISO [Dietary Fats co-treated with obeticholic acid] results in decreased expression of GFER mRNA; [Dietary Fats co-treated with obeticholic acid] results in decreased expression of GFER protein CTD PMID:35267068 NCBI chr10:13,718,489...13,721,782
Ensembl chr10:13,718,489...13,720,869 		JBrowse link
G Gk glycerol kinase decreases expression ISO obeticholic acid results in decreased expression of GK mRNA CTD PMID:27939613 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631 		JBrowse link
G Gpam glycerol-3-phosphate acyltransferase, mitochondrial decreases expression ISO obeticholic acid results in decreased expression of GPAM mRNA CTD PMID:27939613 NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639 		JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 decreases expression ISO obeticholic acid results in decreased expression of GPD1 mRNA CTD PMID:27939613 NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein]; obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in increased expression of GPT protein]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; obeticholic acid promotes the reaction [Dietary Fats results in increased expression of GPT protein] CTD PMID:35267068 PMID:36328986 PMID:36581201 PMID:36787806 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gpx1 glutathione peroxidase 1 increases expression ISO obeticholic acid results in increased expression of GPX1 mRNA CTD PMID:26655953 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024 		JBrowse link
G Gpx2 glutathione peroxidase 2 decreases expression ISO obeticholic acid results in decreased expression of GPX2 mRNA CTD PMID:27939613 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Gpx3 glutathione peroxidase 3 increases expression ISO obeticholic acid results in increased expression of GPX3 mRNA CTD PMID:27939613 NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035 		JBrowse link
G Gsdmd gasdermin D multiple interactions ISO obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in increased cleavage of GSDMD protein] CTD PMID:36328986 NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055 		JBrowse link
G Gsr glutathione-disulfide reductase increases expression ISO obeticholic acid results in increased expression of GSR mRNA CTD PMID:26655953 PMID:27939613 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 decreases expression ISO obeticholic acid results in decreased expression of GSTP1 mRNA CTD PMID:27939613 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226 		JBrowse link
G Gstt1 glutathione S-transferase theta 1 increases expression ISO obeticholic acid results in increased expression of GSTT1 mRNA CTD PMID:27939613 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585 		JBrowse link
G Gys2 glycogen synthase 2 increases expression ISO obeticholic acid results in increased expression of GYS2 mRNA CTD PMID:27939613 NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228 		JBrowse link
G Hist2h2be histone cluster 2 H2B family member E decreases expression ISO obeticholic acid results in decreased expression of H2BC11 mRNA CTD PMID:27939613 NCBI chr 2:183,780,583...183,783,030 JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase decreases expression ISO obeticholic acid results in decreased expression of HMGCR mRNA CTD PMID:27939613 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 decreases expression ISO obeticholic acid results in decreased expression of HMGCS1 mRNA CTD PMID:27939613 NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha decreases expression
multiple interactions		 EXP
ISO		 obeticholic acid results in decreased expression of HNF4A mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of HNF4A mRNA; [Dietary Fats co-treated with obeticholic acid] results in decreased expression of HNF4A protein		 CTD PMID:35267068 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320 		JBrowse link
G Hras HRas proto-oncogene, GTPase decreases expression ISO obeticholic acid results in decreased expression of HRAS mRNA CTD PMID:27939613 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 decreases expression ISO obeticholic acid results in decreased expression of HSD17B7 mRNA CTD PMID:27939613 NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017 		JBrowse link
G Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 decreases expression ISO obeticholic acid results in decreased expression of HSD3B7 mRNA CTD PMID:27939613 NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of HSPA5 protein]; obeticholic acid inhibits the reaction [Palmitic Acid results in increased expression of HSPA5 protein] CTD PMID:26655953 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspg2 heparan sulfate proteoglycan 2 decreases expression ISO obeticholic acid results in decreased expression of HSPG2 mRNA CTD PMID:27939613 NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594 		JBrowse link
G Id2 inhibitor of DNA binding 2 decreases expression ISO obeticholic acid results in decreased expression of ID2 mRNA CTD PMID:27939613 NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400 		JBrowse link
G Idi1 isopentenyl-diphosphate delta isomerase 1 decreases expression ISO obeticholic acid results in decreased expression of IDI1 mRNA CTD PMID:27939613 NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357 		JBrowse link
G Igfals insulin-like growth factor binding protein, acid labile subunit decreases expression ISO obeticholic acid results in decreased expression of IGFALS mRNA CTD PMID:27939613 NCBI chr10:13,897,468...13,903,920
Ensembl chr10:13,898,395...13,902,677 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO obeticholic acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL10 protein]; obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of IL10 protein] CTD PMID:30745416 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of IL18 mRNA] CTD PMID:35688268 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA]; obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B mRNA]; obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of IL1B protein]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA] CTD PMID:27865854 PMID:29660435 PMID:35688268 PMID:38103844 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO obeticholic acid promotes the reaction [Carbon Tetrachloride results in increased expression of IL4 mRNA] CTD PMID:27865854 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL6 mRNA]; obeticholic acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL6 protein]; obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of IL6 mRNA] CTD PMID:29660435 PMID:30745416 PMID:35688268 PMID:36720452 PMID:38103844 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Il6r interleukin 6 receptor decreases expression ISO obeticholic acid results in decreased expression of IL6R mRNA CTD PMID:27939613 NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536 		JBrowse link
G Il6st interleukin 6 cytokine family signal transducer decreases expression ISO obeticholic acid results in decreased expression of IL6ST mRNA CTD PMID:27939613 NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936 		JBrowse link
G Inhbb inhibin subunit beta B increases expression ISO obeticholic acid results in increased expression of INHBB mRNA CTD PMID:27939613 NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832 		JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 decreases expression ISO obeticholic acid results in decreased expression of IRAK1 mRNA CTD PMID:27939613 NCBI chr  X:151,768,621...151,778,521
Ensembl chr  X:151,768,777...151,778,521 		JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 decreases expression ISO obeticholic acid results in decreased expression of IRAK2 mRNA CTD PMID:27939613 NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO obeticholic acid results in increased expression of JUN mRNA CTD PMID:27939613 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit decreases expression ISO obeticholic acid results in decreased expression of JUNB mRNA CTD PMID:27939613 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP NR0B2 protein affects the reaction [obeticholic acid inhibits the reaction [JUND protein binds to TIMP1 promoter]] CTD PMID:15860571 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Krt18 keratin 18 multiple interactions ISO [Dietary Fats co-treated with obeticholic acid] results in decreased expression of KRT18 mRNA CTD PMID:35267068 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 		JBrowse link
G Lbr lamin B receptor decreases expression ISO obeticholic acid results in decreased expression of LBR mRNA CTD PMID:27939613 NCBI chr13:93,539,386...93,564,026
Ensembl chr13:93,538,920...93,564,017 		JBrowse link
G Lcat lecithin cholesterol acyltransferase decreases expression ISO obeticholic acid results in decreased expression of LCAT mRNA CTD PMID:27939613 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231 		JBrowse link
G Ldlr low density lipoprotein receptor decreases expression ISO obeticholic acid results in decreased expression of LDLR mRNA CTD PMID:27939613 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Leng8 leukocyte receptor cluster member 8 increases expression ISO obeticholic acid results in increased expression of LENG8 mRNA CTD PMID:27939613 NCBI chr 1:70,040,785...70,052,662
Ensembl chr 1:70,040,785...70,052,488 		JBrowse link
G Lgi4 leucine-rich repeat LGI family, member 4 increases expression ISO obeticholic acid results in increased expression of LGI4 mRNA CTD PMID:27939613 NCBI chr 1:86,294,539...86,305,909
Ensembl chr 1:86,295,074...86,304,874 		JBrowse link
G Lime1 Lck interacting transmembrane adaptor 1 decreases expression ISO obeticholic acid results in decreased expression of LIME1 mRNA CTD PMID:27939613 NCBI chr 3:168,490,535...168,496,627
Ensembl chr 3:168,490,074...168,493,127 		JBrowse link
G Lipc lipase C, hepatic type decreases expression ISO obeticholic acid results in decreased expression of LIPC mRNA CTD PMID:27939613 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Lpin1 lipin 1 decreases expression ISO obeticholic acid results in decreased expression of LPIN1 mRNA CTD PMID:27939613 NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097 		JBrowse link
G Lpin2 lipin 2 decreases expression ISO obeticholic acid results in decreased expression of LPIN2 mRNA CTD PMID:27939613 NCBI chr 9:111,083,378...111,158,193
Ensembl chr 9:111,083,745...111,158,193 		JBrowse link
G Lss lanosterol synthase decreases expression ISO obeticholic acid results in decreased expression of LSS mRNA CTD PMID:27939613 NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762 		JBrowse link
G Maf MAF bZIP transcription factor increases expression ISO obeticholic acid results in increased expression of MAF mRNA CTD PMID:27939613 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Maff MAF bZIP transcription factor F increases expression ISO obeticholic acid results in increased expression of MAFF mRNA CTD PMID:27939613 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO obeticholic acid inhibits the reaction [Dietary Fats results in decreased expression of MAP1LC3B protein] CTD PMID:26655953 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k3 mitogen activated protein kinase kinase 3 decreases expression ISO obeticholic acid results in decreased expression of MAP2K3 mRNA CTD PMID:27939613 NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression ISO obeticholic acid results in decreased expression of MAP2K6 mRNA CTD PMID:27939613 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map2k7 mitogen activated protein kinase kinase 7 decreases expression ISO obeticholic acid results in decreased expression of MAP2K7 mRNA CTD PMID:27939613 NCBI chr12:2,591,312...2,600,534
Ensembl chr12:2,591,219...2,604,222 		JBrowse link
G Map3k14 mitogen-activated protein kinase kinase kinase 14 decreases expression ISO obeticholic acid results in decreased expression of MAP3K14 mRNA CTD PMID:27939613 NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 decreases expression ISO obeticholic acid results in decreased expression of MAP3K5 mRNA CTD PMID:27939613 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 increases expression ISO obeticholic acid results in increased expression of MAP3K8 mRNA CTD PMID:27939613 NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of MAPK1 protein] CTD PMID:27865854 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk11 mitogen-activated protein kinase 11 decreases expression ISO obeticholic acid results in decreased expression of MAPK11 mRNA CTD PMID:27939613 NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395 		JBrowse link
G Mapk12 mitogen-activated protein kinase 12 decreases expression ISO obeticholic acid results in decreased expression of MAPK12 mRNA CTD PMID:27939613 NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of MAPK3 protein] CTD PMID:27865854 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mdh1 malate dehydrogenase 1 increases expression ISO obeticholic acid results in increased expression of MDH1 mRNA CTD PMID:27939613 NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925 		JBrowse link
G Metrnl meteorin-like, glial cell differentiation regulator decreases expression ISO obeticholic acid results in decreased expression of METRNL mRNA CTD PMID:27939613 NCBI chr10:106,963,880...106,977,875
Ensembl chr10:106,963,880...106,977,869 		JBrowse link
G Mfsd2a MFSD2 lysolipid transporter A, lysophospholipid increases expression ISO obeticholic acid results in increased expression of MFSD2A mRNA CTD PMID:27939613 NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690 		JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase decreases expression ISO obeticholic acid results in decreased expression of MLKL mRNA CTD PMID:27939613 NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502 		JBrowse link
G Mllt11 MLLT11, transcription factor 7 cofactor increases expression ISO obeticholic acid results in increased expression of MLLT11 mRNA CTD PMID:27939613 NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199 		JBrowse link
G Mmp2 matrix metallopeptidase 2 increases activity EXP obeticholic acid results in increased activity of MMP2 protein CTD PMID:15860571 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in increased expression of MPO protein] CTD PMID:36328986 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819 		JBrowse link
G Mrtfb myocardin related transcription factor B decreases expression ISO obeticholic acid results in decreased expression of MRTFB mRNA CTD PMID:27939613 NCBI chr10:1,116,315...1,278,106
Ensembl chr10:1,116,310...1,277,897 		JBrowse link
G Msmo1 methylsterol monooxygenase 1 decreases expression ISO obeticholic acid results in decreased expression of MSMO1 mRNA CTD PMID:27939613 NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016 		JBrowse link
G Mvd mevalonate diphosphate decarboxylase decreases expression ISO obeticholic acid results in decreased expression of MVD mRNA CTD PMID:27939613 NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971 		JBrowse link
G Mvk mevalonate kinase decreases expression ISO obeticholic acid results in decreased expression of MVK mRNA CTD PMID:27939613 NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO obeticholic acid results in decreased expression of MYC mRNA CTD PMID:27939613 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor multiple interactions ISO obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of MYD88 protein] CTD PMID:35688268 PMID:36720452 NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression
multiple interactions		 ISO obeticholic acid results in increased expression of NFE2L2 mRNA
[Dietary Fats co-treated with obeticholic acid] results in decreased expression of NFE2L2 protein		 CTD PMID:27939613 PMID:35267068 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 increases expression
multiple interactions		 ISO
EXP		 obeticholic acid results in increased expression of NFKB1 mRNA
Obeticholic acid inhibits the reaction [ethanol increases expression of NF-kB protein in liver]		 CTD
RGD		 PMID:27939613 PMID:27939985 RGD:15036816 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 decreases expression ISO obeticholic acid results in decreased expression of NFKB2 mRNA CTD PMID:27939613 NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions EXP Obeticholic acid inhibits the reaction [ethanol decreases expression of Nfkbia protein in liver] RGD PMID:27939985 RGD:15036816 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions EXP Obeticholic acid inhibits the reaction [ethanol increases expression of Nrlp3 protein in liver] RGD PMID:27939985 RGD:15036816 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Npw neuropeptide W decreases expression ISO obeticholic acid results in decreased expression of NPW mRNA CTD PMID:27939613 NCBI chr10:13,680,275...13,681,618
Ensembl chr10:13,680,321...13,681,586 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions
increases expression		 ISO
EXP		 obeticholic acid promotes the reaction [PRMT2 protein binds to NR0B2 promoter]
obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR0B2 protein]; obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in decreased expression of NR0B2 protein]; obeticholic acid inhibits the reaction [Dietary Fats results in decreased expression of NR0B2 mRNA]
Obeticholic acid inhibits the reaction [ethanol decreases expression of Nr0b2 protein in liver and intestine]
NR0B2 protein affects the reaction [obeticholic acid inhibits the reaction [JUND protein binds to TIMP1 promoter]]; NR0B2 protein affects the reaction [obeticholic acid results in decreased expression of and results in decreased secretion of TIMP1 protein]; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR0B2 mRNA]; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR0B2 mRNA]
obeticholic acid results in increased expression of NR0B2 mRNA; obeticholic acid results in increased expression of NR0B2 protein		 CTD
RGD		 PMID:15644430 PMID:15860571 PMID:15911693 PMID:15980055 PMID:26655953 More... RGD:15036816 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions
increases expression
increases response to substance		 ISO
EXP		 obeticholic acid results in increased activity of NR1H4 protein
Obeticholic acid inhibits the reaction [ethanol decreases expression of Nr1h4 mRNA and protein in liver and liver cell nuclei and intestine]
obeticholic acid increases expression of Nr1H4 mRNA in rat hepatic stellate cells; obeticholic acid increases expression of Nr1h4 mRNA in bile duct ligation and porcine serum induced models of cirrhosis in rat
obeticholic acid results in increased expression of NR1H4 protein
obeticholic acid results in increased expression of NR1H4 mRNA
obeticholic acid binds to and results in increased activity of NR1H4 protein; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR1H4 mRNA]; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR1H4 mRNA]
NR1H4 protein results in increased susceptibility to obeticholic acid
[obeticholic acid co-treated with 1-Naphthylisothiocyanate] results in increased expression of NR1H4 protein; NR1H4 affects the reaction [obeticholic acid results in increased expression of FOXM1 mRNA]; NR1H4 gene mutant form inhibits the reaction [obeticholic acid inhibits the reaction [TNF results in increased expression of SELP mRNA]]; NR1H4 gene mutant form inhibits the reaction [obeticholic acid results in increased expression of FABP6 mRNA]; NR1H4 gene mutant form inhibits the reaction [obeticholic acid results in increased expression of FGF15 mRNA]; NR1H4 promotes the reaction [obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]]; obeticholic acid binds to and results in increased activity of NR1H4 protein; obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in decreased expression of NR1H4 protein]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of NR1H4 mRNA]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of NR1H4 protein]
obeticholic acid binds to and results in increased activity of NR1H4 protein; obeticholic acid promotes the reaction [NR1H4 protein binds to PRMT1 protein]		 CTD
RGD		 PMID:15860571 PMID:15911693 PMID:15980055 PMID:17567710 PMID:21242261 More... RGD:15036816, RGD:1625201 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr5a2 nuclear receptor subfamily 5, group A, member 2 decreases expression ISO obeticholic acid results in decreased expression of NR5A2 mRNA CTD PMID:27939613 NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326 		JBrowse link
G Ocln occludin multiple interactions ISO obeticholic acid inhibits the reaction [Methamphetamine results in decreased expression of OCLN protein]; obeticholic acid promotes the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of OCLN protein] CTD PMID:35439472 PMID:36720452 NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150 		JBrowse link
G P4hb prolyl 4-hydroxylase subunit beta increases expression ISO obeticholic acid results in increased expression of P4HB mRNA CTD PMID:27939613 NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500 		JBrowse link
G Pc pyruvate carboxylase decreases expression ISO obeticholic acid results in decreased expression of PC mRNA CTD PMID:27939613 NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380 		JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 decreases expression ISO obeticholic acid results in decreased expression of PCK1 mRNA CTD PMID:27939613 NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191 		JBrowse link
G Pfkfb1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 increases expression ISO obeticholic acid results in increased expression of PFKFB1 mRNA CTD PMID:27939613 NCBI chr  X:19,508,522...19,562,165
Ensembl chr  X:19,508,546...19,562,182 		JBrowse link
G Pgm1 phosphoglucomutase 1 decreases expression ISO obeticholic acid results in decreased expression of PGM1 mRNA CTD PMID:27939613 NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728 		JBrowse link
G Pik3cd phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta decreases expression ISO obeticholic acid results in decreased expression of PIK3CD mRNA CTD PMID:27939613 NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 decreases expression ISO obeticholic acid results in decreased expression of PIK3R1 mRNA CTD PMID:27939613 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pltp phospholipid transfer protein decreases expression ISO obeticholic acid results in decreased expression of PLTP mRNA CTD PMID:27939613 NCBI chr 3:153,574,825...153,592,647
Ensembl chr 3:153,574,825...153,592,647 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions
increases expression		 ISO
EXP		 Palmitic Acid inhibits the reaction [obeticholic acid results in increased expression of PPARA mRNA]
Obeticholic acid inhibits the reaction [ethanol decreases expression of Ppara mRNA and protein in liver]
obeticholic acid inhibits the reaction [Ethanol results in decreased expression of PPARA protein]
obeticholic acid results in increased expression of PPARA mRNA; obeticholic acid results in increased expression of PPARA protein		 CTD
RGD		 PMID:15980055 PMID:26655953 PMID:27939985 PMID:27939985 RGD:15036816 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression EXP obeticholic acid results in increased expression of PPARG mRNA; obeticholic acid results in increased expression of PPARG protein CTD PMID:15980055 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Ppp1r3c protein phosphatase 1, regulatory subunit 3C decreases expression ISO obeticholic acid results in decreased expression of PPP1R3C mRNA CTD PMID:27939613 NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961 		JBrowse link
G Ppp2cb protein phosphatase 2 catalytic subunit beta increases expression ISO obeticholic acid results in increased expression of PPP2CB mRNA CTD PMID:27939613 NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576 		JBrowse link
G Ppp2r1b protein phosphatase 2 scaffold subunit A beta increases expression ISO obeticholic acid results in increased expression of PPP2R1B mRNA CTD PMID:27939613 NCBI chr 8:51,195,860...51,228,442
Ensembl chr 8:51,186,717...51,228,485 		JBrowse link
G Prdx1 peroxiredoxin 1 decreases expression ISO obeticholic acid results in decreased expression of PRDX1 mRNA CTD PMID:27939613 NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856 		JBrowse link
G Prdx6 peroxiredoxin 6 decreases expression ISO obeticholic acid results in decreased expression of PRDX6 mRNA CTD PMID:27939613 NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355 		JBrowse link
G Prkca protein kinase C, alpha increases expression ISO obeticholic acid results in increased expression of PRKCA mRNA CTD PMID:27939613 NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012 		JBrowse link
G Prkce protein kinase C, epsilon increases expression ISO obeticholic acid results in increased expression of PRKCE mRNA CTD PMID:27939613 NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719 		JBrowse link
G Prmt1 protein arginine methyltransferase 1 multiple interactions
increases activity		 ISO obeticholic acid promotes the reaction [NR1H4 protein binds to PRMT1 protein]; obeticholic acid promotes the reaction [PRMT1 protein binds to ABCB11 promoter]
obeticholic acid results in increased activity of PRMT1 protein		 CTD PMID:15911693 NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345 		JBrowse link
G Prmt2 protein arginine methyltransferase 2 multiple interactions ISO obeticholic acid promotes the reaction [PRMT2 protein binds to NR0B2 promoter] CTD PMID:15911693 NCBI chr20:12,394,748...12,420,643
Ensembl chr20:12,394,798...12,420,643 		JBrowse link
G Ptbp2 polypyrimidine tract binding protein 2 decreases expression ISO obeticholic acid results in decreased expression of PTBP2 mRNA CTD PMID:27939613 NCBI chr 2:207,812,659...207,874,019
Ensembl chr 2:207,812,920...207,873,506 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of RELA protein]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of and results in increased phosphorylation of RELA protein]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of RELA protein] CTD PMID:29660435 PMID:35688268 PMID:36720452 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Ros1 ROS proto-oncogene 1 , receptor tyrosine kinase increases expression ISO obeticholic acid results in increased expression of ROS1 mRNA CTD PMID:27939613 NCBI chr20:31,432,636...31,583,998
Ensembl chr20:31,432,637...31,583,865 		JBrowse link
G Rps6ka2 ribosomal protein S6 kinase A2 increases expression ISO obeticholic acid results in increased expression of RPS6KA2 mRNA CTD PMID:27939613 NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739 		JBrowse link
G Rps6ka4 ribosomal protein S6 kinase A4 decreases expression ISO obeticholic acid results in decreased expression of RPS6KA4 mRNA CTD PMID:27939613 NCBI chr 1:204,021,805...204,032,781
Ensembl chr 1:204,021,806...204,032,761 		JBrowse link
G Rps6ka5 ribosomal protein S6 kinase A5 decreases expression ISO obeticholic acid results in decreased expression of RPS6KA5 mRNA CTD PMID:27939613 NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224 		JBrowse link
G Rras2 RAS related 2 increases expression ISO obeticholic acid results in increased expression of RRAS2 mRNA CTD PMID:27939613 NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111 		JBrowse link
G Rtp3 receptor (chemosensory) transporter protein 3 increases expression ISO obeticholic acid results in increased expression of RTP3 mRNA CTD PMID:27939613 NCBI chr 8:110,970,154...110,975,000
Ensembl chr 8:110,970,160...110,974,699 		JBrowse link
G Rxra retinoid X receptor alpha decreases expression ISO obeticholic acid results in decreased expression of RXRA mRNA CTD PMID:27939613 NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712 		JBrowse link
G S100a3 S100 calcium binding protein A3 decreases expression ISO obeticholic acid results in decreased expression of S100A3 mRNA CTD PMID:27939613 NCBI chr 2:176,034,283...176,089,702
Ensembl chr 2:176,049,520...176,089,702 		JBrowse link
G Sc5d sterol-C5-desaturase decreases expression ISO obeticholic acid results in decreased expression of SC5D mRNA CTD PMID:27939613 NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 increases expression ISO obeticholic acid results in increased expression of SCARB1 mRNA CTD PMID:27939613 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Sdc1 syndecan 1 increases expression ISO obeticholic acid results in increased expression of SDC1 mRNA CTD PMID:27939613 NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264 		JBrowse link
G Sdha succinate dehydrogenase complex flavoprotein subunit A multiple interactions ISO obeticholic acid inhibits the reaction [Dietary Fats results in decreased expression of SDHA protein] CTD PMID:26655953 NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535 		JBrowse link
G Selp selectin P multiple interactions ISO NR1H4 gene mutant form inhibits the reaction [obeticholic acid inhibits the reaction [TNF results in increased expression of SELP mRNA]]; obeticholic acid inhibits the reaction [TNF results in increased expression of SELP mRNA] CTD PMID:22135065 NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845 		JBrowse link
G Serpina1 serpin family A member 1 decreases expression ISO obeticholic acid results in decreased expression of SERPINA1 mRNA CTD PMID:27939613 NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339 		JBrowse link
G Serpine1 serpin family E member 1 decreases expression ISO obeticholic acid results in decreased expression of SERPINE1 mRNA CTD PMID:27939613 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Sfn stratifin decreases expression ISO obeticholic acid results in decreased expression of SFN mRNA CTD PMID:27939613 NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314 		JBrowse link
G Sigirr single Ig and TIR domain containing decreases expression ISO obeticholic acid results in decreased expression of SIGIRR mRNA CTD PMID:27939613 NCBI chr 1:196,195,363...196,208,692
Ensembl chr 1:196,199,462...196,202,269 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 decreases expression
multiple interactions		 ISO
EXP		 obeticholic acid results in decreased expression of SLC10A1 mRNA
obeticholic acid promotes the reaction [Isoniazid results in decreased expression of SLC10A1 mRNA]
Obeticholic acid inhibits the reaction [ethanol decreases expression of Slc10a1 protein in liver]
[1-Naphthylisothiocyanate co-treated with obeticholic acid] results in decreased expression of SLC10A1 protein; obeticholic acid inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in decreased expression of SLC10A1 mRNA]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein]		 CTD
RGD		 PMID:15644430 PMID:15911693 PMID:29660435 PMID:32673658 PMID:36328986 More... RGD:15036816 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc13a5 solute carrier family 13 member 5 decreases expression ISO obeticholic acid results in decreased expression of SLC13A5 mRNA CTD PMID:27939613 NCBI chr10:56,866,249...56,891,189
Ensembl chr10:56,866,249...56,890,945 		JBrowse link
G Slc25a1 solute carrier family 25 member 1 decreases expression ISO obeticholic acid results in decreased expression of SLC25A1 mRNA CTD PMID:27939613 NCBI chr11:83,055,764...83,058,781
Ensembl chr11:83,055,748...83,058,781 		JBrowse link
G Slc25a10 solute carrier family 25 member 10 decreases expression ISO obeticholic acid results in decreased expression of SLC25A10 mRNA CTD PMID:27939613 NCBI chr10:105,765,598...105,775,159
Ensembl chr10:105,765,372...105,773,556 		JBrowse link
G Slc25a12 solute carrier family 25 member 12 decreases expression ISO obeticholic acid results in decreased expression of SLC25A12 mRNA CTD PMID:27939613 NCBI chr 3:56,097,166...56,191,841
Ensembl chr 3:56,097,269...56,192,100 		JBrowse link
G Slc27a5 solute carrier family 27 member 5 decreases expression ISO obeticholic acid results in decreased expression of SLC27A5 mRNA CTD PMID:27939613 NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172 		JBrowse link
G Slc51a solute carrier family 51 member A increases expression ISO obeticholic acid results in increased expression of SLC51A mRNA; obeticholic acid results in increased expression of SLC51A protein CTD PMID:26655953 PMID:27939613 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta increases expression
multiple interactions		 ISO
EXP		 obeticholic acid results in increased expression of SLC51B mRNA
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLC51B mRNA]		 CTD PMID:26655953 PMID:27255380 PMID:27939613 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions
increases expression		 EXP
ISO		 obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLCO1B2 mRNA]
obeticholic acid results in increased expression of SLCO1B3 mRNA
obeticholic acid results in increased expression of SLCO1B2 mRNA		 CTD PMID:27255380 PMID:27939613 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Socs2 suppressor of cytokine signaling 2 decreases expression ISO obeticholic acid results in decreased expression of SOCS2 mRNA CTD PMID:27939613 NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548 		JBrowse link
G Sod2 superoxide dismutase 2 decreases expression ISO obeticholic acid results in decreased expression of SOD2 mRNA CTD PMID:27939613 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO obeticholic acid inhibits the reaction [Dietary Fats results in decreased expression of SQSTM1 protein] CTD PMID:26655953 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions
decreases expression		 ISO
EXP		 obeticholic acid inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]
Obeticholic acid inhibits the reaction [ethanol increases expression of Srebf1 mRNA and protein in liver]
obeticholic acid results in decreased expression of SREBF1 mRNA		 CTD
RGD		 PMID:27939613 PMID:27939985 PMID:27939985 RGD:15036816 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Srebf2 sterol regulatory element binding transcription factor 2 multiple interactions
decreases expression		 ISO obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of SREBF2 mRNA]
obeticholic acid results in decreased expression of SREBF2 mRNA		 CTD PMID:26655953 PMID:27939613 NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO obeticholic acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of SULT2A1 mRNA] CTD PMID:29660435 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Szrd1 SUZ RNA binding domain containing 1 increases expression ISO obeticholic acid results in increased expression of SZRD1 mRNA CTD PMID:27939613 NCBI chr 5:153,418,748...153,443,286
Ensembl chr 5:153,418,748...153,443,252 		JBrowse link
G Tab1 TGF-beta activated kinase 1/MAP3K7 binding protein 1 decreases expression ISO obeticholic acid results in decreased expression of TAB1 mRNA CTD PMID:27939613 NCBI chr 7:111,675,829...111,707,058
Ensembl chr 7:111,686,371...111,707,058 		JBrowse link
G Tapbp TAP binding protein decreases expression ISO obeticholic acid results in decreased expression of TAPBP mRNA CTD PMID:27939613 NCBI chr20:4,956,937...4,966,191
Ensembl chr20:4,956,937...4,966,181 		JBrowse link
G Tcea2 transcription elongation factor A2 increases expression ISO obeticholic acid results in increased expression of TCEA2 mRNA CTD PMID:27939613 NCBI chr 3:168,796,244...168,804,125
Ensembl chr 3:168,796,331...168,804,116 		JBrowse link
G Tecr trans-2,3-enoyl-CoA reductase decreases expression ISO obeticholic acid results in decreased expression of TECR mRNA CTD PMID:27939613 NCBI chr19:24,526,700...24,568,168
Ensembl chr19:24,541,615...24,568,168 		JBrowse link
G Tedc1 tubulin epsilon and delta complex 1 decreases expression ISO obeticholic acid results in decreased expression of TEDC1 mRNA CTD PMID:27939613 NCBI chr 6:132,234,764...132,245,164
Ensembl chr 6:132,236,925...132,244,928 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression		 EXP
ISO		 obeticholic acid inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]
obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein]
obeticholic acid results in decreased expression of TGFB1 mRNA		 CTD PMID:15980055 PMID:27939613 PMID:35439472 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tgfb2 transforming growth factor, beta 2 decreases expression ISO obeticholic acid results in decreased expression of TGFB2 mRNA CTD PMID:27939613 NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405 		JBrowse link
G Tgfb3 transforming growth factor, beta 3 increases expression ISO obeticholic acid results in increased expression of TGFB3 mRNA CTD PMID:27939613 NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564 		JBrowse link
G Tgfbr1 transforming growth factor, beta receptor 1 decreases expression ISO obeticholic acid results in decreased expression of TGFBR1 mRNA CTD PMID:27939613 NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions
decreases expression		 EXP
ISO		 NR0B2 protein affects the reaction [obeticholic acid inhibits the reaction [JUND protein binds to TIMP1 promoter]]; NR0B2 protein affects the reaction [obeticholic acid results in decreased expression of and results in decreased secretion of TIMP1 protein]; obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA]; obeticholic acid results in decreased expression of and results in decreased secretion of TIMP1 protein
obeticholic acid results in decreased expression of TIMP1 mRNA		 CTD PMID:15860571 PMID:27939613 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Timp2 TIMP metallopeptidase inhibitor 2 multiple interactions EXP obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP2 mRNA] CTD PMID:15860571 NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO obeticholic acid promotes the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TJP1 protein] CTD PMID:35439472 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432 		JBrowse link
G Tk1 thymidine kinase 1 decreases expression ISO obeticholic acid results in decreased expression of TK1 mRNA CTD PMID:27939613 NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TLR4 protein]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of TLR4 protein] CTD PMID:35439472 PMID:35688268 PMID:36720452 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases secretion		 ISO
EXP		 NR1H4 gene mutant form inhibits the reaction [obeticholic acid inhibits the reaction [TNF results in increased expression of SELP mRNA]]; obeticholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF mRNA]; obeticholic acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF protein]; obeticholic acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; obeticholic acid inhibits the reaction [Dietary Fats results in increased expression of TNF protein]; obeticholic acid inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; obeticholic acid inhibits the reaction [TNF results in increased expression of SELP mRNA]
Obeticholic acid inhibits the reaction [ethanol increases expression of Tnf protein in liver]
obeticholic acid results in decreased secretion of TNF protein
obeticholic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]		 CTD
RGD		 PMID:21242261 PMID:22135065 PMID:27865854 PMID:29660435 PMID:30745416 More... RGD:15036816 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B increases expression ISO obeticholic acid results in increased expression of TNFRSF1B mRNA CTD PMID:27939613 NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206 		JBrowse link
G Traf2 Tnf receptor-associated factor 2 decreases expression ISO obeticholic acid results in decreased expression of TRAF2 mRNA CTD PMID:27939613 NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538 		JBrowse link
G Txn1 thioredoxin 1 decreases expression ISO obeticholic acid results in decreased expression of TXN mRNA CTD PMID:27939613 NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629 		JBrowse link
G Txnrd2 thioredoxin reductase 2 decreases expression ISO obeticholic acid results in decreased expression of TXNRD2 mRNA CTD PMID:27939613 NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156 		JBrowse link
G Tyk2 tyrosine kinase 2 decreases expression ISO obeticholic acid results in decreased expression of TYK2 mRNA CTD PMID:27939613 NCBI chr 8:19,641,881...19,667,157
Ensembl chr 8:19,641,884...19,667,044 		JBrowse link
G Tymp thymidine phosphorylase decreases expression ISO obeticholic acid results in decreased expression of TYMP mRNA CTD PMID:27939613 NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874 		JBrowse link
G Ube2e3 ubiquitin-conjugating enzyme E2E 3 increases expression ISO obeticholic acid results in increased expression of UBE2E3 mRNA CTD PMID:27939613 NCBI chr 3:63,786,976...63,851,400
Ensembl chr 3:63,786,650...63,843,237 		JBrowse link
G Ubxn10 UBX domain protein 10 increases expression ISO obeticholic acid results in increased expression of UBXN10 mRNA CTD PMID:27939613 NCBI chr 5:150,953,772...150,959,608
Ensembl chr 5:150,950,731...150,959,744 		JBrowse link
G Uckl1 uridine-cytidine kinase 1-like 1 decreases expression ISO obeticholic acid results in decreased expression of UCKL1 mRNA CTD PMID:27939613 NCBI chr 3:168,674,849...168,687,513
Ensembl chr 3:168,674,849...168,698,091 		JBrowse link
G Ugp2 UDP-glucose pyrophosphorylase 2 increases expression ISO obeticholic acid results in increased expression of UGP2 mRNA CTD PMID:27939613 NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 increases expression
increases glucuronidation		 ISO obeticholic acid results in increased expression of UGT1A1 mRNA
UGT1A1 protein results in increased glucuronidation of obeticholic acid		 CTD PMID:27939613 PMID:31299240 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 increases glucuronidation
multiple interactions		 ISO UGT1A3 protein results in increased glucuronidation of obeticholic acid
[Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of obeticholic acid		 CTD PMID:31299240 NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a5 UDP glucuronosyltransferase family 1 member A5 decreases expression
increases glucuronidation		 ISO obeticholic acid results in decreased expression of UGT1A4 mRNA
UGT1A4 protein results in increased glucuronidation of obeticholic acid		 CTD PMID:27939613 PMID:31299240 NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 decreases expression ISO obeticholic acid results in decreased expression of UGT1A6 mRNA CTD PMID:27939613 NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 decreases expression ISO obeticholic acid results in decreased expression of UGT1A9 mRNA CTD PMID:27939613 NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 decreases expression ISO obeticholic acid results in decreased expression of UGT2B7 mRNA CTD PMID:27939613 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604 		JBrowse link
G Upb1 beta-ureidopropionase 1 decreases expression ISO obeticholic acid results in decreased expression of UPB1 mRNA CTD PMID:27939613 NCBI chr20:13,217,252...13,243,590
Ensembl chr20:13,217,258...13,243,590 		JBrowse link
G Upp1 uridine phosphorylase 1 increases expression ISO obeticholic acid results in increased expression of UPP1 mRNA CTD PMID:27939613 NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462 		JBrowse link
G Upp2 uridine phosphorylase 2 increases expression ISO obeticholic acid results in increased expression of UPP2 mRNA CTD PMID:27939613 NCBI chr 3:43,273,048...43,317,417
Ensembl chr 3:43,273,048...43,317,417 		JBrowse link
G Uroc1 urocanate hydratase 1 increases expression ISO obeticholic acid results in increased expression of UROC1 mRNA CTD PMID:27939613 NCBI chr 4:122,844,933...122,876,584
Ensembl chr 4:122,844,926...122,876,591 		JBrowse link
G Xdh xanthine dehydrogenase increases expression ISO obeticholic acid results in increased expression of XDH mRNA CTD PMID:27939613 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268 		JBrowse link
sodium cholate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of ALB protein CTD PMID:26606054 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein] CTD PMID:27394961 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of BAX protein CTD PMID:27394961 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of BCL2 protein CTD PMID:27394961 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein] CTD PMID:27394961 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO
EXP		 [eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of CCL2 mRNA
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CCL2 mRNA		 CTD PMID:23665937 PMID:26606054 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO [eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of CCL5 mRNA CTD PMID:23665937 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein] CTD PMID:27394961 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ces1d carboxylesterase 1D increases expression ISO Sodium Cholate results in increased expression of CES1 mRNA CTD PMID:9565681 NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035 		JBrowse link
G Cst3 cystatin C multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CST3 protein CTD PMID:26606054 NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CYBB mRNA CTD PMID:26606054 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP
ISO		 [1,2-dilauroylphosphatidylcholine co-treated with 1,2-oleoylphosphatidylcholine co-treated with Phosphatidylserines co-treated with Sodium Cholate] results in increased activity of CYP3A2 protein
[1,2-dilauroylphosphatidylcholine co-treated with 1,2-oleoylphosphatidylcholine co-treated with Phosphatidylserines co-treated with Sodium Cholate] results in increased activity of CYP3A4 protein		 CTD PMID:1627548 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Sodium Cholate co-treated with Dietary Fats] results in decreased expression of CYP7A1 mRNA CTD PMID:23665937 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Fabp1 fatty acid binding protein 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of FABP1 protein CTD PMID:26606054 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein] CTD PMID:27394961 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of GPX2 mRNA CTD PMID:26606054 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HAVCR1 mRNA CTD PMID:26606054 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HIF1A mRNA CTD PMID:26606054 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions ISO [Sodium Cholate co-treated with Dietary Fats] results in decreased expression of HMGCR mRNA CTD PMID:23665937 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HMOX1 mRNA CTD PMID:26606054 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO [eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of ICAM1 mRNA CTD PMID:23665937 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO
EXP		 [eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of IL1B mRNA
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of IL1B mRNA		 CTD PMID:23665937 PMID:26606054 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein] CTD PMID:27394961 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein] CTD PMID:27394961 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO MET gene mutant form affects the susceptibility to [Cholesterol, Dietary co-treated with Sodium Cholate]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [[[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased oxidation of Lipids] which results in increased abundance of Thiobarbituric Acid Reactive Substances]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased abundance of Triglycerides]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased oxidation of Glutathione]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of Bile Acids and Salts]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased uptake of and results in increased oxidation of Lipids] CTD PMID:27394961 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Naglu N-acetyl-alpha-glucosaminidase multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of NAGLU protein CTD PMID:26606054 NCBI chr10:86,001,545...86,009,049
Ensembl chr10:86,001,566...86,008,972 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein] CTD PMID:27394961 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nphs1 NPHS1 adhesion molecule, nephrin multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in decreased expression of NPHS1 mRNA CTD PMID:26606054 NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein] CTD PMID:27394961 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein] CTD PMID:27394961 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein] CTD PMID:27394961 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Rara retinoic acid receptor, alpha multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein] CTD PMID:27394961 NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142 		JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of S100A8 mRNA CTD PMID:26606054 NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643 		JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO [Sodium Cholate co-treated with Dietary Fats] results in increased expression of SCD1 mRNA; eicosapentaenoic acid ethyl ester inhibits the reaction [[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SCD1 mRNA] CTD PMID:23665937 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Soat2 sterol O-acyltransferase 2 multiple interactions ISO [Sodium Cholate co-treated with Dietary Fats] results in increased expression of SOAT2 mRNA; eicosapentaenoic acid ethyl ester inhibits the reaction [[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SOAT2 mRNA] CTD PMID:23665937 NCBI chr 7:133,281,818...133,294,915
Ensembl chr 7:133,281,818...133,294,915 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein] CTD PMID:27394961 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TGFB1 mRNA CTD PMID:26606054 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TLR4 mRNA CTD PMID:26606054 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TNF mRNA CTD PMID:26606054 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein] CTD PMID:27394961 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions EXP [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of VCAM1 mRNA CTD PMID:26606054 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
sulfoglycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc10a1 solute carrier family 10 member 1 increases uptake ISO SLC10A1 protein results in increased uptake of sulfolithocholylglycine CTD PMID:29024779 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
tauro-beta-muricholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 increases expression
multiple interactions		 EXP tauromuricholic acid results in increased expression of ABCB11 protein
tauromuricholic acid results in increased expression of and results in increased activity of ABCB11 protein		 CTD PMID:11672435 PMID:12644037 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression
multiple interactions		 EXP tauromuricholic acid results in increased expression of ABCC2 protein
tauromuricholic acid results in increased expression of and results in increased activity of ABCC2 protein		 CTD PMID:11672435 PMID:12644037 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression EXP tauromuricholic acid results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion
increases abundance		 ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin affects the secretion of tauromuricholic acid]
AHR gene mutant form results in increased secretion of tauromuricholic acid
AHR gene mutant form results in increased abundance of tauromuricholic acid		 CTD PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA CTD PMID:22098667 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA CTD PMID:22098667 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Fech ferrochelatase affects abundance ISO FECH protein affects the abundance of tauromuricholic acid CTD PMID:29906468 NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA CTD PMID:22098667 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Il10 interleukin 10 increases abundance ISO IL10 gene mutant form results in increased abundance of tauromuricholic acid CTD PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 affects abundance ISO NR1H4 protein affects the abundance of tauromuricholic acid CTD PMID:30556042 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions
increases abundance		 ISO [PPARA gene mutant form results in increased susceptibility to Clofibrate] which results in increased abundance of tauromuricholic acid; PPARA gene mutant form inhibits the reaction [Gemfibrozil results in increased abundance of tauromuricholic acid]
PPARA gene mutant form results in increased abundance of tauromuricholic acid		 CTD PMID:24385052 PMID:29175453 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 increases expression EXP tauromuricholic acid results in increased expression of SLC10A2 protein CTD PMID:11672435 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Smad3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of tauromuricholic acid CTD PMID:23034213 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960 		JBrowse link
taurochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport
increases expression		 ISO
EXP		 ABCB11 protein affects the transport of Taurochenodeoxycholic Acid
Taurochenodeoxycholic Acid results in increased expression of ABCB11 protein		 CTD PMID:11343252 PMID:11672435 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression EXP Taurochenodeoxycholic Acid results in increased expression of ABCC2 protein CTD PMID:11672435 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression EXP Taurochenodeoxycholic Acid results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Ahr aryl hydrocarbon receptor increases secretion
increases abundance		 ISO AHR gene mutant form results in increased secretion of Taurochenodeoxycholic Acid
AHR gene mutant form results in increased abundance of Taurochenodeoxycholic Acid		 CTD PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases hydroxylation ISO CYP3A4 protein results in increased hydroxylation of Taurochenodeoxycholic Acid CTD PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Fech ferrochelatase affects abundance ISO FECH protein affects the abundance of Taurochenodeoxycholic Acid CTD PMID:29906468 NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO Taurochenodeoxycholic Acid results in increased phosphorylation of and results in decreased activity of GSK3B protein CTD PMID:20512997 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO Taurochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Il10 interleukin 10 increases abundance ISO IL10 gene mutant form results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 increases expression EXP Taurochenodeoxycholic Acid results in increased expression of SLC10A2 protein CTD PMID:11672435 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Slc51a solute carrier family 51 member A multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid] CTD PMID:32294204 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid] CTD PMID:32294204 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Smad3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:23034213 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression EXP Taurochenodeoxycholic Acid results in increased expression of TGFB1 protein CTD PMID:8743917 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tnf tumor necrosis factor increases expression EXP Taurochenodeoxycholic Acid results in increased expression of TNF protein CTD PMID:8743917 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
taurocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca8 ATP binding cassette subfamily A member 8 affects transport ISO ABCA8 protein affects the transport of Taurocholic Acid CTD PMID:12379217 NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 affects import
decreases transport
increases uptake
increases expression
multiple interactions
increases transport
increases export
affects transport
increases import
affects secretion
decreases uptake		 ISO
EXP		 ABCB11 protein affects the import of Taurocholic Acid
ABCB11 protein mutant form results in decreased transport of Taurocholic Acid
ABCB11 protein results in increased uptake of Taurocholic Acid
Taurocholic Acid results in increased expression of ABCB11 mRNA
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide inhibits the reaction [ABCB11 protein results in increased import of Taurocholic Acid]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Amiodarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Astemizole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atropine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Benzbromarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Bosentan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Budesonide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Calcium deficiency inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; Cefaclor inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Celecoxib inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholates inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clarithromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clotrimazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cyclosporine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diclofenac inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diethylstilbestrol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dipyridamole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Disulfiram inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Elacridar inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; ergocristine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Erythromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ezetimibe inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Felodipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fenofibrate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Floxacillin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glyburide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Imatinib Mesylate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indomethacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Isradipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ketoconazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Kynurenic Acid inhibits the reaction [ABCB11 protein results in increased uptake of Taurocholic Acid]; Lopinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Loratadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Losartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Midazolam inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Mifepristone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; morin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Naproxen inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; nefazodone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nelfinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nicardipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nifedipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrendipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ofloxacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; olmesartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pilsicainide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Progesterone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ranolazine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; repaglinide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Reserpine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosiglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Saquinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Silymarin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; simvastatin acid inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Spironolactone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfamethoxazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfinpyrazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Telmisartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Terfenadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Tinidazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; tipranavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; verlukast inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Vinblastine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
ABCB11 protein affects the transport of Taurocholic Acid
2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside affects the reaction [[Emodin affects the activity of ABCB11 protein] which affects the export of Taurocholic Acid]; [Emodin affects the activity of ABCB11 protein] which affects the export of Taurocholic Acid; GLPG1837 inhibits the reaction [ABCB11 protein mutant form results in decreased transport of Taurocholic Acid]; ivacaftor inhibits the reaction [ABCB11 protein mutant form results in decreased transport of Taurocholic Acid]; Taurocholic Acid results in increased expression of and results in increased activity of ABCB11 protein; Troglitazone inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; troglitazone sulfate inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]
Taurocholic Acid results in increased expression of ABCB11 protein
ABCB11 protein affects the secretion of Taurocholic Acid
ABCB11 protein results in decreased uptake of Taurocholic Acid
ABCB11 protein affects the transport of Taurocholic Acid; ABCB11 protein mutant form affects the transport of Taurocholic Acid		 CTD PMID:10617675 PMID:11113123 PMID:11179459 PMID:11557132 PMID:12518026 More... NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression EXP
ISO		 Taurocholic Acid results in increased expression of ABCB1 protein
Taurocholic Acid results in increased expression of ABCB1A mRNA		 CTD PMID:11113123 PMID:27160211 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 increases expression EXP Taurocholic Acid results in increased expression of ABCB4 protein CTD PMID:11113123 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Taurocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases activity
increases expression
multiple interactions		 EXP
ISO		 Taurocholic Acid results in increased activity of ABCC2 protein; Taurocholic Acid results in increased activity of ABCC2 protein modified form
Taurocholic Acid results in increased expression of ABCC2 mRNA
Taurocholic Acid results in increased expression of and results in increased activity of ABCC2 protein		 CTD PMID:12644037 PMID:15904671 PMID:27160211 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases activity
multiple interactions
increases uptake
affects transport		 ISO
EXP		 Taurocholic Acid results in increased activity of ABCC3 protein
4-cresylglucuronide promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]; hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]
ABCC3 protein affects the transport of Taurocholic Acid		 CTD PMID:11557524 PMID:17569508 PMID:30639138 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression ISO Taurocholic Acid results in increased expression of ABCG2 mRNA CTD PMID:27160211 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion		 ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurocholic Acid]
AHR gene mutant form results in increased secretion of Taurocholic Acid		 CTD PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]] CTD PMID:12388182 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Apoa1 apolipoprotein A1 decreases expression ISO Taurocholic Acid results in decreased expression of APOA1 protein CTD PMID:19445040 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Apoa4 apolipoprotein A4 multiple interactions EXP [Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in increased expression of APOA4 protein CTD PMID:6631239 NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469 		JBrowse link
G Apoe apolipoprotein E multiple interactions EXP [Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression		 ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein] CTD PMID:18512153 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Blvra biliverdin reductase A increases expression ISO Taurocholic Acid results in increased expression of BLVRA mRNA CTD PMID:18706437 NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033 		JBrowse link
G Bnip3l BCL2 interacting protein 3 like increases expression EXP Taurocholic Acid results in increased expression of BNIP3L mRNA; Taurocholic Acid results in increased expression of BNIP3L protein CTD PMID:14530762 NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803 		JBrowse link
G Casp3 caspase 3 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein] CTD PMID:12388182 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP8 protein] CTD PMID:12388182 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP9 protein] CTD PMID:12388182 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cav1 caveolin 1 increases secretion ISO CAV1 protein results in increased secretion of Taurocholic Acid CTD PMID:14647059 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705 		JBrowse link
G Cav2 caveolin 2 increases secretion ISO CAV2 protein results in increased secretion of Taurocholic Acid CTD PMID:14647059 NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]] CTD PMID:21224055 PMID:28505368 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA] CTD PMID:21224055 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression ISO Taurocholic Acid results in increased expression of CCL3 mRNA CTD PMID:21224055 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938 		JBrowse link
G Ccl4 C-C motif chemokine ligand 4 increases expression ISO Taurocholic Acid results in increased expression of CCL4 mRNA CTD PMID:21224055 NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 increases expression ISO Taurocholic Acid results in increased expression of CCL5 mRNA CTD PMID:21224055 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Ccl7 C-C motif chemokine ligand 7 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA] CTD PMID:21224055 NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression		 ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]
Taurocholic Acid results in increased expression of CCND1 mRNA; Taurocholic Acid results in increased expression of CCND1 protein		 CTD PMID:18512153 PMID:18840136 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccne1 cyclin E1 multiple interactions
increases expression		 ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] CTD PMID:18512153 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Cel carboxyl ester lipase multiple interactions ISO Taurocholic Acid inhibits the reaction [Polyphenols results in decreased activity of CEL protein] CTD PMID:16099206 NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035 		JBrowse link
G Cftr CF transmembrane conductance regulator affects uptake
increases activity		 ISO CFTR protein mutant form affects the uptake of Taurocholic Acid
Taurocholic Acid results in increased activity of CFTR protein		 CTD PMID:15099439 PMID:16037545 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199 		JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO Taurocholic Acid results in increased expression of CSF3 mRNA CTD PMID:21224055 NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO Taurocholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 increases expression ISO Taurocholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271 		JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA] CTD PMID:21224055 NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933 		JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 increases expression ISO Taurocholic Acid results in increased expression of CXCL16 mRNA CTD PMID:21224055 NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions		 ISO Taurocholic Acid results in increased expression of CXCL2 mRNA; Taurocholic Acid results in increased expression of CXCL2 protein
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]		 CTD PMID:21224055 PMID:22098667 PMID:26176423 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases expression
multiple interactions		 ISO Taurocholic Acid results in increased expression of CXCL1 mRNA
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]		 CTD PMID:21224055 PMID:22098667 PMID:26176423 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression EXP Taurocholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Taurocholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity EXP Taurocholic Acid results in decreased activity of CYP2C11 protein CTD PMID:8889968 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity
multiple interactions		 EXP Taurocholic Acid results in decreased activity of CYP3A2 protein
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Taurocholic Acid		 CTD PMID:8889968 PMID:34461081 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Taurocholic Acid CTD PMID:34461081 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression		 ISO
EXP		 FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA] CTD PMID:7832767 PMID:16284190 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases activity
decreases expression		 EXP Taurocholic Acid results in decreased activity of CYP7B1 protein
Taurocholic Acid results in decreased expression of CYP7B1 mRNA		 CTD PMID:12029625 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
increases phosphorylation		 ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein] CTD PMID:26518876 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression		 ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL5 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of EGR1 mRNA; Taurocholic Acid results in increased expression of EGR1 protein		 CTD PMID:21224055 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Fech ferrochelatase affects abundance ISO FECH protein affects the abundance of Taurocholic Acid CTD PMID:29906468 NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348 		JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression		 ISO [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA
Taurocholic Acid results in increased expression of FGF15 mRNA		 CTD PMID:16284190 NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 multiple interactions ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16284190 NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242 		JBrowse link
G Hgf hepatocyte growth factor increases uptake EXP HGF protein results in increased uptake of Taurocholic Acid CTD PMID:18031729 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha increases secretion ISO HNF4A protein results in increased secretion of Taurocholic Acid CTD PMID:27160211 NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
increases expression		 EXP
ISO		 rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of ICAM1 mRNA; Taurocholic Acid results in increased expression of ICAM1 protein
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]		 CTD PMID:19237016 PMID:21224055 PMID:22098667 PMID:26176423 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Il10 interleukin 10 increases expression
increases abundance		 ISO Taurocholic Acid results in increased expression of IL10 mRNA
IL10 gene mutant form results in increased abundance of Taurocholic Acid		 CTD PMID:21224055 PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
decreases import		 ISO
EXP		 Taurocholic Acid results in increased expression of IL1B mRNA
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid
IL1B protein results in decreased import of Taurocholic Acid
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein]
Taurocholic Acid results in increased expression of IL1B mRNA; Taurocholic Acid results in increased expression of IL1B protein
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]		 CTD PMID:21224055 PMID:25604657 PMID:30876886 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 multiple interactions
decreases import
increases expression		 EXP
ISO		 astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]
IL6 protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]
Taurocholic Acid results in increased expression of IL6 mRNA; Taurocholic Acid results in increased expression of IL6 protein		 CTD PMID:20035747 PMID:20382593 PMID:25604657 PMID:26518876 PMID:30876886 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Kl Klotho multiple interactions ISO Taurocholic Acid inhibits the reaction [KL protein results in increased hydrolysis of Glucuronides] CTD PMID:14701853 NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080 		JBrowse link
G Klf4 KLF transcription factor 4 increases expression ISO Taurocholic Acid results in increased expression of KLF4 mRNA CTD PMID:27151938 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO Taurocholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation		 ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein] CTD PMID:26518876 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein] CTD PMID:18512153 PMID:26518876 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein] CTD PMID:28505368 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein] CTD PMID:28505368 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mir488 microRNA 488 increases expression ISO Taurocholic Acid results in increased expression of MIR488 mRNA CTD PMID:28851649 NCBI chr13:70,683,064...70,683,142
Ensembl chr13:70,683,064...70,683,142 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
increases expression		 ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 protein]
Taurocholic Acid results in increased expression of MMP2 mRNA; Taurocholic Acid results in increased expression of MMP2 protein		 CTD PMID:26518876 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression		 ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 protein]
Taurocholic Acid results in increased expression of MMP9 mRNA; Taurocholic Acid results in increased expression of MMP9 protein		 CTD PMID:26518876 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mpo myeloperoxidase multiple interactions
increases activity
increases expression		 EXP astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]; Edaravone inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]
Taurocholic Acid results in increased expression of MPO protein		 CTD PMID:16440434 PMID:20035747 PMID:25604657 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression
multiple interactions		 ISO Taurocholic Acid results in increased expression of MYC protein
[NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA
Taurocholic Acid results in increased expression of MYC mRNA
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]		 CTD PMID:18512153 PMID:27151938 PMID:30556042 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Nanog Nanog homeobox increases expression ISO Taurocholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression ISO Taurocholic Acid results in increased expression of NFE2L2 mRNA CTD PMID:27160211 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
decreases expression		 EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein]
Taurocholic Acid results in decreased expression of NFKBIA mRNA; Taurocholic Acid results in decreased expression of NFKBIA protein		 CTD PMID:25604657 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nfkbib NFKB inhibitor beta multiple interactions
decreases expression		 EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein]
Taurocholic Acid results in decreased expression of NFKBIB mRNA; Taurocholic Acid results in decreased expression of NFKBIB protein		 CTD PMID:25604657 NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression		 EXP [Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; resveratrol inhibits the reaction [[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] CTD PMID:16389574 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 increases expression ISO Taurocholic Acid results in increased expression of NR0B2 mRNA CTD PMID:18706437 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
affects response to substance
affects abundance
increases expression
increases export
increases activity		 ISO epiallopregnanolone sulfate inhibits the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; GW 4064 promotes the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; Taurocholic Acid binds to and results in increased activity of NR1H4 protein
NR1H4 protein affects the susceptibility to Taurocholic Acid
NR1H4 protein affects the abundance of Taurocholic Acid
Taurocholic Acid results in increased expression of NR1H4 mRNA
Taurocholic Acid results in increased activity of NR1H4 protein
[NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA; [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]]		 CTD PMID:16284190 PMID:17567710 PMID:18706437 PMID:19445040 PMID:22961653 More... NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression ISO Taurocholic Acid results in increased expression of NR1I2 mRNA CTD PMID:18706437 PMID:27160211 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions
increases expression		 ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene binds to and affects the activity of NR1I3 protein] which results in decreased abundance of Taurocholic Acid
Taurocholic Acid results in increased expression of NR1I3 mRNA		 CTD PMID:26984780 PMID:27160211 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Pnlip pancreatic lipase increases activity
multiple interactions		 EXP Taurocholic Acid results in increased activity of PNLIP protein
orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein]		 CTD PMID:11668201 NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654 		JBrowse link
G Pon1 paraoxonase 1 multiple interactions
decreases expression		 ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16284190 NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360 		JBrowse link
G Por cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Taurocholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO Taurocholic Acid results in increased expression of POU5F1 mRNA CTD PMID:27151938 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of Taurocholic Acid CTD PMID:29175453 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions		 ISO Taurocholic Acid results in increased expression of PTGS2 mRNA
Taurocholic Acid results in increased expression of PTGS2 protein
JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; MK 2206 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]		 CTD PMID:21224055 PMID:26518876 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rab7a RAB7A, member RAS oncogene family decreases expression ISO Taurocholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
increases phosphorylation
affects localization		 EXP
ISO		 astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein]
Taurocholic Acid results in increased phosphorylation of RELA protein
Taurocholic Acid affects the localization of RELA protein modified form
JTE 013 inhibits the reaction [Taurocholic Acid affects the localization of RELA protein modified form]		 CTD PMID:25604657 PMID:26518876 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G S1pr2 sphingosine-1-phosphate receptor 2 multiple interactions ISO S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; Taurocholic Acid results in increased activity of and results in increased uptake of S1PR2 protein CTD PMID:26518876 NCBI chr 8:19,503,276...19,514,169
Ensembl chr 8:19,502,627...19,523,574 		JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA] CTD PMID:28505368 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions
increases expression
increases transport
increases import
increases uptake		 EXP
ISO		 Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLC10A1 mRNA
4-cresol sulfate inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; [Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid; Acetamides analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Acetanilides analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Anthraquinones analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; bisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; bisphenol F inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Piperazines analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Sodium deficiency inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]; Sulfobromophthalein inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green]; Taurocholic Acid promotes the reaction [SLC10A1 protein results in increased uptake of Fluorescein-5-isothiocyanate]; tetrabromobisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; tetrahydrophthalamic acid analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]		 CTD PMID:19464309 PMID:22641618 PMID:23850984 PMID:25106415 PMID:25319728 More... NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 multiple interactions
increases transport
increases uptake		 EXP
ISO		 Bile Acids and Salts inhibits the reaction [SLC10A2 protein results in increased uptake of Taurocholic Acid]
Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid]		 CTD PMID:19464309 PMID:25466967 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Slc19a1 solute carrier family 19 member 1 multiple interactions
decreases activity		 EXP Taurocholic Acid inhibits the reaction [SLC19A1 protein affects the transport of Methotrexate]
Taurocholic Acid results in decreased activity of SLC19A1 protein		 CTD PMID:14612385 NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972 		JBrowse link
G Slc22a6 solute carrier family 22 member 6 multiple interactions ISO Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] CTD PMID:11602689 NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173 		JBrowse link
G Slc22a8 solute carrier family 22 member 8 affects transport ISO SLC22A8 protein affects the transport of Taurocholic Acid CTD PMID:11306713 NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450 		JBrowse link
G Slc23a1 solute carrier family 23 member 1 increases expression ISO Taurocholic Acid results in increased expression of SLC23A1 mRNA CTD PMID:18706437 NCBI chr18:27,214,940...27,230,564
Ensembl chr18:27,216,281...27,230,697 		JBrowse link
G Slc23a2 solute carrier family 23 member 2 increases expression ISO Taurocholic Acid results in increased expression of SLC23A2 mRNA CTD PMID:18706437 NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343 		JBrowse link
G Slc51a solute carrier family 51 member A multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] CTD PMID:32294204 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] CTD PMID:32294204 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects uptake
multiple interactions
increases uptake
increases expression
affects transport		 ISO
EXP		 SLCO1A4 protein affects the uptake of Taurocholic Acid
Bile Acids and Salts inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLCO1A4 mRNA
SLCO1A4 protein affects the transport of Taurocholic Acid		 CTD PMID:19464309 PMID:19833843 PMID:21561886 PMID:27160211 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions
increases expression
increases uptake		 EXP
ISO		 Bile Acids and Salts inhibits the reaction [SLCO1B3 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLCO1B2 mRNA
Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]		 CTD PMID:19464309 PMID:26134461 PMID:27160211 PMID:30639138 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 increases uptake
multiple interactions		 ISO SLCO2B1 protein results in increased uptake of Taurocholic Acid
Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Taurocholic Acid]		 CTD PMID:24285294 NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
decreases expression		 EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein]
Taurocholic Acid results in decreased expression of SOD1 mRNA; Taurocholic Acid results in decreased expression of SOD1 protein		 CTD PMID:25604657 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression
decreases expression		 ISO
EXP		 [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]
Taurocholic Acid results in increased expression of SOD2 mRNA
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]		 CTD PMID:22316666 PMID:25604657 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sort1 sortilin 1 increases sulfation ISO SORT1 gene mutant form results in increased sulfation of Taurocholic Acid CTD PMID:28453831 NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354 		JBrowse link
G Sox2 SRY-box transcription factor 2 increases expression ISO Taurocholic Acid results in increased expression of SOX2 mRNA CTD PMID:27151938 NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338 		JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Taurocholic Acid results in increased expression of SQSTM1 protein CTD PMID:24189133 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 increases phosphorylation
multiple interactions		 EXP Taurocholic Acid results in increased phosphorylation of STAT1 protein
rosiglitazone inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT1 protein]		 CTD PMID:19563079 NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
increases phosphorylation		 ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein] CTD PMID:18512153 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases transport
decreases import
increases expression		 EXP
ISO		 astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]
TNF protein results in decreased transport of Taurocholic Acid
TNF protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]
Taurocholic Acid results in increased expression of TNF mRNA; Taurocholic Acid results in increased expression of TNF protein		 CTD PMID:16389574 PMID:19080501 PMID:19237016 PMID:19563079 PMID:20035747 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions
decreases expression
increases expression		 ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]
Taurocholic Acid results in decreased expression of VCAM1 protein		 CTD PMID:21224055 PMID:26176423 PMID:28851649 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
taurodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions
increases transport
increases abundance		 ISO
EXP		 [Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Ketoconazole results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [Troglitazone results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; Aconitine inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; aurantio-obtusin inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; carboxyatractyloside inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; celastrol inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; cryptotanshinone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; Cyclosporine inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; dihydrotanshinone I inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; diosbulbin B metabolite inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; diosbulbin B promotes the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; Enzymes and Coenzymes inhibits the reaction [celastrol inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [diosbulbin B promotes the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [isobavachalcone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [rhein promotes the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [saikosaponin D analog inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes inhibits the reaction [saikosaponin D inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes promotes the reaction [saikogenin A analog inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes promotes the reaction [saikogenin A inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; Enzymes and Coenzymes promotes the reaction [Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; isobavachalcone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; kansuinin A inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; kansuinin B inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; mesaconitine inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; rhein metabolite inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; rhein promotes the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikogenin A analog inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikogenin A inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikogenin F inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikosaponin D analog inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; saikosaponin D inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; tanshinone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; toosendanin inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]; Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]
[Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid
ABCB11 protein results in increased abundance of Taurodeoxycholic Acid		 CTD PMID:14570929 PMID:20147439 PMID:35101544 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Taurodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion		 ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurodeoxycholic Acid]
AHR gene mutant form results in increased secretion of Taurodeoxycholic Acid		 CTD PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions		 ISO Taurodeoxycholic Acid results in increased activity of CASP3 protein
ursodoxicoltaurine inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP3 protein]		 CTD PMID:12773247 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions		 ISO Taurodeoxycholic Acid results in increased activity of CASP9 protein
ursodoxicoltaurine inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP9 protein]		 CTD PMID:12773247 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 increases response to substance
increases activity		 ISO CHRM3 protein results in increased susceptibility to Taurodeoxycholic Acid
Taurodeoxycholic Acid results in increased activity of CHRM3 protein		 CTD PMID:15964566 NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases hydroxylation ISO CYP3A4 protein results in increased hydroxylation of Taurodeoxycholic Acid CTD PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases activity
decreases expression		 EXP Taurodeoxycholic Acid results in decreased activity of CYP7B1 protein
Taurodeoxycholic Acid results in decreased expression of CYP7B1 mRNA		 CTD PMID:12029625 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Il10 interleukin 10 multiple interactions
increases abundance		 ISO Taurodeoxycholic Acid promotes the reaction [irinotecan results in decreased secretion of IL10 protein]
IL10 gene mutant form results in increased abundance of Taurodeoxycholic Acid		 CTD PMID:26706406 PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 increases activity ISO Taurodeoxycholic Acid results in increased activity of MAPK14 protein CTD PMID:14762791 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity ISO Taurodeoxycholic Acid results in increased activity of NR1H4 protein CTD PMID:17567710 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Pnlip pancreatic lipase affects folding ISO Taurodeoxycholic Acid affects the folding of PNLIP protein CTD PMID:19346257 NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654 		JBrowse link
G Por cytochrome p450 oxidoreductase affects abundance ISO POR gene mutant form affects the abundance of Taurodeoxycholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Stim1 stromal interaction molecule 1 multiple interactions
affects localization		 EXP STIM1 protein promotes the reaction [Taurodeoxycholic Acid results in increased abundance of Calcium]
Taurodeoxycholic Acid affects the localization of STIM1 protein		 CTD PMID:18342630 NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363 		JBrowse link
taurolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects localization
decreases activity
multiple interactions		 EXP
ISO		 Taurolithocholic Acid affects the localization of ABCB11 protein
Taurolithocholic Acid results in decreased activity of ABCB11 protein
Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Taurolithocholic Acid affects the localization of and affects the activity of ABCB11 protein		 CTD PMID:12865277 PMID:15763547 PMID:24014644 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 affects localization
multiple interactions		 EXP Taurolithocholic Acid affects the localization of ABCC2 protein
3-chloroacetylindole inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; [Colchicine co-treated with JTE 013] inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; CYM-5520 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein; Wortmannin inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]		 CTD PMID:31300867 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions		 EXP Taurolithocholic Acid results in increased phosphorylation of AKT1 protein
JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]		 CTD PMID:31300867 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 multiple interactions
affects binding		 ISO [Taurolithocholic Acid binds to and affects the activity of CHRM3 protein] which results in increased abundance of Inositol Phosphates; Taurolithocholic Acid binds to and affects the activity of CHRM3 protein
Taurolithocholic Acid binds to CHRM3 protein		 CTD PMID:12379313 PMID:12464352 NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases hydroxylation ISO CYP3A4 protein results in increased hydroxylation of Taurolithocholic Acid CTD PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions		 ISO Taurolithocholic Acid results in increased expression of FOS mRNA
ursodoxicoltaurine inhibits the reaction [Taurolithocholic Acid results in increased expression of FOS mRNA]		 CTD PMID:18164257 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of Taurolithocholic Acid CTD PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions		 ISO Taurolithocholic Acid results in increased expression of JUN mRNA
ursodoxicoltaurine inhibits the reaction [Taurolithocholic Acid results in increased expression of JUN mRNA]		 CTD PMID:18164257 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Taurolithocholic Acid CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha increases activity
multiple interactions		 EXP Taurolithocholic Acid results in increased activity of PRKACA protein
JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]		 CTD PMID:31300867 NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430 		JBrowse link
G S1pr2 sphingosine-1-phosphate receptor 2 multiple interactions EXP S1PR2 protein affects the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein] CTD PMID:31300867 NCBI chr 8:19,503,276...19,514,169
Ensembl chr 8:19,502,627...19,523,574 		JBrowse link
G Smad3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of Taurolithocholic Acid CTD PMID:23034213 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 increases sulfation ISO SULT2A1 protein results in increased sulfation of Taurolithocholic Acid CTD PMID:36473578 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
taurolithocholic acid sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions
decreases response to substance		 EXP AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein]
AGT protein results in decreased susceptibility to taurolithocholic acid 3-sulfate		 CTD PMID:23300732 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity		 EXP AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein] CTD PMID:23300732 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cftr CF transmembrane conductance regulator decreases activity ISO taurolithocholic acid 3-sulfate results in decreased activity of CFTR protein CTD PMID:15634668 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756 		JBrowse link
G Chrm1 cholinergic receptor, muscarinic 1 affects binding ISO taurolithocholic acid 3-sulfate binds to CHRM1 protein CTD PMID:12464352 NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356 		JBrowse link
G Ifng interferon gamma multiple interactions
increases expression		 ISO Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA] CTD PMID:22517774 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression		 ISO Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA] CTD PMID:22517774 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
tauroursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin decreases expression EXP ursodoxicoltaurine results in decreased expression of A2M mRNA CTD PMID:15885361 NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786 		JBrowse link
G Aadat aminoadipate aminotransferase decreases expression EXP ursodoxicoltaurine results in decreased expression of AADAT mRNA CTD PMID:15885361 NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332 		JBrowse link
G Aatf apoptosis antagonizing transcription factor increases expression EXP ursodoxicoltaurine results in increased expression of AATF mRNA CTD PMID:15885361 NCBI chr10:69,299,029...69,392,207
Ensembl chr10:69,299,037...69,392,201 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 decreases expression
multiple interactions
increases expression		 EXP
ISO		 ursodoxicoltaurine results in decreased expression of ABCB11 mRNA
[ursodoxicoltaurine co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCB11 protein
ursodoxicoltaurine results in increased expression of and results in increased activity of ABCB11 protein
ursodoxicoltaurine results in increased expression of ABCB11 protein		 CTD PMID:11672435 PMID:12644037 PMID:15885361 PMID:36787806 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
increases expression		 EXP
ISO		 ursodoxicoltaurine results in increased expression of and results in increased activity of ABCC2 protein
[ursodoxicoltaurine co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC2 protein
ursodoxicoltaurine results in increased expression of ABCC2 protein		 CTD PMID:11672435 PMID:12644037 PMID:36787806 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression EXP ursodoxicoltaurine results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Acly ATP citrate lyase decreases expression EXP ursodoxicoltaurine results in decreased expression of ACLY mRNA CTD PMID:15885361 NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of ACSL1 mRNA CTD PMID:15885361 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Actn1 actinin, alpha 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of ACTN1 mRNA CTD PMID:15885361 NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251 		JBrowse link
G Adh1c alcohol dehydrogenase 1C (class I), gamma polypeptide decreases expression EXP ursodoxicoltaurine results in decreased expression of ADH1 mRNA CTD PMID:15885361 NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892 		JBrowse link
G Adk adenosine kinase decreases expression EXP ursodoxicoltaurine results in decreased expression of ADK mRNA CTD PMID:15885361 NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510 		JBrowse link
G Agt angiotensinogen decreases expression
multiple interactions		 EXP ursodoxicoltaurine results in decreased expression of AGT mRNA
ursodoxicoltaurine inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased expression of FN1 protein]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein]		 CTD PMID:15885361 PMID:25398788 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977 		JBrowse link
G Ahr aryl hydrocarbon receptor increases abundance
increases secretion		 ISO AHR gene mutant form results in increased abundance of ursodoxicoltaurine
AHR gene mutant form results in increased secretion of ursodoxicoltaurine		 CTD PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 decreases expression EXP ursodoxicoltaurine results in decreased expression of AKR1D1 mRNA CTD PMID:15885361 NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of AKT1 protein CTD PMID:12721362 PMID:25398788 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Amy2a3 amylase 2a3 decreases expression EXP ursodoxicoltaurine results in decreased expression of AMY1A mRNA CTD PMID:15885361 NCBI chr 2:201,317,916...201,326,487
Ensembl chr 2:201,317,920...201,326,532 		JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 affects expression
decreases expression		 EXP ursodoxicoltaurine affects the expression of APAF1 mRNA; ursodoxicoltaurine affects the expression of APAF1 protein
ursodoxicoltaurine results in decreased expression of APAF1 mRNA		 CTD PMID:15885361 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540 		JBrowse link
G Apoa1 apolipoprotein A1 decreases expression EXP ursodoxicoltaurine results in decreased expression of APOA1 mRNA CTD PMID:15885361 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Apob apolipoprotein B multiple interactions ISO [ursodoxicoltaurine co-treated with Indomethacin] results in increased expression of APOB mRNA; [ursodoxicoltaurine co-treated with Tunicamycin] results in increased expression of APOB mRNA; ursodoxicoltaurine inhibits the reaction [Allopurinol results in decreased secretion of APOB protein]; ursodoxicoltaurine inhibits the reaction [Fluorouracil results in decreased expression of APOB mRNA]; ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in decreased secretion of APOB protein] CTD PMID:32535746 NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497 		JBrowse link
G App amyloid beta precursor protein multiple interactions ISO
EXP		 ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of TRP53 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased activity of CASP2 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased activity of CASP6 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased expression of TRP53 protein]
ursodoxicoltaurine affects the reaction [APP protein modified form affects the localization of NR3C2 protein]; ursodoxicoltaurine inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]; ursodoxicoltaurine inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]		 CTD PMID:16728529 PMID:16923170 PMID:18368144 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561 		JBrowse link
G Aqp8 aquaporin 8 decreases expression EXP ursodoxicoltaurine results in decreased expression of AQP8 mRNA CTD PMID:15885361 NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158 		JBrowse link
G Arg1 arginase 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of ARG1 mRNA CTD PMID:15885361 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422 		JBrowse link
G Arl1 ADP-ribosylation factor like GTPase 1 increases expression EXP ursodoxicoltaurine results in increased expression of ARL1 mRNA CTD PMID:15885361 NCBI chr 7:23,120,004...23,131,173
Ensembl chr 7:23,119,589...23,131,898 		JBrowse link
G As3mt arsenite methyltransferase decreases expression EXP ursodoxicoltaurine results in decreased expression of AS3MT mRNA CTD PMID:15885361 NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872 		JBrowse link
G Atf4 activating transcription factor 4 decreases expression
multiple interactions		 ISO ursodoxicoltaurine results in decreased expression of ATF4 mRNA
ursodoxicoltaurine inhibits the reaction [pachymic acid results in increased expression of ATF4 protein]
ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of ATF4 mRNA]		 CTD PMID:24312631 PMID:28223344 PMID:35524978 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO
EXP		 ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]
ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of ATF6 mRNA]		 CTD PMID:20165829 PMID:28223344 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions
increases phosphorylation		 ISO
EXP		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in decreased activity of BAD protein]; ursodoxicoltaurine results in increased phosphorylation of and results in decreased activity of BAD protein
ursodoxicoltaurine results in increased phosphorylation of and affects the localization of BAD protein; Wortmannin inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and affects the localization of BAD protein]
ursodoxicoltaurine results in increased phosphorylation of BAD protein		 CTD PMID:12721362 PMID:15190125 PMID:17559149 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
decreases expression
increases expression		 ISO
EXP		 ursodoxicoltaurine affects the localization of and results in decreased susceptibility to BAX protein; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased expression of BAX protein]
ursodoxicoltaurine results in decreased expression of BAX protein
ursodoxicoltaurine inhibits the reaction [3-nitropropionic acid affects the localization of BAX protein]; ursodoxicoltaurine inhibits the reaction [Glutamic Acid results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [TP53 protein results in increased expression of BAX mRNA]
ursodoxicoltaurine results in increased expression of BAX protein		 CTD PMID:11080188 PMID:12627974 PMID:12721362 PMID:15255934 PMID:16923170 More... NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions		 EXP
ISO		 ursodoxicoltaurine results in increased expression of BCL2 mRNA; ursodoxicoltaurine results in increased expression of BCL2 protein
ursodoxicoltaurine inhibits the reaction [Glutamic Acid results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [shikonin inhibits the reaction [Glutamic Acid results in decreased expression of BCL2 protein]]
ursodoxicoltaurine inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein]
ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [pachymic acid results in decreased expression of BCL2 mRNA]		 CTD PMID:12721362 PMID:15255934 PMID:16923170 PMID:29751043 PMID:35028790 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of BCL2L1 mRNA CTD PMID:12721362 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G C4b complement C4B decreases expression EXP ursodoxicoltaurine results in decreased expression of C4B mRNA CTD PMID:15885361 NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681 		JBrowse link
G Calr calreticulin multiple interactions EXP ursodoxicoltaurine promotes the reaction [Cisplatin results in increased expression of CALR mRNA] CTD PMID:33631298 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414 		JBrowse link
G Canx calnexin multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of CANX protein] CTD PMID:27588471 NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821 		JBrowse link
G Casp12 caspase 12 multiple interactions ISO
EXP		 ursodoxicoltaurine inhibits the reaction [Thapsigargin results in increased cleavage of CASP12 protein]
ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased cleavage of CASP12 protein]; ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of CASP12 mRNA]		 CTD PMID:12198651 PMID:33631298 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037 		JBrowse link
G Casp2 caspase 2 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased activity of CASP2 protein] CTD PMID:16923170 NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379 		JBrowse link
G Casp3 caspase 3 multiple interactions
decreases activity		 EXP
ISO		 ursodoxicoltaurine inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]; ursodoxicoltaurine inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [Neurotoxins results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein]
ursodoxicoltaurine inhibits the reaction [1-Naphthylisothiocyanate results in increased cleavage of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of CASP3 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]
ursodoxicoltaurine inhibits the reaction [Cyclosporine results in increased cleavage of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [pachymic acid results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]
ursodoxicoltaurine results in decreased activity of CASP3 protein		 CTD PMID:12198651 PMID:12773247 PMID:15190125 PMID:15222754 PMID:17436368 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp4 caspase 4 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP4 protein] CTD PMID:17559149 NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092 		JBrowse link
G Casp6 caspase 6 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased activity of CASP6 protein] CTD PMID:16923170 NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502 		JBrowse link
G Casp7 caspase 7 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased activity of CASP7 protein]; ursodoxicoltaurine inhibits the reaction [Thapsigargin results in increased activity of CASP7 protein] CTD PMID:12198651 PMID:17559149 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO [Chenodeoxycholic Acid co-treated with ursodoxicoltaurine] results in increased activity of CASP9 protein; ursodoxicoltaurine inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP9 protein] CTD PMID:12773247 PMID:14976352 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ccn2 cellular communication network factor 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of CCN2 mRNA CTD PMID:15885361 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression		 EXP ursodoxicoltaurine inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]
ursodoxicoltaurine results in decreased expression of CCND1 mRNA; ursodoxicoltaurine results in decreased expression of CCND1 protein		 CTD PMID:15885361 PMID:17431217 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cdh17 cadherin 17 decreases expression EXP ursodoxicoltaurine results in decreased expression of CDH17 mRNA CTD PMID:15885361 NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884 		JBrowse link
G Cdh2 cadherin 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of CDH2 mRNA CTD PMID:15885361 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression EXP ursodoxicoltaurine results in increased expression of CEBPD mRNA CTD PMID:15885361 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Xylitol results in increased expression of CHAC1 protein] CTD PMID:32275922 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526 		JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of CITED2 mRNA CTD PMID:15885361 NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897 		JBrowse link
G Cps1 carbamoyl-phosphate synthase 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of CPS1 mRNA CTD PMID:15885361 NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of CREB1 protein]; calphostin C inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of CREB1 protein]; KN 62 inhibits the reaction [ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of CREB1 protein]; ursodoxicoltaurine results in increased phosphorylation of and results in increased activity of CREB1 protein CTD PMID:15861431 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816 		JBrowse link
G Cs citrate synthase multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in decreased activity of CS protein]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in decreased expression of CS mRNA] CTD PMID:28223344 NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421 		JBrowse link
G Csad cysteine sulfinic acid decarboxylase decreases expression EXP ursodoxicoltaurine results in decreased expression of CSAD mRNA CTD PMID:15885361 NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615 		JBrowse link
G Cth cystathionine gamma-lyase decreases expression EXP ursodoxicoltaurine results in decreased expression of CTH mRNA CTD PMID:15885361 NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of CYP1A2 mRNA CTD PMID:15885361 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of CYP27A1 mRNA CTD PMID:15885361 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of CYP2A2 mRNA CTD PMID:15885361 NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 decreases expression EXP ursodoxicoltaurine results in decreased expression of CYP2B3 mRNA CTD PMID:15885361 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c12 cytochrome P450, family 2, subfamily c, polypeptide 12 decreases expression EXP ursodoxicoltaurine results in decreased expression of CYP2C12 mRNA CTD PMID:15885361 NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019 		JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 decreases expression EXP ursodoxicoltaurine results in decreased expression of CYP2F4 mRNA CTD PMID:15885361 NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases hydroxylation ISO CYP3A4 protein results in increased hydroxylation of ursodoxicoltaurine CTD PMID:36473578 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp4f1 cytochrome P450, family 4, subfamily f, polypeptide 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of CYP4F1 mRNA CTD PMID:15885361 NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP7A1 protein] CTD PMID:36787806 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions EXP
ISO		 ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of DDIT3 mRNA]; ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]
ursodoxicoltaurine inhibits the reaction [2,4-dichlorophenol results in increased expression of DDIT3 mRNA]; ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of DDIT3 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of DDIT3 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of DDIT3 mRNA]
ursodoxicoltaurine inhibits the reaction [Cyclosporine results in increased expression of and affects the localization of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [hydroquinone results in increased expression of and affects the localization of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [pachymic acid results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]		 CTD PMID:23544086 PMID:24053669 PMID:24802810 PMID:27853103 PMID:28223344 More... NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dpp4 dipeptidylpeptidase 4 decreases expression EXP ursodoxicoltaurine results in decreased expression of DPP4 mRNA CTD PMID:15885361 NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901 		JBrowse link
G E2f1 E2F transcription factor 1 increases expression
decreases expression		 EXP ursodoxicoltaurine results in increased expression of E2F1 mRNA
ursodoxicoltaurine results in decreased expression of E2F1 protein		 CTD PMID:15255934 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361 		JBrowse link
G Edn1 endothelin 1 decreases expression ISO ursodoxicoltaurine results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2AK3 protein]; ursodoxicoltaurine inhibits the reaction [Nicotine results in increased phosphorylation of EIF2AK3 protein]; ursodoxicoltaurine promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2AK3 protein]] CTD PMID:26803847 PMID:35028790 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO
EXP		 ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]
ursodoxicoltaurine inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2S1 protein]; ursodoxicoltaurine promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2S1 protein]]		 CTD PMID:24802810 PMID:35028790 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of ENPP1 mRNA CTD PMID:15885361 NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715 		JBrowse link
G Ergic3 ERGIC and golgi 3 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Tunicamycin results in decreased expression of ERGIC3 protein] CTD PMID:27588471 NCBI chr 3:144,525,059...144,534,813
Ensembl chr 3:144,525,092...144,534,813 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] CTD PMID:29031535 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Esrrg estrogen-related receptor gamma multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Dronabinol results in increased expression of ESRRG mRNA] CTD PMID:31054322 NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397 		JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression ISO ursodoxicoltaurine results in decreased expression of FABP4 mRNA CTD PMID:24312631 NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578 		JBrowse link
G Fads1 fatty acid desaturase 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of FADS1 mRNA CTD PMID:15885361 NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734 		JBrowse link
G Fads3 fatty acid desaturase 3 decreases expression EXP ursodoxicoltaurine results in decreased expression of FADS3 mRNA CTD PMID:15885361 NCBI chr 1:206,685,667...206,702,538
Ensembl chr 1:206,685,894...206,704,769 		JBrowse link
G Fah fumarylacetoacetate hydrolase decreases expression EXP ursodoxicoltaurine results in decreased expression of FAH mRNA CTD PMID:15885361 NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505 		JBrowse link
G Fas Fas cell surface death receptor decreases expression EXP ursodoxicoltaurine results in decreased expression of FAS mRNA CTD PMID:14623915 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Dronabinol results in increased expression of FLT1 mRNA] CTD PMID:31054322 NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626 		JBrowse link
G Fmo3 flavin containing dimethylaniline monoxygenase 3 decreases expression EXP ursodoxicoltaurine results in decreased expression of FMO3 mRNA CTD PMID:15885361 NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028 		JBrowse link
G Fn1 fibronectin 1 decreases expression
multiple interactions		 EXP ursodoxicoltaurine results in decreased expression of FN1 mRNA
ursodoxicoltaurine inhibits the reaction [AGT protein results in increased expression of FN1 protein]		 CTD PMID:15885361 PMID:25398788 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Taurolithocholic Acid results in increased expression of FOS mRNA] CTD PMID:18164257 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Foxo1 forkhead box O1 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Ethanol results in decreased acetylation of FOXO1 protein] CTD PMID:23544086 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790 		JBrowse link
G Ftcd formimidoyltransferase cyclodeaminase decreases expression EXP ursodoxicoltaurine results in decreased expression of FTCD mRNA CTD PMID:15885361 NCBI chr20:12,055,203...12,068,717
Ensembl chr20:12,055,208...12,068,735 		JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of G6PC1 mRNA]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of G6PC1 protein] CTD PMID:23544086 NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804 		JBrowse link
G Gamt guanidinoacetate N-methyltransferase decreases expression EXP ursodoxicoltaurine results in decreased expression of GAMT mRNA CTD PMID:15885361 NCBI chr 7:9,448,590...9,451,413
Ensembl chr 7:9,448,628...9,451,778 		JBrowse link
G Gckr glucokinase regulator decreases expression EXP ursodoxicoltaurine results in decreased expression of GCKR mRNA CTD PMID:15885361 NCBI chr 6:25,044,592...25,075,834
Ensembl chr 6:25,045,100...25,075,654 		JBrowse link
G Glud1 glutamate dehydrogenase 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of GLUD1 mRNA CTD PMID:15885361 NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957 		JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 decreases expression ISO ursodoxicoltaurine results in decreased expression of GPBAR1 mRNA CTD PMID:24312631 NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO ursodoxicoltaurine affects the reaction [NR1H4 protein affects the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]]; ursodoxicoltaurine promotes the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein] CTD PMID:36787806 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsta5 glutathione S-transferase alpha 5 decreases expression EXP ursodoxicoltaurine results in decreased expression of GSTA5 mRNA CTD PMID:15885361 NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472 		JBrowse link
G Gstm5 glutathione S-transferase, mu 5 decreases expression EXP ursodoxicoltaurine results in decreased expression of GSTM3 mRNA CTD PMID:15885361 NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 increases expression EXP ursodoxicoltaurine results in increased expression of GSTP1 mRNA CTD PMID:15885361 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226 		JBrowse link
G Haao 3-hydroxyanthranilate 3,4-dioxygenase decreases expression EXP ursodoxicoltaurine results in decreased expression of HAAO mRNA CTD PMID:15885361 NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877 		JBrowse link
G Hadh hydroxyacyl-CoA dehydrogenase decreases expression EXP ursodoxicoltaurine results in decreased expression of HADH mRNA CTD PMID:15885361 NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353 		JBrowse link
G Hbp1 HMG-box transcription factor 1 increases expression EXP ursodoxicoltaurine results in increased expression of HBP1 mRNA CTD PMID:15885361 NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787 		JBrowse link
G Hdac3 histone deacetylase 3 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Ethanol promotes the reaction [HDAC3 protein binds to HDAC4 protein binds to HDAC5 protein binds to HDAC7 protein]] CTD PMID:23544086 NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856 		JBrowse link
G Hdac4 histone deacetylase 4 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Ethanol promotes the reaction [HDAC3 protein binds to HDAC4 protein binds to HDAC5 protein binds to HDAC7 protein]]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of HDAC4 protein] CTD PMID:23544086 NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164 		JBrowse link
G Hdac5 histone deacetylase 5 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Ethanol promotes the reaction [HDAC3 protein binds to HDAC4 protein binds to HDAC5 protein binds to HDAC7 protein]]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of HDAC5 protein] CTD PMID:23544086 NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235 		JBrowse link
G Hdac7 histone deacetylase 7 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Ethanol promotes the reaction [HDAC3 protein binds to HDAC4 protein binds to HDAC5 protein binds to HDAC7 protein]]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of HDAC7 protein] CTD PMID:23544086 NCBI chr 7:128,923,918...128,961,926
Ensembl chr 7:128,923,920...128,962,072 		JBrowse link
G Hdhd2 haloacid dehalogenase-like hydrolase domain containing 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of HDHD2 mRNA CTD PMID:15885361 NCBI chr18:70,488,315...70,526,471
Ensembl chr18:70,474,926...70,526,470 		JBrowse link
G Hpn hepsin decreases expression EXP ursodoxicoltaurine results in decreased expression of HPN mRNA CTD PMID:15885361 NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811 		JBrowse link
G Hrg histidine-rich glycoprotein decreases expression EXP ursodoxicoltaurine results in decreased expression of HRG mRNA CTD PMID:15885361 NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases expression
multiple interactions
decreases abundance		 EXP
ISO		 ursodoxicoltaurine results in decreased expression of HSD11B1 mRNA
ursodoxicoltaurine inhibits the reaction [Nicotine results in increased expression of HSD11B1 mRNA]
HSD11B1 gene mutant form results in decreased abundance of ursodoxicoltaurine		 CTD PMID:15885361 PMID:25061560 PMID:26803847 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 decreases expression EXP ursodoxicoltaurine results in decreased expression of HSD17B6 mRNA CTD PMID:15885361 NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression		 EXP
ISO		 ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]
ursodoxicoltaurine inhibits the reaction [2,4-dichlorophenol results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [2,4-dichlorophenol results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of HSPA5 mRNA]
ursodoxicoltaurine results in increased expression of HSPA5 protein
ursodoxicoltaurine inhibits the reaction [Amiodarone results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Amiodarone results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Thapsigargin results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Xylitol results in increased expression of HSPA5 protein]		 CTD PMID:12198651 PMID:20165829 PMID:24802810 PMID:25160872 PMID:25295624 More... NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Ifna1 interferon, alpha 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 mRNA]; ursodoxicoltaurine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 protein] CTD PMID:15885359 NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925 		JBrowse link
G Igf1 insulin-like growth factor 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of IGF1 mRNA CTD PMID:15885361 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression EXP ursodoxicoltaurine results in increased expression of IGFBP1 mRNA CTD PMID:15885361 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il10 interleukin 10 increases abundance ISO IL10 gene mutant form results in increased abundance of ursodoxicoltaurine CTD PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Palmitic Acid results in increased secretion of IL1B protein] CTD PMID:29031535 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Palmitic Acid results in increased secretion of IL6 protein] CTD PMID:29031535 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] CTD PMID:20165829 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] CTD PMID:20165829 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G Itpr1 inositol 1,4,5-trisphosphate receptor, type 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of ITPR1 mRNA]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of ITPR1 mRNA] CTD PMID:28223344 NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491 		JBrowse link
G Itpr2 inositol 1,4,5-trisphosphate receptor, type 2 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of ITPR2 mRNA]; ursodoxicoltaurine inhibits the reaction [N-palmitoylsphingosine results in increased expression of ITPR2 mRNA] CTD PMID:28223344 NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Taurolithocholic Acid results in increased expression of JUN mRNA] CTD PMID:18164257 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Kng2 kininogen 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of KNG2 mRNA CTD PMID:15885361 NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971 		JBrowse link
G Ldha lactate dehydrogenase A multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Acetaminophen results in decreased activity of LDHA protein] CTD PMID:38042273 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Lgals5 galectin 5 decreases expression EXP ursodoxicoltaurine results in decreased expression of LGALS5 mRNA CTD PMID:15885361 NCBI chr10:63,853,949...63,857,198
Ensembl chr10:63,853,935...63,857,153 		JBrowse link
G Lgals9 galectin 9 decreases expression EXP ursodoxicoltaurine results in decreased expression of LGALS9 mRNA CTD PMID:15885361 NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045 		JBrowse link
G Limk2 LIM domain kinase 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of LIMK2 mRNA CTD PMID:15885361 NCBI chr14:78,208,182...78,286,106
Ensembl chr14:78,218,063...78,286,007 		JBrowse link
G Lmbrd1 LMBR1 domain containing 1 increases expression EXP ursodoxicoltaurine results in increased expression of LMBRD1 mRNA CTD PMID:15885361 NCBI chr 9:27,096,387...27,178,095
Ensembl chr 9:27,096,297...27,178,090 		JBrowse link
G Lox lysyl oxidase decreases expression EXP ursodoxicoltaurine results in decreased expression of LOX mRNA CTD PMID:15885361 NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477 		JBrowse link
G Maob monoamine oxidase B decreases expression EXP ursodoxicoltaurine results in decreased expression of MAOB mRNA CTD PMID:15885361 NCBI chr  X:5,907,327...6,010,996
Ensembl chr  X:5,907,266...6,011,003 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions EXP ursodoxicoltaurine inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein] CTD PMID:18368144 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129 		JBrowse link
G Masp2 MBL associated serine protease 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of MASP2 mRNA CTD PMID:15885361 NCBI chr 5:159,035,892...159,049,561
Ensembl chr 5:159,035,911...159,049,580 		JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression EXP ursodoxicoltaurine results in increased expression of MDM2 mRNA CTD PMID:15885361 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915 		JBrowse link
G Mef2a myocyte enhancer factor 2a multiple interactions ISO
EXP		 ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein] CTD PMID:20165829 NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948 		JBrowse link
G Mfn2 mitofusin 2 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of MFN2 mRNA] CTD PMID:28223344 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in decreased phosphorylation of MTOR protein] CTD PMID:24802810 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Mx2 MX dynamin like GTPase 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of MX2 mRNA CTD PMID:15885361 NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342 		JBrowse link
G Nfia nuclear factor I/A decreases expression EXP ursodoxicoltaurine results in decreased expression of NFIA mRNA CTD PMID:15885361 NCBI chr 5:112,436,655...112,781,878
Ensembl chr 5:112,436,644...112,775,885 		JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression EXP ursodoxicoltaurine results in increased expression of NFKBIA protein CTD PMID:12721362 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 protein] CTD PMID:29031535 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of NOS2 mRNA]; ursodoxicoltaurine inhibits the reaction [Gentamicins results in increased expression of NOS2 protein] CTD PMID:29751043 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR0B2 protein] CTD PMID:36787806 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1d2 nuclear receptor subfamily 1, group D, member 2 increases expression EXP ursodoxicoltaurine results in increased expression of NR1D2 mRNA CTD PMID:15885361 NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO [ursodoxicoltaurine co-treated with 1-Naphthylisothiocyanate] results in increased expression of NR1H4 protein; ursodoxicoltaurine affects the reaction [NR1H4 protein affects the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]] CTD PMID:36787806 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions ISO
EXP		 ursodoxicoltaurine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 mRNA]; ursodoxicoltaurine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 protein]
[ursodoxicoltaurine co-treated with TGFB1 protein] results in increased localization of NR3C1 protein		 CTD PMID:15222754 PMID:15885359 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375 		JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 affects binding
increases expression
increases localization
multiple interactions		 EXP ursodoxicoltaurine binds to NR3C2 protein
ursodoxicoltaurine results in increased expression of NR3C2 mRNA
ursodoxicoltaurine results in increased localization of NR3C2 protein
[ursodoxicoltaurine binds to NR3C2 protein] which affects the localization of NR3C2 protein; [ursodoxicoltaurine co-treated with TGFB1 protein] results in increased localization of NR3C2 protein; ursodoxicoltaurine affects the reaction [APP protein modified form affects the localization of NR3C2 protein]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 mRNA]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 protein]		 CTD PMID:15222754 PMID:16728529 NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885 		JBrowse link
G Nup62 nucleoporin 62 increases expression EXP ursodoxicoltaurine results in increased expression of NUP62 mRNA CTD PMID:15885361 NCBI chr 1:95,298,995...95,314,902
Ensembl chr 1:95,295,526...95,315,174 		JBrowse link
G Os9 OS9, endoplasmic reticulum lectin multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of OS9 mRNA] CTD PMID:33631298 NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745 		JBrowse link
G Otc ornithine transcarbamylase decreases expression EXP ursodoxicoltaurine results in decreased expression of OTC mRNA CTD PMID:15885361 NCBI chr  X:12,453,834...12,529,954
Ensembl chr  X:12,453,834...12,566,918 		JBrowse link
G Pacs2 phosphofurin acidic cluster sorting protein 2 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of PACS2 mRNA] CTD PMID:28223344 NCBI chr 6:132,096,992...132,156,702
Ensembl chr 6:132,096,901...132,154,583 		JBrowse link
G Pah phenylalanine hydroxylase decreases expression EXP ursodoxicoltaurine results in decreased expression of PAH mRNA CTD PMID:15885361 NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [Chenodeoxycholic Acid co-treated with ursodoxicoltaurine] results in increased cleavage of PARP1 protein CTD PMID:14976352 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pc pyruvate carboxylase multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased activity of PC protein] CTD PMID:28223344 NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380 		JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Ethanol results in decreased acetylation of PCK1 protein]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of PCK1 mRNA]; ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of PCK1 protein] CTD PMID:23544086 NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191 		JBrowse link
G Pdlim1 PDZ and LIM domain 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of PDLIM1 mRNA CTD PMID:15885361 NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076 		JBrowse link
G Pecr peroxisomal trans-2-enoyl-CoA reductase decreases expression EXP ursodoxicoltaurine results in decreased expression of PECR mRNA CTD PMID:15885361 NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511 		JBrowse link
G Phyh phytanoyl-CoA 2-hydroxylase decreases expression EXP ursodoxicoltaurine results in decreased expression of PHYH mRNA CTD PMID:15885361 NCBI chr17:73,329,461...73,346,359
Ensembl chr17:73,329,082...73,346,409 		JBrowse link
G Por cytochrome p450 oxidoreductase affects abundance ISO POR gene mutant form affects the abundance of ursodoxicoltaurine CTD PMID:25034404 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of ursodoxicoltaurine CTD PMID:29175453 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO
EXP		 ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein] CTD PMID:20165829 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656 		JBrowse link
G Psen1 presenilin 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of TRP53 protein] CTD PMID:16923170 NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of RB1 protein CTD PMID:15255934 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rnf138 ring finger protein 138 increases expression EXP ursodoxicoltaurine results in increased expression of RNF138 mRNA CTD PMID:15885361 NCBI chr18:12,291,557...12,315,931
Ensembl chr18:12,291,590...12,315,930 		JBrowse link
G S100a6 S100 calcium binding protein A6 decreases expression EXP ursodoxicoltaurine results in decreased expression of S100A6 mRNA CTD PMID:15885361 NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180 		JBrowse link
G Scarb2 scavenger receptor class B, member 2 increases expression EXP ursodoxicoltaurine results in increased expression of SCARB2 mRNA CTD PMID:15885361 NCBI chr14:15,558,271...15,609,813
Ensembl chr14:15,558,236...15,609,813 		JBrowse link
G Scd stearoyl-CoA desaturase decreases expression EXP ursodoxicoltaurine results in decreased expression of SCD1 mRNA CTD PMID:15885361 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Scp2 sterol carrier protein 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of SCP2 mRNA CTD PMID:15885361 NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287 		JBrowse link
G Serp1 stress-associated endoplasmic reticulum protein 1 increases expression EXP ursodoxicoltaurine results in increased expression of SERP1 mRNA CTD PMID:15885361 NCBI chr 2:142,757,254...142,761,243
Ensembl chr 2:142,757,270...142,761,116 		JBrowse link
G Serpina1 serpin family A member 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased activity of CASP7 protein]; ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]; ursodoxicoltaurine inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP4 protein] CTD PMID:17559149 NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339 		JBrowse link
G Serpind1 serpin family D member 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of SERPIND1 mRNA CTD PMID:15885361 NCBI chr11:83,664,517...83,675,593
Ensembl chr11:83,664,518...83,675,519 		JBrowse link
G Sh3bp5 SH3-domain binding protein 5 decreases expression EXP ursodoxicoltaurine results in decreased expression of SH3BP5 mRNA CTD PMID:15885361 NCBI chr16:6,583,462...6,678,344
Ensembl chr16:6,583,465...6,698,975 		JBrowse link
G Sirt2 sirtuin 2 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Ethanol results in increased expression of SIRT2 protein] CTD PMID:23544086 NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO [1-Naphthylisothiocyanate co-treated with ursodoxicoltaurine] results in decreased expression of SLC10A1 protein CTD PMID:36787806 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 increases expression EXP ursodoxicoltaurine results in increased expression of SLC10A2 protein CTD PMID:11672435 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Slc22a8 solute carrier family 22 member 8 decreases expression EXP ursodoxicoltaurine results in decreased expression of SLC22A8 mRNA CTD PMID:15885361 NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450 		JBrowse link
G Slc26a1 solute carrier family 26 member 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of SLC26A1 mRNA CTD PMID:15885361 NCBI chr14:1,040,565...1,045,851
Ensembl chr14:1,040,243...1,045,849 		JBrowse link
G Slc27a2 solute carrier family 27 member 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of SLC27A2 mRNA CTD PMID:15885361 NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208 		JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP
ISO		 ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein] CTD PMID:20165829 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565 		JBrowse link
G Slc37a4 solute carrier family 37 member 4 decreases expression EXP ursodoxicoltaurine results in decreased expression of SLC37A4 mRNA CTD PMID:15885361 NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301 		JBrowse link
G Slc38a3 solute carrier family 38, member 3 decreases expression EXP ursodoxicoltaurine results in decreased expression of SLC38A3 mRNA CTD PMID:15885361 NCBI chr 8:108,323,889...108,339,959
Ensembl chr 8:108,323,894...108,339,988 		JBrowse link
G Slc4a2 solute carrier family 4 member 2 multiple interactions ISO [1-Naphthylisothiocyanate co-treated with ursodoxicoltaurine] results in increased expression of SLC4A2 protein CTD PMID:36787806 NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965 		JBrowse link
G Slc51b SLC51 subunit beta multiple interactions ISO [ursodoxicoltaurine co-treated with 1-Naphthylisothiocyanate] results in increased expression of SLC51B protein CTD PMID:36787806 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slc6a9 solute carrier family 6 member 9 increases expression EXP ursodoxicoltaurine results in increased expression of SLC6A9 mRNA CTD PMID:15885361 NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728 		JBrowse link
G Smad3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of ursodoxicoltaurine CTD PMID:23034213 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960 		JBrowse link
G Snca synuclein alpha multiple interactions ISO 3-Hydroxybutyric Acid promotes the reaction [ursodoxicoltaurine inhibits the reaction [SNCA protein results in increased susceptibility to Rotenone]]; ursodoxicoltaurine inhibits the reaction [SNCA protein results in increased susceptibility to Rotenone] CTD PMID:16239214 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]] CTD PMID:25398788 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Stmn1 stathmin 1 increases expression EXP ursodoxicoltaurine results in increased expression of STMN1 mRNA CTD PMID:15885361 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of SULT1A1 mRNA CTD PMID:15885361 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562 		JBrowse link
G Sult1b1 sulfotransferase family 1B member 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of SULT1B1 mRNA CTD PMID:15885361 NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483 		JBrowse link
G Tagln transgelin decreases expression EXP ursodoxicoltaurine results in decreased expression of TAGLN mRNA CTD PMID:15885361 NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668 		JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase decreases expression EXP ursodoxicoltaurine results in decreased expression of TDO2 mRNA CTD PMID:15885361 NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP [ursodoxicoltaurine co-treated with TGFB1 protein] results in increased localization of NR3C1 protein; [ursodoxicoltaurine co-treated with TGFB1 protein] results in increased localization of NR3C2 protein; ursodoxicoltaurine inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; ursodoxicoltaurine inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 mRNA]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 protein]; ursodoxicoltaurine inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein] CTD PMID:15222754 PMID:25398788 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tgfbi transforming growth factor, beta induced decreases expression EXP ursodoxicoltaurine results in decreased expression of TGFBI mRNA CTD PMID:15885361 NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240 		JBrowse link
G Tgm2 transglutaminase 2 decreases expression EXP ursodoxicoltaurine results in decreased expression of TGM2 mRNA CTD PMID:15885361 NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981 		JBrowse link
G Thrsp thyroid hormone responsive decreases expression EXP ursodoxicoltaurine results in decreased expression of THRSP mRNA CTD PMID:15885361 NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075 		JBrowse link
G Tm4sf4 transmembrane 4 L six family member 4 decreases expression EXP ursodoxicoltaurine results in decreased expression of TM4SF4 mRNA CTD PMID:15885361 NCBI chr 2:141,570,321...141,621,263
Ensembl chr 2:141,481,902...141,621,200 		JBrowse link
G Tmem37 transmembrane protein 37 decreases expression EXP ursodoxicoltaurine results in decreased expression of TMEM37 mRNA CTD PMID:15885361 NCBI chr13:31,184,322...31,191,477
Ensembl chr13:31,171,355...31,191,077 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
affects response to substance		 EXP
ISO		 ursodoxicoltaurine inhibits the reaction [TP53 protein results in increased expression of BAX mRNA]; ursodoxicoltaurine results in increased expression of and results in increased stability of TP53 protein
ursodoxicoltaurine inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of TRP53 protein]; ursodoxicoltaurine inhibits the reaction [APP gene mutant form results in increased expression of TRP53 protein]
TP53 protein affects the susceptibility to ursodoxicoltaurine		 CTD PMID:15255934 PMID:16923170 PMID:17431217 PMID:17881359 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Uggt1 UDP-glucose glycoprotein glucosyltransferase 1 multiple interactions EXP ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of UGGT1 mRNA]; ursodoxicoltaurine inhibits the reaction [Cisplatin results in increased expression of UGGT1 protein] CTD PMID:33631298 NCBI chr 9:38,355,229...38,468,473
Ensembl chr 9:38,359,089...38,468,467 		JBrowse link
G Ugt2b UDP glycosyltransferase 2 family, polypeptide B decreases expression EXP ursodoxicoltaurine results in decreased expression of UGT2B mRNA CTD PMID:15885361 NCBI chr14:20,630,572...20,665,062
Ensembl chr14:20,630,250...20,651,776 		JBrowse link
G Upb1 beta-ureidopropionase 1 decreases expression EXP ursodoxicoltaurine results in decreased expression of UPB1 mRNA CTD PMID:15885361 NCBI chr20:13,217,252...13,243,590
Ensembl chr20:13,217,258...13,243,590 		JBrowse link
G Vdac1 voltage-dependent anion channel 1 multiple interactions ISO ursodoxicoltaurine inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of VDAC1 mRNA] CTD PMID:28223344 NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO ursodoxicoltaurine inhibits the reaction [Dronabinol results in increased expression of VEGFA mRNA] CTD PMID:31054322 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions EXP
ISO		 ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]
ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [pachymic acid results in increased expression of XBP1 protein]		 CTD PMID:20165829 PMID:35524978 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693 		JBrowse link
ursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aadat aminoadipate aminotransferase decreases expression EXP Ursodeoxycholic Acid results in decreased expression of AADAT mRNA CTD PMID:15885361 NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 increases expression
multiple interactions
decreases expression		 ISO
EXP		 Ursodeoxycholic Acid results in increased expression of ABCB11 mRNA; Ursodeoxycholic Acid results in increased expression of ABCB11 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein]; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 protein]
Ursodeoxycholic Acid results in decreased expression of ABCB11 mRNA		 CTD PMID:11438506 PMID:12187295 PMID:14684751 PMID:25055961 PMID:25418378 More... NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression ISO
EXP		 Ursodeoxycholic Acid results in increased expression of ABCB1 mRNA
Ursodeoxycholic Acid results in increased expression of ABCB1A mRNA		 CTD PMID:15885361 PMID:16678547 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 increases expression ISO Ursodeoxycholic Acid results in increased expression of ABCB4 mRNA CTD PMID:25582706 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 increases expression
multiple interactions		 EXP
ISO		 Ursodeoxycholic Acid results in increased expression of ABCC1 mRNA
Ursodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]		 CTD PMID:16101123 PMID:16764892 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression
affects expression
multiple interactions
increases activity		 ISO
EXP		 Ursodeoxycholic Acid results in increased expression of ABCC2; Ursodeoxycholic Acid results in increased expression of ABCC2 protein
Ursodeoxycholic Acid affects the expression of ABCC2 mRNA; Ursodeoxycholic Acid affects the expression of ABCC2 protein
ABCC2 affects the reaction [Ursodeoxycholic Acid results in increased secretion of Nitric Oxide]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein]; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased activity of ABCC2 protein]; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]; Ursodeoxycholic Acid promotes the reaction [ABCC2 protein results in increased export of S-(2,4-dinitrophenyl)glutathione]
Ursodeoxycholic Acid results in increased activity of ABCC2 protein
NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC2 mRNA]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC2 protein]
Ursodeoxycholic Acid results in increased expression of ABCC2 mRNA; Ursodeoxycholic Acid results in increased expression of ABCC2 protein		 CTD PMID:11438506 PMID:12606635 PMID:12971955 PMID:15843489 PMID:15956029 More... NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions
affects expression
increases expression		 ISO
EXP		 NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC3 mRNA]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC3 protein]
Ursodeoxycholic Acid affects the expression of ABCC3 protein
Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC3 protein]; Ursodeoxycholic Acid promotes the reaction [NFE2L2 protein binds to ABCC3 promoter]
Ursodeoxycholic Acid results in increased expression of ABCC3 mRNA; Ursodeoxycholic Acid results in increased expression of ABCC3 protein		 CTD PMID:12971955 PMID:16472600 PMID:16764892 PMID:18687751 PMID:25055961 More... NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions
affects expression
increases expression		 ISO
EXP		 NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC4 mRNA]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC4 protein]
Ursodeoxycholic Acid affects the expression of ABCC4 protein
Ursodeoxycholic Acid promotes the reaction [NFE2L2 protein binds to ABCC4 promoter]
Ursodeoxycholic Acid results in increased expression of ABCC4 mRNA; Ursodeoxycholic Acid results in increased expression of ABCC4 protein		 CTD PMID:16472600 PMID:18687751 PMID:25582706 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 increases expression ISO Ursodeoxycholic Acid results in increased expression of ABCG5 mRNA CTD PMID:25582706 NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563 		JBrowse link
G Abcg8 ATP binding cassette subfamily G member 8 increases expression ISO Ursodeoxycholic Acid results in increased expression of ABCG8 mRNA CTD PMID:25582706 NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912 		JBrowse link
G Actn1 actinin, alpha 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of ACTN1 mRNA CTD PMID:15885361 NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251 		JBrowse link
G Ahr aryl hydrocarbon receptor increases expression
multiple interactions
increases secretion		 ISO Ursodeoxycholic Acid results in increased expression of AHR mRNA
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Ursodeoxycholic Acid]
AHR gene mutant form results in increased secretion of Ursodeoxycholic Acid		 CTD PMID:18687751 PMID:29452137 PMID:32679164 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 decreases activity ISO Ursodeoxycholic Acid results in decreased activity of AKR1C1 protein CTD PMID:12604236 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions
decreases activity		 ISO Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone]
Ursodeoxycholic Acid results in decreased activity of AKR1C2 protein		 CTD PMID:8573067 PMID:12604236 PMID:23261716 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 decreases activity ISO Ursodeoxycholic Acid results in decreased activity of AKR1C3 protein CTD PMID:12604236 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased phosphorylation of AKT1 protein] CTD PMID:19073151 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Ankrd28 ankyrin repeat domain 28 affects expression ISO Ursodeoxycholic Acid affects the expression of ANKRD28 mRNA CTD PMID:18422935 NCBI chr16:6,918,487...7,050,244
Ensembl chr16:6,914,336...7,050,249 		JBrowse link
G Ap2m1 adaptor related protein complex 2 subunit mu 1 affects expression ISO Ursodeoxycholic Acid affects the expression of AP2M1 mRNA CTD PMID:18422935 NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140 		JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of APAF1 mRNA; Ursodeoxycholic Acid results in decreased expression of APAF1 protein CTD PMID:15885361 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540 		JBrowse link
G Apoa1 apolipoprotein A1 increases expression ISO Ursodeoxycholic Acid results in increased expression of APOA1 mRNA CTD PMID:15115973 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Apom apolipoprotein M multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein] CTD PMID:22160096 NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550 		JBrowse link
G Aqp8 aquaporin 8 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of AQP8 mRNA CTD PMID:15885361 NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158 		JBrowse link
G Arg1 arginase 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of ARG1 mRNA CTD PMID:15885361 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422 		JBrowse link
G Arl1 ADP-ribosylation factor like GTPase 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of ARL1 mRNA CTD PMID:15885361 NCBI chr 7:23,120,004...23,131,173
Ensembl chr 7:23,119,589...23,131,898 		JBrowse link
G Arnt aryl hydrocarbon receptor nuclear translocator multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of ARNT protein] CTD PMID:14761680 NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580 		JBrowse link
G Atf4 activating transcription factor 4 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of ATF4 mRNA CTD PMID:24312631 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of ATP8B1 mRNA CTD PMID:25582706 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions
decreases expression		 ISO
EXP		 Ursodeoxycholic Acid results in increased expression of BAX
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [E2F1 protein results in increased expression of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Okadaic Acid results in increased expression of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of and results in increased localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of BAX protein]
Ursodeoxycholic Acid results in decreased expression of BAX protein
Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Nitroprusside affects the localization of BAX protein]]; triciribine inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Nitroprusside affects the localization of BAX protein]]; Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased expression of and affects the localization of BAX protein]		 CTD PMID:9562975 PMID:10510466 PMID:14514686 PMID:15970352 PMID:17461466 More... NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression		 EXP
ISO		 Ursodeoxycholic Acid inhibits the reaction [Rotenone results in decreased expression of BCL2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of BCL2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of BCL2 protein]
Ursodeoxycholic Acid results in decreased expression of BCL2
Ursodeoxycholic Acid results in decreased expression of BCL2 protein
Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]		 CTD PMID:14514686 PMID:15970352 PMID:17461466 PMID:21419764 PMID:25502462 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bet1 Bet1 golgi vesicular membrane trafficking protein increases expression EXP Ursodeoxycholic Acid results in increased expression of BET1 mRNA CTD PMID:15885361 NCBI chr 4:32,116,232...32,126,592
Ensembl chr 4:32,116,235...32,126,617 		JBrowse link
G Blvra biliverdin reductase A increases expression ISO
EXP		 Ursodeoxycholic Acid results in increased expression of BLVRA mRNA
Ursodeoxycholic Acid results in increased expression of BLVRA mRNA; Ursodeoxycholic Acid results in increased expression of BLVRA protein		 CTD PMID:18706437 NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033 		JBrowse link
G C4bpa complement component 4 binding protein, alpha affects expression ISO Ursodeoxycholic Acid affects the expression of C4BPA mRNA CTD PMID:18422935 NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205 		JBrowse link
G Capn2 calpain 2 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of CAPN2 mRNA CTD PMID:15885361 NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969 		JBrowse link
G Car2 carbonic anhydrase 2 multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [CAR2 results in increased expression of IL2 mRNA] CTD PMID:15816485 NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818 		JBrowse link
G Casp3 caspase 3 multiple interactions
decreases activity		 ISO
EXP		 [oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein]; FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein]; methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein]; pifithrin inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein]; RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein]; rottlerin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein]; TP53 mutant form inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP3 protein]; Ursodeoxycholic Acid promotes the reaction [irinotecan results in increased activity of CASP3 protein]; Ursodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein
Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein]
Ursodeoxycholic Acid results in decreased activity of CASP3 protein		 CTD PMID:14514686 PMID:15222754 PMID:15970352 PMID:16310035 PMID:16432164 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp6 caspase 6 multiple interactions ISO benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP6 protein]; FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein]; methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein]; RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein]; rottlerin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein]; TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein]; Ursodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP6 protein CTD PMID:21362627 NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502 		JBrowse link
G Casp7 caspase 7 multiple interactions ISO Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein]
Ursodeoxycholic Acid analog inhibits the reaction [TNF protein results in increased activity of CASP7 protein]; Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP7 protein]		 CTD PMID:21146893 PMID:22178905 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp8 caspase 8 multiple interactions
increases activity		 ISO
EXP		 [oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased cleavage of and results in increased activity of CASP8 protein; FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein]; pifithrin inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP8 protein]; RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein]; TP53 mutant form inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP8 protein]; Ursodeoxycholic Acid promotes the reaction [irinotecan results in increased activity of CASP8 protein]
Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein]
Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of CASP8 protein]		 CTD PMID:16432164 PMID:19728331 PMID:21146893 PMID:21362627 PMID:25502462 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO
EXP		 Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP9 protein]
Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of CASP9 mRNA]; Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of CASP9 protein]		 CTD PMID:22178905 PMID:25502462 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression		 ISO Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]
Ursodeoxycholic Acid results in increased expression of CCL2 mRNA
Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]		 CTD PMID:21146893 PMID:24312631 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]
Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein]		 CTD PMID:21146893 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Ccn2 cellular communication network factor 2 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of CCN2 mRNA CTD PMID:15885361 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734 		JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions		 ISO
EXP		 Ursodeoxycholic Acid results in decreased expression of CCND1 protein
Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of CCND1 protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]
Ursodeoxycholic Acid results in decreased expression of CCND1 mRNA; Ursodeoxycholic Acid results in decreased expression of CCND1 protein		 CTD PMID:12496057 PMID:15885361 PMID:17431217 PMID:17461466 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of CCND3 protein CTD PMID:17461466 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371 		JBrowse link
G Cct3 chaperonin containing TCP1 subunit 3 affects expression ISO Ursodeoxycholic Acid affects the expression of CCT3 mRNA CTD PMID:18422935 NCBI chr 2:173,765,701...173,790,353
Ensembl chr 2:173,765,698...173,790,757 		JBrowse link
G Cct5 chaperonin containing TCP1 subunit 5 affects expression ISO Ursodeoxycholic Acid affects the expression of CCT5 mRNA CTD PMID:18422935 NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930 		JBrowse link
G Cd14 CD14 molecule increases expression EXP Ursodeoxycholic Acid results in increased expression of CD14 mRNA CTD PMID:15885361 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261 		JBrowse link
G Cd248 CD248 molecule affects expression ISO Ursodeoxycholic Acid affects the expression of CD248 mRNA CTD PMID:18422935 NCBI chr 1:202,373,676...202,376,240
Ensembl chr 1:202,373,676...202,376,240 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
decreases expression		 EXP Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of CDH1 protein]
Ursodeoxycholic Acid results in decreased expression of CDH1 mRNA		 CTD PMID:12496057 PMID:15885361 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdh17 cadherin 17 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of CDH17 mRNA CTD PMID:15885361 NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CEBPB] CTD PMID:18444174 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression EXP Ursodeoxycholic Acid results in increased expression of CEBPD mRNA CTD PMID:15885361 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator increases expression ISO Ursodeoxycholic Acid analog results in increased expression of CFLAR protein CTD PMID:21146893 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of CITED2 mRNA CTD PMID:15885361 NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897 		JBrowse link
G Cnp 2',3'-cyclic nucleotide 3' phosphodiesterase affects expression ISO Ursodeoxycholic Acid affects the expression of CNP mRNA CTD PMID:18422935 NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720 		JBrowse link
G Col3a1 collagen type III alpha 1 chain decreases expression EXP Ursodeoxycholic Acid results in decreased expression of COL3A1 mRNA CTD PMID:18479249 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547 		JBrowse link
G Crebbp CREB binding protein decreases expression EXP Ursodeoxycholic Acid results in decreased expression of CREBBP mRNA CTD PMID:19493473 NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888 		JBrowse link
G Cryab crystallin, alpha B decreases expression EXP Ursodeoxycholic Acid results in decreased expression of CRYAB mRNA CTD PMID:15885361 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157 		JBrowse link
G Cse1l chromosome segregation 1 like affects expression ISO Ursodeoxycholic Acid affects the expression of CSE1L mRNA CTD PMID:18422935 NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865 		JBrowse link
G Cspg4 chondroitin sulfate proteoglycan 4 affects expression ISO Ursodeoxycholic Acid affects the expression of CSPG4 mRNA CTD PMID:18422935 NCBI chr 8:57,264,962...57,300,010
Ensembl chr 8:57,264,962...57,300,010 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression ISO Ursodeoxycholic Acid results in increased expression of CXCL1 mRNA CTD PMID:24312631 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression EXP Ursodeoxycholic Acid results in increased expression of CXCL10 mRNA CTD PMID:15885361 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 decreases expression
decreases secretion		 ISO Ursodeoxycholic Acid results in decreased expression of CXCL2 mRNA; Ursodeoxycholic Acid results in decreased expression of CXCL2 protein
Ursodeoxycholic Acid results in decreased secretion of CXCL2 protein		 CTD PMID:17888421 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases expression ISO Ursodeoxycholic Acid results in increased expression of CXCL1 mRNA CTD PMID:24312631 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [benzo(a)pyrene 7,8-dihydrodiol results in increased expression of CYP1A1 mRNA] CTD PMID:10706104 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of CYP26A1 mRNA CTD PMID:15885361 NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 increases expression
decreases expression		 EXP
ISO		 Ursodeoxycholic Acid results in increased expression of CYP27A1 mRNA
Ursodeoxycholic Acid results in decreased expression of CYP27A1 mRNA		 CTD PMID:16764892 PMID:25582706 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2B1 protein] CTD PMID:10453939 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 decreases expression
affects expression
multiple interactions		 EXP
ISO		 Ursodeoxycholic Acid results in decreased expression of CYP2B3 mRNA
Ursodeoxycholic Acid affects the expression of CYP2B10 protein
Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein]		 CTD PMID:15885361 PMID:16472600 PMID:32198087 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C11 protein] CTD PMID:10453939 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066 		JBrowse link
G Cyp2c12 cytochrome P450, family 2, subfamily c, polypeptide 12 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of CYP2C12 mRNA CTD PMID:15885361 NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP2C6V1 protein] CTD PMID:10453939 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c7 cytochrome P450, family 2, subfamily c, polypeptide 7 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of CYP2C7 mRNA CTD PMID:15885361 NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP2E1 protein] CTD PMID:10453939 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
increases expression
affects metabolic processing
increases hydroxylation		 EXP
ISO		 [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Ursodeoxycholic Acid; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of and results in decreased activity of CYP3A2 protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP3A2 mRNA]
Ursodeoxycholic Acid results in increased expression of CYP3A2 mRNA
[CYP3A4 protein results in increased metabolism of Lithocholic Acid] which results in increased abundance of Ursodeoxycholic Acid
Ursodeoxycholic Acid results in increased expression of CYP3A4 mRNA
CYP3A4 protein affects the metabolism of Ursodeoxycholic Acid
CYP3A4 protein results in increased hydroxylation of Ursodeoxycholic Acid		 CTD PMID:10453939 PMID:15708356 PMID:16678547 PMID:19255942 PMID:19487251 More... NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 increases expression
multiple interactions		 EXP Ursodeoxycholic Acid results in increased expression of CYP3A23-3A1 mRNA
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Ursodeoxycholic Acid		 CTD PMID:19255942 PMID:34461081 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030 		JBrowse link
G Cyp4a1 cytochrome P450, family 4, subfamily a, polypeptide 1 multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in decreased expression of CYP4A1 protein] CTD PMID:10453939 NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
increases expression
decreases expression		 EXP
ISO		 [Tretinoin co-treated with Ursodeoxycholic Acid] results in decreased expression of CYP7A1 mRNA; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of CYP7A1 mRNA]
Tretinoin promotes the reaction [Ursodeoxycholic Acid results in decreased expression of CYP7A1 mRNA]; Ursodeoxycholic Acid promotes the reaction [Tretinoin results in decreased expression of CYP7A1 mRNA]
Ursodeoxycholic Acid results in increased expression of CYP7A1 mRNA		 CTD PMID:14684751 PMID:16487557 PMID:16764892 PMID:20671298 PMID:21274875 More... NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of CYP7B1 mRNA CTD PMID:20671298 NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698 		JBrowse link
G Cyp8b1 cytochrome P450 family 8 subfamily B member 1 increases expression
decreases expression		 EXP
ISO		 Ursodeoxycholic Acid results in increased expression of CYP8B1 mRNA
Ursodeoxycholic Acid results in decreased expression of CYP8B1 mRNA		 CTD PMID:16764892 PMID:25582706 NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166 		JBrowse link
G Dap3 death associated protein 3 affects expression ISO Ursodeoxycholic Acid affects the expression of DAP3 mRNA CTD PMID:18422935 NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression EXP Ursodeoxycholic Acid results in increased expression of DDIT3 mRNA CTD PMID:15885361 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dhx9 DExH-box helicase 9 affects expression ISO Ursodeoxycholic Acid affects the expression of DHX9 mRNA CTD PMID:18422935 NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069 		JBrowse link
G Dlat dihydrolipoamide S-acetyltransferase affects expression ISO Ursodeoxycholic Acid affects the expression of DLAT mRNA CTD PMID:18422935 NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479 		JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein multiple interactions
increases expression		 ISO DLC1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased activity of RHOA protein]
Ursodeoxycholic Acid results in increased expression of DLC1 protein		 CTD PMID:21455586 NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439 		JBrowse link
G Dmgdh dimethylglycine dehydrogenase decreases expression EXP Ursodeoxycholic Acid results in decreased expression of DMGDH mRNA CTD PMID:15885361 NCBI chr 2:24,912,600...24,987,533
Ensembl chr 2:24,912,578...24,987,528 		JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 increases expression
decreases expression		 EXP
ISO		 Ursodeoxycholic Acid results in increased expression of DNAJC3 mRNA
Ursodeoxycholic Acid results in decreased expression of DNAJC3 mRNA		 CTD PMID:15885361 PMID:24312631 NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181 		JBrowse link
G Dnase2b deoxyribonuclease 2 beta decreases expression EXP Ursodeoxycholic Acid results in decreased expression of DNASE2B mRNA CTD PMID:15885361 NCBI chr 2:235,470,915...235,515,211
Ensembl chr 2:235,470,919...235,486,295 		JBrowse link
G Dpp4 dipeptidylpeptidase 4 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of DPP4 mRNA CTD PMID:15885361 NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901 		JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions
decreases expression		 EXP NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]]; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased expression of E2F1 protein]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased expression of E2F1 protein]; Ursodeoxycholic Acid inhibits the reaction [E2F1 protein results in increased expression of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [E2F1 protein results in increased expression of TP53 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein] CTD PMID:14514686 PMID:15222754 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361 		JBrowse link
G Eci1 enoyl-CoA delta isomerase 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of ECI1 mRNA CTD PMID:15885361 NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061 		JBrowse link
G Edn1 endothelin 1 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of EDN1 mRNA; Ursodeoxycholic Acid results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Edn2 endothelin 2 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of EDN2 protein CTD PMID:15691296 NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein] CTD PMID:14747693 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of EGLN3 mRNA CTD PMID:15885361 NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766 		JBrowse link
G Egr1 early growth response 1 multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of EGR1 mRNA] CTD PMID:18590720 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Eif1 eukaryotic translation initiation factor 1 affects expression ISO Ursodeoxycholic Acid affects the expression of EIF1 mRNA CTD PMID:18422935 NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327 		JBrowse link
G Ep300 E1A binding protein p300 multiple interactions ISO [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to NR3C1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to NR3C1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form]; Ursodeoxycholic Acid promotes the reaction [EP300 protein binds to SLC4A2 promoter] CTD PMID:18188457 NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088 		JBrowse link
G Ermp1 endoplasmic reticulum metallopeptidase 1 affects expression ISO Ursodeoxycholic Acid affects the expression of ERMP1 mRNA CTD PMID:18422935 NCBI chr 1:227,383,992...227,422,120
Ensembl chr 1:227,387,920...227,436,909 		JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of FABP4 mRNA CTD PMID:24312631 NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578 		JBrowse link
G Fabp6 fatty acid binding protein 6 multiple interactions
increases expression		 ISO Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased expression of FABP6 mRNA]
Ursodeoxycholic Acid results in increased expression of FABP6 mRNA		 CTD PMID:15935148 PMID:25582706 NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282 		JBrowse link
G Fadd Fas associated via death domain multiple interactions ISO FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein]; FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein]; FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein]; FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] CTD PMID:21362627 NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653 		JBrowse link
G Fads1 fatty acid desaturase 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of FADS1 mRNA CTD PMID:15885361 NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734 		JBrowse link
G Fads3 fatty acid desaturase 3 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of FADS3 mRNA CTD PMID:15885361 NCBI chr 1:206,685,667...206,702,538
Ensembl chr 1:206,685,894...206,704,769 		JBrowse link
G Fam169a family with sequence similarity 169, member A affects expression ISO Ursodeoxycholic Acid affects the expression of FAM169A mRNA CTD PMID:18422935 NCBI chr 2:28,384,162...28,441,361
Ensembl chr 2:28,383,784...28,438,910 		JBrowse link
G Fasn fatty acid synthase decreases expression EXP
ISO		 Ursodeoxycholic Acid results in decreased expression of FASN mRNA CTD PMID:15885361 PMID:24312631 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression		 ISO Ursodeoxycholic Acid promotes the reaction [Tretinoin results in increased expression of FGF19 mRNA]
Ursodeoxycholic Acid results in increased expression of FGF19 mRNA
Ursodeoxycholic Acid results in increased expression of FGF15 mRNA		 CTD PMID:21274875 PMID:25055961 PMID:25582706 NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287 		JBrowse link
G Fgg fibrinogen gamma chain affects expression ISO Ursodeoxycholic Acid affects the expression of FGG mRNA CTD PMID:18422935 NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322 		JBrowse link
G Fgl1 fibrinogen-like 1 affects expression ISO Ursodeoxycholic Acid affects the expression of FGL1 mRNA CTD PMID:18422935 NCBI chr16:51,120,652...51,150,907
Ensembl chr16:51,120,694...51,151,093 		JBrowse link
G Gamt guanidinoacetate N-methyltransferase decreases expression EXP Ursodeoxycholic Acid results in decreased expression of GAMT mRNA CTD PMID:15885361 NCBI chr 7:9,448,590...9,451,413
Ensembl chr 7:9,448,628...9,451,778 		JBrowse link
G Gars1 glycyl-tRNA synthetase 1 affects expression ISO Ursodeoxycholic Acid affects the expression of GARS1 mRNA CTD PMID:18422935 NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609 		JBrowse link
G Gckr glucokinase regulator decreases expression EXP Ursodeoxycholic Acid results in decreased expression of GCKR mRNA CTD PMID:15885361 NCBI chr 6:25,044,592...25,075,834
Ensembl chr 6:25,045,100...25,075,654 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased expression of GCLC mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]]; Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLC mRNA]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]
Ursodeoxycholic Acid results in increased expression of GCLC mRNA; Ursodeoxycholic Acid results in increased expression of GCLC protein
NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of GCLC mRNA]		 CTD PMID:18687751 PMID:19073151 PMID:20146260 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions
increases expression		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased expression of GCLM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLM mRNA] CTD PMID:19073151 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Got1 glutamic-oxaloacetic transaminase 1 multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of GOT1 protein] CTD PMID:38104874 NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633 		JBrowse link
G Gpbar1 G protein-coupled bile acid receptor 1 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of GPBAR1 mRNA CTD PMID:24312631 NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168 		JBrowse link
G Gpnmb glycoprotein nmb decreases expression EXP Ursodeoxycholic Acid results in decreased expression of GPNMB mRNA CTD PMID:15885361 NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP
ISO		 Ursodeoxycholic Acid inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in increased activity of GPT protein]
Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of GPT protein]		 CTD PMID:15950962 PMID:27743861 PMID:38104874 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Grb14 growth factor receptor bound protein 14 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of GRB14 mRNA CTD PMID:15885361 NCBI chr 3:49,568,210...49,683,805
Ensembl chr 3:49,568,210...49,683,889 		JBrowse link
G Gss glutathione synthetase multiple interactions
increases expression		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased expression of GSS mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]]; Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GSS mRNA]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA] CTD PMID:19073151 PMID:20146260 NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198 		JBrowse link
G Gsta5 glutathione S-transferase alpha 5 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of GSTA5 mRNA CTD PMID:15885361 NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472 		JBrowse link
G Gstm5 glutathione S-transferase, mu 5 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of GSTM3 mRNA CTD PMID:15885361 NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553 		JBrowse link
G Haao 3-hydroxyanthranilate 3,4-dioxygenase decreases expression EXP Ursodeoxycholic Acid results in decreased expression of HAAO mRNA CTD PMID:15885361 NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877 		JBrowse link
G Hbp1 HMG-box transcription factor 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of HBP1 mRNA CTD PMID:15885361 NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787 		JBrowse link
G Hdhd2 haloacid dehalogenase-like hydrolase domain containing 2 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of HDHD2 mRNA CTD PMID:15885361 NCBI chr18:70,488,315...70,526,471
Ensembl chr18:70,474,926...70,526,470 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions
increases expression		 ISO
EXP		 Ursodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF mRNA]; Ursodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein]; Ursodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of HGF mRNA]; Ursodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of HGF protein]
Ursodeoxycholic Acid results in increased expression of HGF mRNA		 CTD PMID:11983124 PMID:15802798 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of HIF1A mRNA]; Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of HIF1A protein] CTD PMID:38104874 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase decreases activity EXP Ursodeoxycholic Acid results in decreased activity of HMGCR protein CTD PMID:6832710 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703 		JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of HMGCS2 mRNA CTD PMID:15885361 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130 		JBrowse link
G Hnf1a HNF1 homeobox A multiple interactions ISO [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to NR3C1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to NR3C1 protein binds to SLC4A2 promoter]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to SLC4A2 promoter]; Ursodeoxycholic Acid promotes the reaction [HNF1A protein binds to SLC4A2 promoter] CTD PMID:18188457 NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104 		JBrowse link
G Hnf1b HNF1 homeobox B multiple interactions ISO [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to NR3C1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form] CTD PMID:18188457 NCBI chr10:68,735,894...68,789,888
Ensembl chr10:68,735,894...68,789,888 		JBrowse link
G Hpn hepsin decreases expression EXP Ursodeoxycholic Acid results in decreased expression of HPN mRNA CTD PMID:15885361 NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased activity of HRAS protein] CTD PMID:12839936 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hrg histidine-rich glycoprotein decreases expression EXP Ursodeoxycholic Acid results in decreased expression of HRG mRNA CTD PMID:15885361 NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389 		JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 multiple interactions
increases abundance		 ISO [HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Ursodeoxycholic Acid
HSD11B1 gene mutant form results in increased abundance of Ursodeoxycholic Acid		 CTD PMID:21453287 PMID:25061560 NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687 		JBrowse link
G Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of HSD17B6 mRNA CTD PMID:15885361 NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of HSPA5 mRNA CTD PMID:24312631 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Ifng interferon gamma multiple interactions ISO
EXP		 Ursodeoxycholic Acid inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]
Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IFNG protein]; Ursodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Ursodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]		 CTD PMID:8568266 PMID:12620498 PMID:32198087 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Igfals insulin-like growth factor binding protein, acid labile subunit decreases expression EXP Ursodeoxycholic Acid results in decreased expression of IGFALS mRNA CTD PMID:15885361 NCBI chr10:13,897,468...13,903,920
Ensembl chr10:13,898,395...13,902,677 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of IGFBP1 mRNA CTD PMID:15885361 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Il10 interleukin 10 multiple interactions
decreases abundance		 EXP
ISO		 Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of IL10 protein]
IL10 gene mutant form results in decreased abundance of Ursodeoxycholic Acid		 CTD PMID:25502462 PMID:27580383 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression		 EXP
ISO		 Tretinoin inhibits the reaction [Ursodeoxycholic Acid results in decreased expression of IL1B mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein]; Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of IL1B protein]; Ursodeoxycholic Acid inhibits the reaction [Tretinoin results in decreased expression of IL1B mRNA]
Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased secretion of IL1B protein]		 CTD PMID:21274875 PMID:25502462 PMID:32198087 PMID:38104874 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [CAR2 results in increased expression of IL2 mRNA] CTD PMID:15816485 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566 		JBrowse link
G Il6 interleukin 6 multiple interactions
decreases secretion		 ISO
EXP		 Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]
Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL6 protein]
Ursodeoxycholic Acid results in decreased secretion of IL6 protein
Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6 mRNA]; Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6 protein]; Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased secretion of IL6 protein]		 CTD PMID:17888421 PMID:18590720 PMID:21146893 PMID:38104874 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Impdh2 inosine monophosphate dehydrogenase 2 affects expression ISO Ursodeoxycholic Acid affects the expression of IMPDH2 mRNA CTD PMID:18422935 NCBI chr 8:109,256,705...109,261,365
Ensembl chr 8:109,256,728...109,261,359 		JBrowse link
G Irs2 insulin receptor substrate 2 increases expression EXP Ursodeoxycholic Acid results in increased expression of IRS2 mRNA CTD PMID:15885361 NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482 		JBrowse link
G Ivl involucrin decreases expression ISO Ursodeoxycholic Acid results in decreased expression of IVL protein CTD PMID:10769631 NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100 		JBrowse link
G Klf15 KLF transcription factor 15 increases expression EXP Ursodeoxycholic Acid results in increased expression of KLF15 mRNA CTD PMID:15885361 NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374 		JBrowse link
G Kras KRAS proto-oncogene, GTPase multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased mutagenesis of KRAS gene] CTD PMID:12839936 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Krt18 keratin 18 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of KRT18 mRNA CTD PMID:15885361 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 		JBrowse link
G Krt19 keratin 19 multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Tretinoin results in decreased expression of KRT19 mRNA] CTD PMID:21274875 NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799 		JBrowse link
G Lgals5 galectin 5 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of LGALS5 mRNA CTD PMID:15885361 NCBI chr10:63,853,949...63,857,198
Ensembl chr10:63,853,935...63,857,153 		JBrowse link
G Lman1 lectin, mannose-binding, 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of LMAN1 mRNA CTD PMID:15885361 NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851 		JBrowse link
G Lox lysyl oxidase decreases expression EXP Ursodeoxycholic Acid results in decreased expression of LOX mRNA CTD PMID:15885361 NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477 		JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein] CTD PMID:20146260 NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365 		JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein] CTD PMID:20146260 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Magi3 membrane associated guanylate kinase, WW and PDZ domain containing 3 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of MAGI3 mRNA CTD PMID:15885361 NCBI chr 2:191,514,726...191,717,048
Ensembl chr 2:191,518,506...191,716,735 		JBrowse link
G Maob monoamine oxidase B decreases expression EXP Ursodeoxycholic Acid results in decreased expression of MAOB mRNA CTD PMID:15885361 NCBI chr  X:5,907,327...6,010,996
Ensembl chr  X:5,907,266...6,011,003 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation		 ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK1 protein] CTD PMID:14747693 PMID:24312631 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:14747693 PMID:24312631 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mbp myelin basic protein affects expression ISO Ursodeoxycholic Acid affects the expression of MBP mRNA CTD PMID:18422935 NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression ISO Ursodeoxycholic Acid analog results in increased expression of MCL1 protein CTD PMID:21146893 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions
increases expression		 EXP
ISO		 [Ursodeoxycholic Acid promotes the reaction [TP53 protein binds to MDM2 protein]] which results in increased degradation of TP53 protein; MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid affects the localization of TP53 protein]; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]; Ursodeoxycholic Acid promotes the reaction [TP53 protein binds to MDM2 protein]
MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased ubiquitination of TP53 protein]
Ursodeoxycholic Acid results in increased expression of MDM2 mRNA		 CTD PMID:14514686 PMID:15222754 PMID:15885361 PMID:17881359 PMID:20807506 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase increases expression EXP Ursodeoxycholic Acid results in increased expression of MET mRNA CTD PMID:11983124 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Mgll monoglyceride lipase decreases expression EXP Ursodeoxycholic Acid results in decreased expression of MGLL mRNA CTD PMID:15885361 NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179 		JBrowse link
G Mir21 microRNA 21 increases expression ISO
EXP		 Ursodeoxycholic Acid results in increased expression of MIR21 mRNA CTD PMID:20689055 NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Tretinoin results in decreased expression of MMP2 mRNA] CTD PMID:21274875 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mpo myeloperoxidase decreases activity ISO Ursodeoxycholic Acid results in decreased activity of MPO protein CTD PMID:17888421 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819 		JBrowse link
G Msn moesin decreases expression EXP Ursodeoxycholic Acid results in decreased expression of MSN mRNA CTD PMID:15885361 NCBI chr  X:60,996,043...61,064,011
Ensembl chr  X:60,995,951...61,065,628 		JBrowse link
G Mt2A metallothionein 2A increases expression EXP Ursodeoxycholic Acid results in increased expression of MT2A mRNA CTD PMID:10491327 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Myh9 myosin, heavy chain 9 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of MYH9 mRNA CTD PMID:15885361 NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457 		JBrowse link
G Nap1l1 nucleosome assembly protein 1-like 1 affects expression ISO Ursodeoxycholic Acid affects the expression of NAP1L1 mRNA CTD PMID:18422935 NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases localization
increases expression		 ISO
EXP		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased localization of NFE2L2 protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 protein]]; Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 protein]
NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC2 mRNA]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC2 protein]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC3 mRNA]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC3 protein]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC4 mRNA]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of ABCC4 protein]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of GCLC mRNA]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of NR1I2 mRNA]; NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of NR5A2 mRNA]
Ursodeoxycholic Acid promotes the reaction [NFE2L2 protein binds to ABCC3 promoter]; Ursodeoxycholic Acid promotes the reaction [NFE2L2 protein binds to ABCC4 promoter]; Ursodeoxycholic Acid promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; Ursodeoxycholic Acid results in increased activity of and results in increased localization of NFE2L2 protein
Ursodeoxycholic Acid results in increased expression of NFE2L2 mRNA		 CTD PMID:18687751 PMID:19073151 PMID:20146260 PMID:25582706 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO
EXP		 Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]
Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of NFKB1 mRNA]		 CTD PMID:21146893 PMID:25502462 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha decreases degradation ISO Ursodeoxycholic Acid results in decreased degradation of NFKBIA protein CTD PMID:15473667 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
decreases expression
increases expression		 EXP
ISO		 Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NOS2 protein]; Ursodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of NOS2 protein]
Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA]
Ursodeoxycholic Acid results in decreased expression of NOS2 protein
Ursodeoxycholic Acid results in increased expression of NOS2		 CTD PMID:12496057 PMID:12620498 PMID:17438113 PMID:18479249 PMID:18590720 More... NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression		 EXP
ISO		 Ursodeoxycholic Acid promotes the reaction [NFE2L2 protein binds to NQO1 promoter]
Ursodeoxycholic Acid results in increased expression of NQO1 mRNA; Ursodeoxycholic Acid results in increased expression of NQO1 protein		 CTD PMID:18687751 PMID:25582706 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 increases expression EXP
ISO		 Ursodeoxycholic Acid results in increased expression of NR0B2 mRNA CTD PMID:16764892 PMID:18706437 PMID:21274875 PMID:25055961 PMID:25582706 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
increases expression
affects binding
multiple interactions
decreases expression		 ISO
EXP		 Ursodeoxycholic Acid results in increased activity of NR1H4 protein
Ursodeoxycholic Acid results in increased expression of NR1H4 mRNA; Ursodeoxycholic Acid results in increased expression of NR1H4 protein
Ursodeoxycholic Acid binds to NR1H4 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 protein]; Ursodeoxycholic Acid inhibits the reaction [Tretinoin results in increased expression of NR1H4 mRNA]
Ursodeoxycholic Acid results in decreased expression of NR1H4 mRNA
Chenodeoxycholic Acid inhibits the reaction [Ursodeoxycholic Acid binds to NR1H4 protein]; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Ursodeoxycholic Acid inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
ursodeoxycholic acid inhibits the reaction [1-naphthyl isothiocyanate decreases expression of nr1h4 mRNA and protein in rat liver]; ursodeoxycholic acid increases expression of nr1h4 mRNA and protein in rat embryonic liver cells		 CTD
RGD		 PMID:14684751 PMID:15935148 PMID:17567710 PMID:18706437 PMID:21274875 More... RGD:15042872 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression
multiple interactions		 ISO Ursodeoxycholic Acid results in increased expression of NR1I2 mRNA
NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of NR1I2 mRNA]		 CTD PMID:18687751 PMID:18706437 PMID:25582706 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 multiple interactions
increases activity
increases localization
increases expression
affects localization		 EXP
ISO		 [Ursodeoxycholic Acid co-treated with TGFB1 protein] results in increased localization of NR3C1 protein; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]]; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]]; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]]; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased expression of E2F1 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of NR3C1 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of NR3C1 protein]; Ursodeoxycholic Acid results in increased expression of and results in increased localization of NR3C1 protein
Ursodeoxycholic Acid results in increased activity of NR3C1 protein
Ursodeoxycholic Acid results in increased localization of NR3C1 protein
Ursodeoxycholic Acid results in increased expression of NR3C1 mRNA
Ursodeoxycholic Acid affects the localization of NR3C1 protein
[Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to NR3C1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to NR3C1 protein binds to SLC4A2 promoter]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to NR3C1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [NR3C1 protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] results in increased localization of NR3C1 protein; [Ursodeoxycholic Acid co-treated with NR3C1] results in decreased expression of HLA-DRA mRNA		 CTD PMID:8568266 PMID:15222754 PMID:15674094 PMID:16175607 PMID:18188457 More... NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375 		JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 multiple interactions
increases localization
increases expression		 EXP [Ursodeoxycholic Acid co-treated with TGFB1 protein] results in increased localization of NR3C2 protein; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased expression of E2F1 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 protein]
Ursodeoxycholic Acid results in increased localization of NR3C2 protein
Ursodeoxycholic Acid results in increased expression of NR3C2 mRNA		 CTD PMID:15222754 NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885 		JBrowse link
G Nr5a2 nuclear receptor subfamily 5, group A, member 2 increases expression
multiple interactions		 ISO Ursodeoxycholic Acid results in increased expression of NR5A2 mRNA
NFE2L2 affects the reaction [Ursodeoxycholic Acid results in increased expression of NR5A2 mRNA]		 CTD PMID:18687751 NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326 		JBrowse link
G Nucb2 nucleobindin 2 increases expression EXP Ursodeoxycholic Acid results in increased expression of NUCB2 mRNA CTD PMID:15885361 NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353 		JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator increases expression EXP Ursodeoxycholic Acid results in increased expression of NUPR1 mRNA CTD PMID:15885361 NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281 		JBrowse link
G Oaf out at first homolog affects expression ISO Ursodeoxycholic Acid affects the expression of OAF mRNA CTD PMID:18422935 NCBI chr 8:43,594,362...43,612,334
Ensembl chr 8:43,594,363...43,612,334 		JBrowse link
G Oplah 5-oxoprolinase (ATP-hydrolysing) decreases expression EXP Ursodeoxycholic Acid results in decreased expression of OPLAH mRNA CTD PMID:15885361 NCBI chr 7:108,011,472...108,051,751
Ensembl chr 7:108,011,475...108,035,297 		JBrowse link
G Otc ornithine transcarbamylase decreases expression EXP Ursodeoxycholic Acid results in decreased expression of OTC mRNA CTD PMID:15885361 NCBI chr  X:12,453,834...12,529,954
Ensembl chr  X:12,453,834...12,566,918 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO [oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased cleavage of PARP1 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein]; FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein]; RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein]; TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] CTD PMID:19728331 PMID:21362627 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein] CTD PMID:17438113 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Perp p53 apoptosis effector related to PMP22 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of PERP mRNA CTD PMID:15885361 NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511 		JBrowse link
G Pgr progesterone receptor multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [[Ethinyl Estradiol co-treated with Progesterone] results in increased expression of PGR protein] CTD PMID:14728856 NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344 		JBrowse link
G Pklr pyruvate kinase L/R decreases expression EXP Ursodeoxycholic Acid results in decreased expression of PKLR mRNA CTD PMID:15885361 NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870 		JBrowse link
G Pla2g2a phospholipase A2 group IIA multiple interactions EXP Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased activity of PLA2G2A protein]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of PLA2G2A mRNA]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of PLA2G2A protein] CTD PMID:10025872 NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression ISO Ursodeoxycholic Acid results in decreased expression of PPARG mRNA CTD PMID:24312631 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Prdx1 peroxiredoxin 1 increases expression ISO Ursodeoxycholic Acid results in increased expression of PRDX1 mRNA; Ursodeoxycholic Acid results in increased expression of PRDX1 protein CTD PMID:18687751 NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856 		JBrowse link
G Prkcb protein kinase C, beta increases activity ISO Ursodeoxycholic Acid results in increased activity of PRKCB protein CTD PMID:7705931 NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536 		JBrowse link
G Prkcd protein kinase C, delta multiple interactions
increases response to substance
increases localization		 ISO Acetylcysteine inhibits the reaction [Ursodeoxycholic Acid results in increased localization of PRKCD protein]; Butylated Hydroxyanisole inhibits the reaction [Ursodeoxycholic Acid results in increased localization of PRKCD protein]; diphenyleneiodonium inhibits the reaction [Ursodeoxycholic Acid results in increased localization of PRKCD protein]; methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased localization of PRKCD protein]
PRKCD results in increased susceptibility to Ursodeoxycholic Acid		 CTD PMID:21362627 NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352 		JBrowse link
G Prnp prion protein decreases expression EXP Ursodeoxycholic Acid results in decreased expression of PRNP mRNA CTD PMID:15885361 NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO
EXP		 Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of PTGS2]
Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of PTGS2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of PTGS2 protein]		 CTD PMID:12496057 PMID:12839936 PMID:18444174 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Ptma prothymosin alpha increases expression EXP Ursodeoxycholic Acid results in increased expression of PTMA mRNA CTD PMID:15885361 NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333 		JBrowse link
G Rab6a RAB6A, member RAS oncogene family increases expression EXP Ursodeoxycholic Acid results in increased expression of RAB6A mRNA CTD PMID:15885361 NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715 		JBrowse link
G Rac1 Rac family small GTPase 1 multiple interactions
affects expression		 ISO RAC1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased expression of TNFRSF10B]
Ursodeoxycholic Acid affects the expression of RAC1 mRNA		 CTD PMID:18422935 PMID:21362627 NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of RAF1 protein] CTD PMID:14747693 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases expression ISO Ursodeoxycholic Acid results in decreased expression of RB1 protein modified form CTD PMID:17461466 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rbbp6 RB binding protein 6, ubiquitin ligase affects expression ISO Ursodeoxycholic Acid affects the expression of RBBP6 mRNA CTD PMID:18422935 NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678 		JBrowse link
G Rffl ring finger and FYVE-like domain containing E3 ubiquitin protein ligase affects expression ISO Ursodeoxycholic Acid affects the expression of RFFL mRNA CTD PMID:18422935 NCBI chr10:67,740,711...67,803,669
Ensembl chr10:67,740,712...67,824,434 		JBrowse link
G Rhoa ras homolog family member A multiple interactions
decreases activity		 ISO DLC1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased activity of RHOA protein] CTD PMID:21455586 NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746 		JBrowse link
G Rhobtb3 Rho-related BTB domain containing 3 affects expression ISO Ursodeoxycholic Acid affects the expression of RHOBTB3 mRNA CTD PMID:18422935 NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041 		JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein]; RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein]; RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein]; RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] CTD PMID:21362627 NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824 		JBrowse link
G Rnf138 ring finger protein 138 increases expression EXP Ursodeoxycholic Acid results in increased expression of RNF138 mRNA CTD PMID:15885361 NCBI chr18:12,291,557...12,315,931
Ensembl chr18:12,291,590...12,315,930 		JBrowse link
G Rnf181 ring finger protein 181 increases expression EXP Ursodeoxycholic Acid results in increased expression of RNF181 mRNA CTD PMID:15885361 NCBI chr 4:104,414,586...104,421,433
Ensembl chr 4:104,414,605...104,421,309 		JBrowse link
G Rpl10 ribosomal protein L10 affects expression ISO Ursodeoxycholic Acid affects the expression of RPL10 mRNA CTD PMID:18422935 NCBI chr  X:152,054,562...152,056,769
Ensembl chr  X:152,054,452...152,056,761 		JBrowse link
G Rpl27 ribosomal protein L27 affects expression ISO Ursodeoxycholic Acid affects the expression of RPL27 mRNA CTD PMID:18422935 NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193 		JBrowse link
G Rpl32 ribosomal protein L32 affects expression ISO Ursodeoxycholic Acid affects the expression of RPL32 mRNA CTD PMID:18422935 NCBI chr 4:148,864,048...148,867,612
Ensembl chr 4:148,864,044...148,867,612 		JBrowse link
G Rpl35a ribosomal protein L35A affects expression ISO Ursodeoxycholic Acid affects the expression of RPL35A mRNA CTD PMID:18422935 NCBI chr11:67,726,031...67,729,953
Ensembl chr11:67,726,032...67,729,942
Ensembl chr 5:67,726,032...67,729,942 		JBrowse link
G Rpl39l1 ribosomal protein L39 like 1 affects expression ISO Ursodeoxycholic Acid affects the expression of RPL39L mRNA CTD PMID:18422935 NCBI chr10:5,455,712...5,459,828
Ensembl chr10:5,454,559...5,462,029 		JBrowse link
G Rpl6 ribosomal protein L6 affects expression ISO Ursodeoxycholic Acid affects the expression of RPL6 mRNA CTD PMID:18422935 NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921 		JBrowse link
G Rplp2 ribosomal protein lateral stalk subunit P2 affects expression ISO Ursodeoxycholic Acid affects the expression of RPLP2 mRNA CTD PMID:18422935 NCBI chr 1:196,546,086...196,548,636
Ensembl chr 1:196,546,352...196,548,645 		JBrowse link
G Rps13 ribosomal protein S13 affects expression ISO Ursodeoxycholic Acid affects the expression of RPS13 mRNA CTD PMID:18422935 NCBI chr 1:170,572,925...170,575,355
Ensembl chr 1:170,572,921...170,575,355
Ensembl chr 3:170,572,921...170,575,355 		JBrowse link
G Rps27l ribosomal protein S27-like affects expression ISO Ursodeoxycholic Acid affects the expression of RPS27L mRNA CTD PMID:18422935 NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418 		JBrowse link
G Rps28 ribosomal protein S28 affects expression ISO Ursodeoxycholic Acid affects the expression of RPS28 mRNA CTD PMID:18422935 NCBI chr 7:14,607,801...14,609,170
Ensembl chr 7:14,607,801...14,609,170
Ensembl chr16:14,607,801...14,609,170 		JBrowse link
G RT1-Da RT1 class II, locus Da multiple interactions
increases expression		 ISO [Ursodeoxycholic Acid co-treated with NR3C1] results in decreased expression of HLA-DRA mRNA; Ursodeoxycholic Acid inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]
Ursodeoxycholic Acid results in increased expression of HLA-DRA mRNA		 CTD PMID:8568266 NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455 		JBrowse link
G S100a6 S100 calcium binding protein A6 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of S100A6 mRNA CTD PMID:15885361 NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180 		JBrowse link
G Samd4b sterile alpha motif domain containing 4B affects expression ISO Ursodeoxycholic Acid affects the expression of SAMD4B mRNA CTD PMID:18422935 NCBI chr 1:83,689,413...83,728,652
Ensembl chr 1:83,689,413...83,713,853 		JBrowse link
G Scd stearoyl-CoA desaturase decreases expression ISO Ursodeoxycholic Acid results in decreased expression of SCD mRNA CTD PMID:24312631 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Sct secretin multiple interactions
increases response to substance
increases activity		 EXP 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT]; Colchicine inhibits the reaction [SCT results in increased susceptibility to Ursodeoxycholic Acid analog]; Colchicine inhibits the reaction [SCT results in increased susceptibility to Ursodeoxycholic Acid]; Colchicine inhibits the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT]; Go 6976 inhibits the reaction [SCT results in increased susceptibility to Ursodeoxycholic Acid analog]; Go 6976 inhibits the reaction [SCT results in increased susceptibility to Ursodeoxycholic Acid]; Go 6976 inhibits the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT]; SLC4A2 affects the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT]; U 0126 inhibits the reaction [SCT results in increased susceptibility to Ursodeoxycholic Acid analog]; U 0126 inhibits the reaction [SCT results in increased susceptibility to Ursodeoxycholic Acid]; U 0126 inhibits the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT]; wortmannin inhibits the reaction [SCT results in increased susceptibility to Ursodeoxycholic Acid analog]; wortmannin inhibits the reaction [SCT results in increased susceptibility to Ursodeoxycholic Acid]; wortmannin inhibits the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT]
SCT results in increased susceptibility to Ursodeoxycholic Acid; SCT results in increased susceptibility to Ursodeoxycholic Acid analog		 CTD PMID:22194894 NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658 		JBrowse link
G Serp1 stress-associated endoplasmic reticulum protein 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of SERP1 mRNA CTD PMID:15885361 NCBI chr 2:142,757,254...142,761,243
Ensembl chr 2:142,757,270...142,761,116 		JBrowse link
G Sf3b1 splicing factor 3b, subunit 1 affects expression ISO Ursodeoxycholic Acid affects the expression of SF3B1 mRNA CTD PMID:18422935 NCBI chr 9:56,492,403...56,532,300
Ensembl chr 9:56,492,403...56,532,300 		JBrowse link
G Shld2 shieldin complex subunit 2 affects expression ISO Ursodeoxycholic Acid affects the expression of SHLD2 mRNA CTD PMID:18422935 NCBI chr16:9,544,940...9,640,323
Ensembl chr16:9,548,660...9,639,965 		JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions
increases expression
affects expression		 EXP
ISO		 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein]; Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]
Ursodeoxycholic Acid results in increased expression of SLC10A1 mRNA
Ursodeoxycholic Acid affects the expression of SLC10A1 mRNA
Ursodeoxycholic Acid results in increased expression of SLC10A1 protein		 CTD PMID:16487557 PMID:16764892 PMID:25582706 PMID:27743861 PMID:32198087 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670 		JBrowse link
G Slc10a2 solute carrier family 10 member 2 increases expression EXP
ISO		 Ursodeoxycholic Acid results in increased expression of SLC10A2 mRNA CTD PMID:16764892 PMID:25582706 NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475 		JBrowse link
G Slc22a8 solute carrier family 22 member 8 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of SLC22A8 mRNA CTD PMID:15885361 NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450 		JBrowse link
G Slc23a1 solute carrier family 23 member 1 increases expression ISO Ursodeoxycholic Acid results in increased expression of SLC23A1 mRNA CTD PMID:18706437 NCBI chr18:27,214,940...27,230,564
Ensembl chr18:27,216,281...27,230,697 		JBrowse link
G Slc23a2 solute carrier family 23 member 2 increases expression ISO Ursodeoxycholic Acid results in increased expression of SLC23A2 mRNA CTD PMID:18706437 NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343 		JBrowse link
G Slc25a5 solute carrier family 25 member 5 affects expression ISO Ursodeoxycholic Acid affects the expression of SLC25A5 mRNA CTD PMID:18422935 NCBI chr  X:116,031,896...116,034,963
Ensembl chr  X:116,031,803...116,034,967 		JBrowse link
G Slc26a1 solute carrier family 26 member 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of SLC26A1 mRNA CTD PMID:15885361 NCBI chr14:1,040,565...1,045,851
Ensembl chr14:1,040,243...1,045,849 		JBrowse link
G Slc27a5 solute carrier family 27 member 5 multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] CTD PMID:22531947 NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172 		JBrowse link
G Slc28a2 solute carrier family 28 member 2 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of SLC28A2 mRNA CTD PMID:15885361 NCBI chr 3:109,324,815...109,387,702
Ensembl chr 3:109,366,996...109,387,702 		JBrowse link
G Slc2a2 solute carrier family 2 member 2 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of SLC2A2 mRNA CTD PMID:15885361 NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933 		JBrowse link
G Slc4a2 solute carrier family 4 member 2 multiple interactions EXP
ISO		 SLC4A2 affects the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT]
[Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to NR3C1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to NR3C1 protein binds to SLC4A2 promoter]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to SLC4A2 promoter]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to NR3C1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [NR3C1 protein binds to SLC4A2 promoter alternative form]; [Ursodeoxycholic Acid co-treated with Dexamethasone] results in increased activity of SLC4A2 protein; [Ursodeoxycholic Acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form; Ursodeoxycholic Acid promotes the reaction [EP300 protein binds to SLC4A2 promoter]; Ursodeoxycholic Acid promotes the reaction [HNF1A protein binds to SLC4A2 promoter]		 CTD PMID:18188457 PMID:22194894 NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965 		JBrowse link
G Slc51a solute carrier family 51 member A increases expression ISO Ursodeoxycholic Acid results in increased expression of SLC51A mRNA CTD PMID:25055961 PMID:25582706 NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485 		JBrowse link
G Slc51b SLC51 subunit beta increases expression ISO Ursodeoxycholic Acid results in increased expression of SLC51B mRNA CTD PMID:25055961 PMID:25582706 NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects expression
increases expression
multiple interactions		 ISO
EXP		 Ursodeoxycholic Acid affects the expression of SLCO1A4 mRNA
Ursodeoxycholic Acid results in increased expression of SLCO1A4 mRNA
Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLCO1A2 mRNA]		 CTD PMID:18687751 PMID:25582706 PMID:27743861 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573 		JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 decreases expression
increases expression
increases uptake
multiple interactions		 EXP
ISO		 Ursodeoxycholic Acid results in decreased expression of SLCO1B3 mRNA
Ursodeoxycholic Acid results in increased expression of SLCO1B2 mRNA
SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid; SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite
Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite]		 CTD PMID:15885361 PMID:16534140 PMID:25582706 PMID:31299240 NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981 		JBrowse link
G Smad3 SMAD family member 3 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of SMAD3 mRNA; Ursodeoxycholic Acid results in decreased expression of SMAD3 protein CTD PMID:19493473 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960 		JBrowse link
G Smad7 SMAD family member 7 increases expression EXP Ursodeoxycholic Acid results in increased expression of SMAD7 mRNA; Ursodeoxycholic Acid results in increased expression of SMAD7 protein CTD PMID:19493473 NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765 		JBrowse link
G Soat1 sterol O-acyltransferase 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of SOAT1 mRNA CTD PMID:15885361 NCBI chr13:68,552,274...68,597,529
Ensembl chr13:68,552,317...68,597,494 		JBrowse link
G Spry4 sprouty RTK signaling antagonist 4 affects expression ISO Ursodeoxycholic Acid affects the expression of SPRY4 mRNA CTD PMID:18422935 NCBI chr18:30,436,513...30,451,426
Ensembl chr18:30,436,443...30,453,004 		JBrowse link
G Sptbn1 spectrin, beta, non-erythrocytic 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of SPTBN1 mRNA CTD PMID:15885361 NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507 		JBrowse link
G Ssbp1 single stranded DNA binding protein 1 affects expression ISO Ursodeoxycholic Acid affects the expression of SSBP1 mRNA CTD PMID:18422935 NCBI chr 4:69,266,024...69,276,135
Ensembl chr 4:69,266,102...69,276,135 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO [Amantadine co-treated with Ursodeoxycholic Acid co-treated with 7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester] results in increased activity of STAT1 CTD PMID:15918519 NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of STAT3 mRNA]; Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of STAT3 protein] CTD PMID:38104874 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Stk3 serine/threonine kinase 3 affects expression ISO Ursodeoxycholic Acid affects the expression of STK3 mRNA CTD PMID:18422935 NCBI chr 7:66,053,209...66,323,292
Ensembl chr 7:66,052,345...66,323,233 		JBrowse link
G Stmn1 stathmin 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of STMN1 mRNA CTD PMID:15885361 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of SULT1A1 mRNA CTD PMID:15885361 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562 		JBrowse link
G Sult1b1 sulfotransferase family 1B member 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of SULT1B1 mRNA CTD PMID:15885361 NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 increases sulfation
affects expression
multiple interactions		 ISO
EXP		 SULT2A1 protein results in increased sulfation of Ursodeoxycholic Acid
Ursodeoxycholic Acid affects the expression of SULT2A1 protein
Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SULT2A1 mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SULT2A1 protein]		 CTD PMID:16472600 PMID:20102295 PMID:32198087 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tagln transgelin decreases expression EXP Ursodeoxycholic Acid results in decreased expression of TAGLN mRNA CTD PMID:15885361 NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668 		JBrowse link
G Tat tyrosine aminotransferase multiple interactions EXP Dactinomycin inhibits the reaction [Ursodeoxycholic Acid promotes the reaction [Dexamethasone results in increased activity of TAT protein]]; Sphingosine inhibits the reaction [Ursodeoxycholic Acid promotes the reaction [Dexamethasone results in increased activity of TAT protein]]; Ursodeoxycholic Acid promotes the reaction [Dexamethasone results in increased activity of TAT protein]; Ursodeoxycholic Acid promotes the reaction [Dexamethasone results in increased expression of TAT mRNA] CTD PMID:9398635 NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031 		JBrowse link
G Tbxa2r thromboxane A2 receptor decreases expression EXP Ursodeoxycholic Acid results in decreased expression of TBXA2R protein CTD PMID:18479249 NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176 		JBrowse link
G Tbxas1 thromboxane A synthase 1 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of TBXAS1 protein CTD PMID:18479249 NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression		 EXP [Ursodeoxycholic Acid co-treated with TGFB1 protein] results in increased localization of NR3C1 protein; [Ursodeoxycholic Acid co-treated with TGFB1 protein] results in increased localization of NR3C2 protein; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]]; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]]; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of BCL2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of BCL2 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of NR3C1 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of NR3C1 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of NR3C2 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 mRNA]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]; Ursodeoxycholic Acid inhibits the reaction [Tretinoin results in decreased expression of TGFB1 mRNA]
Ursodeoxycholic Acid results in decreased expression of TGFB1 mRNA; Ursodeoxycholic Acid results in decreased expression of TGFB1 protein		 CTD PMID:10510466 PMID:14514686 PMID:15222754 PMID:18479249 PMID:19493473 More... NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tgfbi transforming growth factor, beta induced decreases expression EXP Ursodeoxycholic Acid results in decreased expression of TGFBI mRNA CTD PMID:15885361 NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240 		JBrowse link
G Tgm2 transglutaminase 2 decreases expression EXP Ursodeoxycholic Acid results in decreased expression of TGM2 mRNA CTD PMID:15885361 NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981 		JBrowse link
G Thrsp thyroid hormone responsive decreases expression EXP Ursodeoxycholic Acid results in decreased expression of THRSP mRNA CTD PMID:15885361 NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075 		JBrowse link
G Tmem176b transmembrane protein 176B decreases expression EXP Ursodeoxycholic Acid results in decreased expression of TMEM176B mRNA CTD PMID:15885361 NCBI chr 4:77,766,928...77,774,740
Ensembl chr 4:77,766,928...77,774,384 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
decreases secretion		 ISO
EXP		 Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein results in increased activity of CASP7 protein]; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA]
Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of TNF mRNA]; Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased secretion of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA]
Ursodeoxycholic Acid affects the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [Rotenone results in increased expression of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [Tretinoin results in decreased expression of TNF mRNA]
Ursodeoxycholic Acid results in decreased expression of TNF mRNA; Ursodeoxycholic Acid results in decreased expression of TNF protein
Ursodeoxycholic Acid results in decreased secretion of TNF protein		 CTD PMID:17438113 PMID:17888421 PMID:18590720 PMID:21146893 PMID:21274875 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions ISO Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] CTD PMID:21146893 NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases ubiquitination
affects response to substance
affects localization		 ISO
EXP		 MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased ubiquitination of TP53 protein]; TP53 mutant form inhibits the reaction [[Oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein]; TP53 mutant form inhibits the reaction [[Oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP8 protein]
[Ursodeoxycholic Acid promotes the reaction [TP53 protein binds to MDM2 protein]] which results in increased degradation of TP53 protein; MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid affects the localization of TP53 protein]; NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]]; NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]]; Ursodeoxycholic Acid affects the localization of and results in decreased phosphorylation of TP53 protein; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of TP53 mRNA]; Ursodeoxycholic Acid inhibits the reaction [E2F1 protein results in increased expression of TP53 protein]; Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]; Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of and results in increased localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [TP53 protein results in increased expression of BAX protein]; Ursodeoxycholic Acid promotes the reaction [TP53 protein binds to MDM2 protein]; Ursodeoxycholic Acid results in increased ubiquitination of and results in increased degradation of TP53 protein
TP53 protein affects the susceptibility to Ursodeoxycholic Acid
Ursodeoxycholic Acid inhibits the reaction [Cisplatin results in increased expression of TRP53 protein]		 CTD PMID:14514686 PMID:15222754 PMID:17431217 PMID:17881359 PMID:18558085 More... NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Trib3 tribbles pseudokinase 3 increases expression EXP Ursodeoxycholic Acid results in increased expression of TRIB3 mRNA CTD PMID:15885361 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497 		JBrowse link
G Ubd ubiquitin D decreases expression EXP Ursodeoxycholic Acid results in decreased expression of UBD mRNA CTD PMID:15885361 NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639
Ensembl chr20:1,385,864...1,408,639 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 increases expression
multiple interactions		 ISO
EXP		 Ursodeoxycholic Acid results in increased expression of UGT1A1 mRNA
Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; Ursodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein]		 CTD PMID:18687751 PMID:32198087 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 increases glucuronidation
multiple interactions		 ISO UGT1A3 protein results in increased glucuronidation of Ursodeoxycholic Acid
[Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of Ursodeoxycholic Acid		 CTD PMID:31299240 NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a5 UDP glucuronosyltransferase family 1 member A5 increases glucuronidation ISO UGT1A4 protein results in increased glucuronidation of Ursodeoxycholic Acid CTD PMID:31299240 NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 increases glucuronidation ISO UGT1A9 protein results in increased glucuronidation of Ursodeoxycholic Acid CTD PMID:31299240 NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt2b1 UDP glucuronosyltransferase 2 family, polypeptide B1 multiple interactions
increases glucuronidation		 EXP
ISO		 Ursodeoxycholic Acid promotes the reaction [Ethinyl Estradiol results in decreased activity of UGT2B1 protein]; Ursodeoxycholic Acid promotes the reaction [Ethinyl Estradiol results in decreased expression of UGT2B1 protein]
UGT2B17 protein results in increased glucuronidation of Ursodeoxycholic Acid		 CTD PMID:12663690 PMID:31299240 NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986 		JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases glucuronidation ISO UGT2B7 protein results in increased glucuronidation of Ursodeoxycholic Acid CTD PMID:31299240 NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604 		JBrowse link
G Wdr33 WD repeat domain 33 affects expression ISO Ursodeoxycholic Acid affects the expression of WDR33 mRNA CTD PMID:18422935 NCBI chr18:23,432,233...23,535,460
Ensembl chr18:23,432,191...23,468,597 		JBrowse link
G Wif1 Wnt inhibitory factor 1 increases expression EXP Ursodeoxycholic Acid results in increased expression of WIF1 mRNA CTD PMID:15885361 NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:56,548,053...56,618,360 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19811
    chemical entity 19840
      atom 19809
        nonmetal atom 19747
          carbon atom 19734
            organic molecular entity 19705
              lipid 17920
                steroid 14672
                  cholane derivative 982
                    C24-steroid + 982
                    cholane ester 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19811
    subatomic particle 19809
      composite particle 19809
        hadron 19840
          baryon 19809
            nucleon 19809
              atomic nucleus 19809
                atom 19809
                  main group element atom 19759
                    p-block element atom 19759
                      carbon group element atom 19708
                        carbon atom 19734
                          organic molecular entity 19705
                            organic molecule 19658
                              organic cyclic compound 19471
                                organic polycyclic compound 17244
                                  steroid 14672
                                    steroid fundamental parent 14483
                                      cholane 999
                                        cholane derivative 982
                                          C24-steroid + 982
                                          cholane ester 0
paths to the root